Title: Impacts on labour force and healthcare services related to mental-health issues following an acute SARS-CoV-2 infection: rapid review

Authors: Jennifer Pillay, Liza Bialy, Sabrina Saba, Samantha Guitard, Sholeh Rahman, Maria Tan, Lisa Hartling

Supplemental file

Table S1: Eligibility Criteria	Page number 2
Search Strategy	3
Included Studies	24
Excluded Studies	28
Table S2. Risk of Bias Assessments	54
Table S3a: Study Characteristics for Labour Force Outcomes with Control Groups	58
Table S3b: Study Characteristics for Labour Force Outcomes without Control Groups	73
Table S4a: Study Characteristics for Mental Health Service Use with Control Groups	80
Table S4b. Study Characteristics for Mental Health Service Use without Control Groups	84
Supplementary Figures	102

Table S1. Eligibility Criteria

Domain	Inclusion criteria	Exclusion criteria
Population	For a) impacts on the labour force and healthcare costs: people of any	
	age experiencing new/worsening/recurring MH symptoms/disorder at	
	in the study may be broader, including the general population or people	
	with previous SARS-CoV-2 infection.	
	For b) impact on healthcare services use related to MH issues: people	
	of any age with confirmed (e.g., by laboratory testing) or suspected	
	least 4 weeks previous to outcome assessment. The population	
	examined in the study may be broader, including the general population	
	or those tested for SARs-CoV-2 infection.	
	Specific populations: age (5-17 vs. 18-65 vs. 65+ years), sex,	
	race/ethnicity, socioeconomic status (via income or if not reported	
	educational level), reintection status, vaccination status (UVs. tuli dosing	
	among pre-Omicron variants), severity of acute infection, pre and/or co-	
	existing conditions	
Exposure & Comparison(s)	None required	
	Notes: Participants may be enrolled or have participated in a treatment	
	study (that may or may not target their MH symptoms), though the	
	effects of different treatments will not be considered.	
	We will include data for a concurrent control group without previous	
	confirmed/suspected SARS-CoV-2 infection (ideally but not required to	
	nave negative testing at baseline and during follow-up) ("nealthy control")	
Outcomes &	a) Among those with new-onset/worsened/recurring MH	
analyses	symptoms/disorders after infection:	
	• Economic burden (e.g., labor and healthcare costs)	
	Return to work (e.g., loss of income due to inability to return to work/abanga in ich reasonabilities, properties of individuals	
	returning to work full time/part time/not returning, sick days, long-	
	term disability claims)	
	 Productivity loss (e.g., presenteeism, leaveism, annual 	
	wages/income lost, impairment in the ability to perform job	
	b) After-infection MH services use, including referrals as a proxy. Any	
	type of service provider is eligible. If all participants are identified to	
	have a MH issue we will consider including outcomes related to use of	
Timing of	post-covid/multidisciplinary clinics. Outcomes measured >4 weeks after a SARS-CoV-2 infection	
events/outcome		
assessment		
Study design,	Primary research and modelling studies/economic analyses using	Conference
publication type	secondary data sources with run texts. Studies must include h230 people with MH symptoms after COV/ID-19	austracts, reviews
Publication type		studies.
Country	Any	
Language	English or French	

Search Strategy

Ovid Medline(R) ALL

#	Searches	Results
1	("after covid*" or post-covid* or postcovid* or post-coronavir* or postcoronavir* or post-sarscov* or post- sars-cov*).ti,ab,kf.	15763
2	((convalesc* or post-acute or postacute or "after acute" or "after discharg*" or "after hospital discharg*" or "after recover*" or "following acute" or post-infect* or postrecovery or post-recovery or post-viral or postviral or post-discharg* or postdischarg* or survivor\$1) adj3 (COVID or COVID-19 or COVID19 or coronavirus* or corona virus* or 2019-nCoV or 19nCoV or 2019nCoV or nCoV or n-CoV or SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or 2019-novel CoV or sarscov* or "sars cov 2" or "sars cov2" or Sars-coronavirus2 or "novel CoV" or "severe acute respiratory syndrome")).ti,ab,kf.	6547
3	(("after" or "at least" or beyond or exceeding or follow* or "greater than" or "in excess of" or later* or longer or "more than" or surpassing or upward* or longitud*) adj3 (week? or wk or wks or month? or mo or mos or year? or yr or yrs)).ti,ab,kf.	1786889
4	(COVID or COVID-19 or COVID19 or coronavirus* or corona virus* or 2019-nCoV or 19nCoV or 2019nCoV or nCoV or n-CoV or SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or 2019-novel CoV or sarscov* or "sars cov 2" or "sars cov2" or Sars-coronavirus2 or "novel CoV" or "severe acute respiratory syndrome").ti,ab,kf.	412347
5	3 and 4	24298
6	or/1-2,5 [AFTER COVID]	40289
7	Post-Acute COVID-19 Syndrome/	2864
8	Covid-19/rh	214
9	("postcovid condition*" or "post-covid condition*" or "postcovid syndrome*" or "post-covid syndrome*").ti,ab,kf.	761
10	((longhaul or long-haul or long or longterm or long-term) adj (COVID or COVID-19 or COVID19 or coronavirus* or corona virus*)).ti,ab,kf.	4529
11	(PASC or ((postacute or post-acute) adj2 (COVID or COVID-19 or COVID19 or coronavirus* or corona virus* or sarscov* or "sars cov 2" or "sars cov2" or "severe acute respiratory syndrome"))).ti,ab,kf.	1678

12	((COVID* or coronavirus* or "corona virus*" or ICD or "International Classification of Diseases" or "international statistical classification of diseases") and (B94* or Uo9* or RAo2*)).ti,ab,kf.	25
13	((late-effect* or late-onset or persist* or postrecovery or post-recovery or "after initial infection") adj3 (COVID or COVID-19 or COVID19 or coronavirus* or corona virus* or 2019-nCoV or 19nCoV or 2019nCoV or nCoV or n-CoV or SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or 2019-novel CoV or sarscov* or "sars cov 2" or "sars cov2" or Sars-coronavirus2 or "novel CoV" or "severe acute respiratory syndrome")).ti,ab,kf.	2252
14	(("covid* care" or longcovid* or long-covid* or longhaul* or long-haul* or PASC or "postacute covid*" or "post-acute covid*" or "postacute sars*" or "post-acute sars*" or "post severe acute respiratory syndrome" or postcovid* or post-covid*) adj3 (centre or centres or center or centers or clinic or clinics or integrative or interdisciplinary or inter-disciplinary or multidisciplinary or multi-disciplinary or program or programs or programme or programmes or rehab or rehabilitation)).ti,ab,kf.	550
15	or/7-14 [PCC]	8364
16	Mental health/	64736
17	((emotional or mental) adj (health or hygiene or wellbeing or well-being or wellness)).ti,ab,kf.	253450
18	exp Mental Disorders/	1458134
19	exp Adaptation, psychological/	140812
20	exp Emotions/	419966
21	Affective symptoms/ or Delusions/ or Depersonalization/ or Mental fatigue/ or Obsessive behavior/ or Paranoid behavior/ or Problem behavior/ or exp Self-injurious behavior/ or exp Stress, Psychological/ or Occupational stress/	264715
22	(anxious* or Anxiet* or "attempted suicide*" or bereavement or bipolar* or compulsive* or compulsion* or Coping or Coronaphobia or delusion* or depressed or depressi* or dysthymi* or "Emotional regulation" or "emotional distress" or "Emotional disregulation" or "Emotional dysregulation" or fear* or grief or grieving or Hypochondriasis or hypomania or hypomanic or hypo-mania or hypo-manic or mania or manic or neuros#s or neurotic or obsession* or obsessive* or panic* or phobia* or phobic or post-trauma* or posttrauma* or PTSD or psychosis or psychoses or psychotic or selfharm* or self-harm* or self-injur* or selfinjur* or Suicidal* or worried or worries or worry*).ti,ab,kf.	1132262

23	((adjustment or affective or alcohol-induced or amnestic* or attention-deficit or ADHD or behaviour* or	520071
	behavior* or conduct or compulsi* or conversion or dissociative or eating or emotional or hyperactiv* or	
	hyper-activ* or impulse or impulsive* or mental or mood or neuro-behavio?ral or neuro-cognitive or	
	neuro-psych* or neurobehavio?ral or neurocognitive or neuropsych* or obsessi* or personality or	
	psychiatric or psychological or stress or trauma or somatoform or sleep or tic or tics or drug-induced or	
	social functioning) adj1 (condition* or diagnos#s or disorder* or disturbed or disturbance* or episod* or ill	
	or illness* or impact* or phenomena or phenomenon or sequela* or symptom*)).ti,ab,kf.	
24	(alcoholism or (alcohol or anxiolytic* or drug? or hypnotic* or multi-drug? or multidrug? or nicotine or	157360
	tobacco or opiate* or opioid* or poly-drug? or polydrug? or polysubstance? or poly-substance? or	
	psychoactive* or medication or psycho-active * or sedative* or stimulant? or substance?)) adj3 (abus* or	
	addict* or mis-us* or misus* or over-us* or overus* or "problem* use" or "use disorder*")).ti,ab,kf.	
25	Mental fatigue/	1885
26	Cognitive dysfunction/	38121
27	exp Neurobehavioral Manifestations/ not Intellectual disability/	251187
28	((brain or cognitive or mental or mind or thinking) adi (confusion or fatigue or fog or fogg* or cloud* or	3695
	fuzz*)) ti ab.kf	5 55
29	((cognitive or cognition) adj1 (disorder* or dysfunction or impact* or impair*)).ti,ab,kf.	122372
30	0/10-29 [MENTAL REALTH ISSUES]	2921221
31	*Incidence/ or *Prevalence/ or *Risk/ or *Odds Ratio/	6034
32	(Incidence* or prevalen* or probabilit* or predict* or risk or risks or "odds ratio*").ti,ab,kf.	6020600
33	((new or newly or recent) adj3 (onset or diagnos\$2 or problem\$1)).ti,ab,kf.	130591
34	(declin* or deteriorat* or provok* or provocation or recur* or trigger* or worsen*).ti,ab,kr.	1843951
35	(rate or rates).ti,kf.	278875
36	(incident adj3 (anxious* or anxiety or cogniti* or depress* or "mental health" or "mental disorder*" or	2352
	"mental illness*" or mood or neurocogniti* or neuro-cogniti* or neuropsych* or neuro-psych* or	
	psvch*)),ti.ab.kf.	
37	or/31-36 [NEW ONSET]	7555687
L		1

38	30 and 37 [NEW ONSET MH ISSUES]	925114
39	6 and 38 [NEW ONSET MH ISSUES AFTER COVID]	4385
40	Post-Acute COVID-19 Syndrome/px [Psychology]	5
41	(15 and 30) or 40 [PCC + MH ISSUES]	2013
42	39 or 41 [PCC + MH ISSUES OR NEW ONSET MH ISSUES AFTER COVID]	5549
43	Employment/	51055
44	Return to Work/	3736
45	Return to school/	62
46	((assum* or reenter* or re-enter* or reentry or re-entry or restart* or resum* or return* or start*) adj3 (employ* or job or jobs or work* or college or school or university)).ti,ab,kf.	28046
47	(back-to-work or employabilit* or workabilit*).ti,ab,kf.	3304
48	((able or abilit* or capabl* or incapabl* or capacit* or incapacit* or disable* or disabilit* or inabilit* or unable* or limit*) adj5 (employ* or job or jobs or work* or college or school or university)).ti,ab,kf.	83594
49	Sick Leave/	6850
50	((disabilt* or sick* or ill or illness* or unwell or "not well") adj5 (days or leave or "time off" or absenc* or absent* or presenc* or present)).ti,ab,kf.	27226
51	((shortterm or short-term or longterm or long-term) adj3 (disabl* or disabilit*)).ti,ab,kf.	6188
52	Absenteeism/	9815
53	Presenteeism/	608
54	(absence* or absentee* or presentee* or leaveism or leavism).ti,ab,kf.	719536
55	"labo?r participation".ti,ab,kf.	177
56	Occupational Medicine/	23488
57	((industrial* or occupational*) adj medicine).ti,ab,kf.	9579

58	Efficiency/	15738
59	((efficien* or productiv*) adj3 (declin* or decreas* or diminish* or less* or lose or losing or loss or losses or lost or low or lower* or reduc*)).ti,ab,kf.	110833
60	((labo?r or staff*) adj1 (impact* or issue or issues or shortage*)).ti,ab,kf.	2732
61	("work ability index" or "work productivity and impairment questionnaire" or "occupational status item" or "symptom burden questionnaire for long covid").ti,ab,kf.	588
62	or/43-61 [WORK PRODUCTIVITY - ADAPTED FROM COVID-END]	1040057
63	exp health care costs/	72511
64	exp "cost of illness"/	33817
65	((disease or diseases or disabilit* or sick* or ill or illness* or unwell or "not well") adj5 (cost or costs or costly or costing or economic* or expenditure? or expens* or financ*)).ti,ab,kf.	42847
66	(burden* adj1 (health or healthcare or "health care")).ti,ab,kf.	12232
67	Financial Stress/	1161
68	((econom* or financ*) adj3 (challeng* or difficult* or distress* or hardship* or pressur* or problem* or strain*)).ti,ab,kf.	23322
69	((econom* or financ*) adj burden*).ti,ab,kf.	26652
70	or/63-69 [COST OF ILLNESS]	184676
71	Economics/	27522
72	exp "Costs and Cost Analysis"/	268109
73	Economics, Nursing/	4013
74	Economics, Medical/	9262
75	Economics, Pharmaceutical/	3122
76	exp Economics, Hospital/	25784

77	Economics, Dental/	1921
78	exp "Fees and Charges"/	31441
79	exp Budgets/	14170
80	budget*.ti,ab,kf.	37169
81	(economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or finance or finances or financed).ti,kf.	289839
82	(economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or finance or finances or financed).ab. /freq=2	395970
83	(cost* adj2 (effective* or utilit* or benefit* or minimi* or analy* or outcome or outcomes)).ab,kf.	218173
84	(value adj2 (money or monetary)).ti,ab,kf.	3144
85	exp models, economic/	16256
86	economic model*.ab,kf.	4357
87	markov chains/	16069
88	markov.ti,ab,kf.	30075
89	monte carlo method/	32599
90	monte carlo.ti,ab,kf.	61874
91	exp Decision Theory/	13531
92	(decision* adj2 (tree* or analy* or model*)).ti,ab,kf.	40573
93	or/71-92	925885
94	((socioeconomic* or socio-economic* or economic or economical or economies or economy or societ* or labo?r or productivity or "mental health care" or "mental healthcare" or "mental health service*") adj2 (impact\$1 or effect\$1 or burden\$1 or cost\$1 or loss or losses)).ti,ab,kf.	90718

95	62 or 70 or 93 or 94 [SOCIOECONOMIC IMPACT]	1989256
96	42 and 95 [COVID MH ISSUES SocEc IMPACT]	622
97	6 or 15 [AFTER COVID OR PCC]	43618
98	exp Mental health services/	106543
99	Psychiatric rehabilitation/	741
100	exp Psychotherapy/	221046
101	Psychosocial support systems/	1009
102	or/98-101	316912
103	Help-Seeking Behavior/ or Patient acceptance of health care/ or "Referral and consultation"/	131170
104	102 and 103	13095
105	exp Mental Health Services/ec, sd, sn [Statistics and numerical data, Supply & distribution, Economic aspects]	17739
106	Psychiatric Rehabilitation/ec, sd, sn	45
107	Psychotherapy/ec, sd, sn	1527
108	or/105-107	19066
109	((cogniti* or "e-mental health" or "e-mentalhealth" or "emental health" or "ementalhealth" or helpline* or help-line* or hotline or hot-line or "mental health" or psycholog* or psychosocial or psycho-social or psychiatr* or suicid* or telepsychiatr* or tele-psych*) adj5 (assessment* or burden or consults or consultation* or counsel?ing or evaluation* or impact* or referral* or shortage* or seek or seeking or sought or strain* or therapy or therapies or treatment* or "use" or usage* or utilis* or utiliz* or visit or visits)).ti,ab,kf.	271916
110	104 or 108 or 109 [MH SERVICES USE]	291674
111	97 and 110 [AFTER COVID/PCC + MH SERVICES USE]	1900
112	96 or 111 [AFTER COVID/PCC - SOCIOEC IMPACT OR MH SERVICES USE]	2369

113	(Case Reports.pt. or (case report? or case study or case studies).ti.) not (review* or trial*).ti,ab,kf,hw.	2171816
114	(comment or editorial or news or newspaper article).pt.	1719976
115	112 not (113 or 114) [Remove editorials, etc]	2287
116	remove duplicates from 115	2270

Ovid Embase

#	Searches	Results
1	("after covid*" or post-covid* or postcovid* or post-coronavir* or postcoronavir* or post-sarscov* or post-sars-cov*).ti,ab.	20778
2	((convalesc* or post-acute or postacute or "after acute" or "after discharg*" or "after hospital discharg*" or "after recover*" or "following acute" or post-infect* or postrecovery or post-recovery or post-viral or postviral or post-discharg* or postdischarg* or survivor\$1) adj3 (COVID or COVID-19 or COVID19 or coronavirus* or corona virus* or 2019-nCoV or 19nCoV or 2019nCoV or nCoV or n-CoV or SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or 2019-novel CoV or sarscov* or "sars cov 2" or "sars cov2" or Sars-coronavirus2 or "novel CoV" or "severe acute respiratory syndrome")).ti,ab.	8202
3	(("after" or "at least" or beyond or exceeding or follow* or "greater than" or "in excess of" or later* or longer or "more than" or surpassing or upward* or longitud*) adj3 (week? or wk or wks or month? or mo or mos or year? or yr or yrs)).ti,ab.	2672418
4	(COVID or COVID-19 or COVID19 or coronavirus* or corona virus* or 2019-nCoV or 19nCoV or 2019nCoV or nCoV or n-CoV or SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or 2019- novel CoV or sarscov* or "sars cov 2" or "sars cov2" or Sars-coronavirus2 or "novel CoV" or "severe acute respiratory syndrome").ti,ab.	462412
5	3 and 4	35465
6	or/1-2,5 [AFTER COVID]	55072
7	long COVID/	6572
8	coronavirus disease 2019/rh	328

9	("postcovid condition*" or "post-covid condition*" or "postcovid syndrome*" or "post-covid syndrome*").ti,ab.	915
10	((longhaul or long-haul or long or longterm or long-term) adj (COVID or COVID-19 or COVID19 or coronavirus* or corona virus*)).ti,ab.	4791
11	(PASC or ((postacute or post-acute) adj2 (COVID or COVID-19 or COVID19 or coronavirus* or corona virus* or sarscov* or "sars cov 2" or "sars cov2" or "severe acute respiratory syndrome"))).ti,ab.	1763
12	((COVID* or coronavirus* or "corona virus*" or ICD or "International Classification of Diseases" or "international statistical classification of diseases") and (B94* or Uo9* or RA02*)).ti,ab.	48
13	((late-effect* or late-onset or persist* or postrecovery or post-recovery or "after initial infection") adj3 (COVID or COVID-19 or COVID19 or coronavirus* or corona virus* or 2019-nCoV or 19nCoV or 2019nCoV or nCoV or n-CoV or SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or 2019- novel CoV or sarscov* or "sars cov 2" or "sars cov2" or Sars-coronavirus2 or "novel CoV" or "severe acute respiratory syndrome")).ti,ab.	2815
14	(("covid* care" or longcovid* or long-covid* or longhaul* or long-haul* or PASC or "postacute covid*" or "post-acute covid*" or "postacute sars*" or "post-acute sars*" or "post severe acute respiratory syndrome" or postcovid* or post-covid*) adj3 (centre or centres or center or centers or clinic or clinics or integrative or interdisciplinary or inter-disciplinary or multidisciplinary or multi-disciplinary or program or programs or programme or programmes or rehab or rehabilitation)).ti,ab.	890
15	or/7-14 [PCC]	11678
16	((emotional or mental) adj (health or hygiene or wellbeing or well-being or wellness)).ti,ab.	242479 292070
18	exp mental disease/	2748391
19	exp psychological adjustment/	10912
20	exp emotion/ or sadness/	794151
21	exp mental stress/	206269

22	(anxious* or Anxiet* or "attempted suicide*" or bereavement or bipolar* or compulsive* or compulsion* or Coping or Coronaphobia or delusion* or depressed or depressi* or dysthymi* or "Emotional regulation" or "emotional distress" or "Emotional disregulation" or "Emotional dysregulation" or fear* or grief or grieving or Hypochondriasis or hypomania or hypomanic or hypo-	1472940
	mania or hypo-manic or mania or manic or neuros#s or neurotic or obsession* or obsessive* or panic* or phobia* or phobic or post-trauma* or posttrauma* or PTSD or psychosis or psychoses or psychotic or selfharm* or self-harm* or self-injur* or selfinjur* or Suicidal* or worried or worries or	
	worry*).ti,ab.	
23	((adjustment or affective or alcohol-induced or amnestic* or attention-deficit or ADHD or behaviour* or behavior* or conduct or compulsi* or conversion or dissociative or eating or emotional or hyperactiv* or hyper-activ* or impulse or impulsive* or mental or mood or neuro-behavio?ral or neuro-cognitive or neuro-psych* or neurobehavio?ral or neurocognitive or neuropsych* or obsessi* or personality or psychiatric or psychological or stress or trauma or somatoform or sleep or tic or tics or drug-induced or social functioning) adj1 (condition* or diagnos#s or disorder* or disturbed or disturbance* or episod* or ill or illness* or impact* or phenomena or phenomenon or sequela* or symptom*)).ti,ab.	680507
24	((alcoholism or (alcohol or anxiolytic* or drug? or hypnotic* or multi-drug? or multidrug? or nicotine or tobacco or opiate* or opioid* or poly-drug? or polydrug? or polysubstance? or poly-substance? or psychoactive* or medication or psycho-active * or sedative* or stimulant? or substance?)) adj3 (abus* or addict* or "mis-us*" or misus* or "over-us*" or overus* or "problem* use" or "use disorder*")).ti,ab.	211722
25	Mental fatigue/	769
26	cognitive defect/ or mild cognitive impairment/	251759
27	(exp disorders of higher cerebral function/ or perception disorder/) not mental deficiency/	944041
28	((brain or cognitive or mental or mind or thinking) adj (confusion or fatigue or fog or fogg* or cloud* or fuzz*)).ti,ab.	5278
29	((cognitive or cognition) adj1 (disorder* or dysfunction or impact* or impair*)).ti,ab.	178098
30	or/16-29 [MENTAL HEALTH ISSUES]	4075310
31	*incidence/ or *prevalence/ or *risk/ or *odds ratio/	200594

32	(Incidence* or prevalen* or probabilit* or predict* or risk or risks or "odds ratio*").ti,ab.	8257118
33	((new or newly or recent) adj3 (onset or diagnos\$2 or problem\$1)).ti,ab.	230157
34	(declin* or deteriorat* or provok* or provocation or recur* or trigger* or worsen*).ti,ab.	2583392
35	(rate or rates).ti,kf.	372357
36	(incident adj3 (anxious* or anxiety or cogniti* or depress* or "mental health" or "mental disorder*" or "mental illness*" or mood or neurocogniti* or neuro-cogniti* or neuropsych* or neuro-psych* or psych*)).ti,ab.	3195
37	or/31-36 [NEW ONSET]	10296807
38	30 and 37 [NEW ONSET MH ISSUES]	1431111
39	6 and 38 [NEW ONSET MH ISSUES AFTER COVID]	7181
40	15 and 30 [PCC + MH Issues]	3923
41	39 or 40 [PCC + MH ISSUES OR NEW ONSET MH ISSUES AFTER COVID]	9600
42	employment/	78981
43	return to work/ or work resumption/	13573
44	return to school/ or school reentry/	721
45	((assum* or reenter* or re-enter* or reentry or re-entry or restart* or resum* or return* or start*) adj3 (employ* or job or jobs or work* or college or school or university)).ti,ab.	37488
46	(back-to-work or employabilit* or workabilit*).ti,ab.	3669
47	((able or abilit* or capabl* or incapabl* or capacit* or incapacit* or disable* or disabilit* or inabilit* or unable* or limit*) adj5 (employ* or job or jobs or work* or college or school or university)).ti,ab.	106159
48	medical leave/	8849
49	((disabilt* or sick* or ill or illness* or unwell or "not well") adj5 (days or leave or "time off" or absenc* or absent* or presenc* or present)).ti,ab.	36461
50	((shortterm or short-term or longterm or long-term) adj3 (disabl* or disabilit*)).ti,ab.	9256

51	absenteeism/	20180
52	presenteeism/	2471
53	(absence* or absentee* or presentee* or leaveism or leavism).ti,ab.	938870
54	"labo?r participation".ti,ab.	173
55	occupational medicine/	12457
56	((industrial* or occupational*) adj medicine).ti,ab.	6960
57	productivity/	50857
58	((efficien* or productiv*) adj3 (declin* or decreas* or diminish* or less* or lose or losing or loss or losses or lost or low or lower* or reduc*)).ti,ab.	129955
59	((labo?r or staff*) adj1 (impact* or issue or issues or shortage*)).ti,ab.	3526
60	("work ability index" or "work productivity and impairment questionnaire" or "occupational status item" or "symptom burden questionnaire for long covid").ti,ab.	750
61	or/42-60 [WORK PRODUCTIVITY]	1360388
61 62	or/42-60 [WORK PRODUCTIVITY] exp health care cost/	1360388 347261
61 62 63	or/42-60 [WORK PRODUCTIVITY] exp health care cost/ exp "cost of illness"/	1360388 347261 21518
61 62 63 64	or/42-60 [WORK PRODUCTIVITY] exp health care cost/ exp "cost of illness"/ ((disease or diseases or disabilit* or sick* or ill or illness* or unwell or "not well") adj5 (cost or costs or costly or costing or economic* or expenditure? or expens* or financ*)).ti,ab.	1360388 347261 21518 54827
61 62 63 64 65	or/42-60 [WORK PRODUCTIVITY] exp health care cost/ exp "cost of illness"/ ((disease or diseases or disabilit* or sick* or ill or illness* or unwell or "not well") adj5 (cost or costs or costly or costing or economic* or expenditure? or expens* or financ*)).ti,ab. (burden* adj1 (health or healthcare or "health care")).ti,ab.	1360388 347261 21518 54827 16317
61 62 63 64 65 66	or/42-60 [WORK PRODUCTIVITY]exp health care cost/exp "cost of illness"/((disease or diseases or disabilit* or sick* or ill or illness* or unwell or "not well") adj5 (cost or costs or costly or costing or economic* or expenditure? or expens* or financ*)).ti,ab.(burden* adj1 (health or healthcare or "health care")).ti,ab.financial stress/ or financial distress/	1360388 347261 21518 54827 16317 4090
61 62 63 64 65 66 67	or/42-60 [WORK PRODUCTIVITY] exp health care cost/ exp "cost of illness"/ ((disease or diseases or disabilit* or sick* or ill or illness* or unwell or "not well") adj5 (cost or costs or costly or costing or economic* or expenditure? or expens* or financ*)).ti,ab. (burden* adj1 (health or healthcare or "health care")).ti,ab. financial stress/ or financial distress/ ((econom* or financ*) adj3 (challeng* or difficult* or distress* or hardship* or pressur* or problem* or strain*)).ti,ab.	1360388 347261 21518 54827 16317 4090 29750
61 62 63 64 65 66 67 68	or/42-60 [WORK PRODUCTIVITY] exp health care cost/ exp "cost of illness"/ ((disease or diseases or disabilit* or sick* or ill or illness* or unwell or "not well") adj5 (cost or costs or costly or costing or economic* or expenditure? or expens* or financ*)).ti,ab. (burden* adj1 (health or healthcare or "health care")).ti,ab. financial stress/ or financial distress/ ((econom* or financ*) adj3 (challeng* or difficult* or distress* or hardship* or pressur* or problem* or strain*)).ti,ab. ((econom* or financ*) adj burden*).ti,ab.	1360388 347261 21518 54827 16317 4090 29750 41737
61 62 63 64 65 66 67 68 68 69	or/42-60 [WORK PRODUCTIVITY] exp health care cost/ exp "cost of illness"/ ((disease or diseases or disabilit* or sick* or ill or illness* or unwell or "not well") adj5 (cost or costs or costly or costing or economic* or expenditure? or expens* or financ*)).ti,ab. (burden* adj1 (health or healthcare or "health care")).ti,ab. financial stress/ or financial distress/ ((econom* or financ*) adj3 (challeng* or difficult* or distress* or hardship* or pressur* or problem* or strain*)).ti,ab. ((econom* or financ*) adj burden*).ti,ab.	1360388 347261 21518 54827 16317 4090 29750 29750 41737 464094

71	Cost/	63791
72	exp Health Economics/	1052441
73	Budget/	34164
74	budget*.ti,ab,kf.	49153
75	(economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or finance or finances or financed).ti,kf.	356219
76	(economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or finance or finances or financed).ab. /freq=2	551423
77	(cost* adj2 (effective* or utilit* or benefit* or minimi* or analy* or outcome or outcomes)).ab,kf.	301323
78	(value adj2 (money or monetary)).ti,ab,kf.	4228
79	Statistical Model/	176015
80	exp economic model/	4002
81	economic model*.ab,kf.	6507
82	Probability/	150710
83	markov.ti,ab,kf.	39471
84	monte carlo method/	52272
85	monte carlo.ti,ab,kf.	65216
86	Decision Theory/	1859
87	Decision Tree/	23059
88	(decision* adj2 (tree* or analy* or model*)).ti,ab,kf.	54781
89	or/70-88 [Economic evaluation & models - CADTH]	2060146

90	((socioeconomic* or socio-economic* or economic or economical or economies or economy or societ* or labo?r or productivity or "mental health care" or "mental healthcare" or "mental health service*") adj2 (impact\$1 or effect\$1 or burden\$1 or cost\$1 or loss or losses)).ti,ab.	119083
91	61 or 69 or 89 or 90 [SOCIOECONOMIC IMPACT]	3402473
92	41 and 91 [COVID MH ISSUES SocEc IMPACT]	1455
93	6 or 15 [AFTER COVID OR PCC]	59662
94	exp mental health service/	66831
95	psychosocial rehabilitation/ or mental health recovery/	2782
96	exp psychotherapy/	300861
97	psychosocial care/	23764
98	or/94-97	379921
99	help seeking behavior/ or patient referral/	177720
100	98 and 99	9937
101	((cogniti* or "e-mental health" or "e-mentalhealth" or "emental health" or "ementalhealth" or helpline* or hotline or hot-line or "mental health" or psycholog* or psychosocial or psycho-social	367495
102	100 or 101 [MH SERVICES USE]	373393
103	93 and 102 [AFTER COVID/PCC + MH SERVICES USE]	2488
104	92 or 103 [AFTER COVID/PCC - SOCIOEC IMPACT OR MH SERVICES USE]	3658
105	(Case Reports.pt. or (case report? or case study or case studies).ti.) not (review* or trial*).ti,ab,kf,hw.	361950
106	(comment or editorial or news or newspaper article).pt.	791889
107	104 not (105 or 106) [Remove editorials, opinion pieces etc]	3573

108	remove duplicates from 107	3511
		1

Ovid PsycInfo

#	Searches	Results
1	("after covid*" or post-covid* or postcovid* or post-coronavir* or postcoronavir* or post-sarscov* or post-sars-cov*).ti,ab,id.	1362
2	((convalesc* or post-acute or postacute or "after acute" or "after discharg*" or "after hospital discharg*" or "after recover*" or "following acute" or post-infect* or postrecovery or post-recovery or post-viral or postviral or post-discharg* or postdischarg* or survivor\$1) adj3 (COVID or COVID-19 or COVID19 or coronavirus* or corona virus* or 2019-nCoV or 19nCoV or 2019nCoV or nCoV or n-CoV or SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or 2019-novel CoV or sarscov* or "sars cov 2" or "sars cov2" or Sars-coronavirus2 or "novel CoV" or "severe acute respiratory syndrome")).ti,ab,id.	391
3	(("after" or "at least" or beyond or exceeding or follow* or "greater than" or "in excess of" or later* or longer or "more than" or surpassing or upward* or longitud*) adj3 (week? or wk or wks or month? or mo or mos or year? or yr or yrs)).ti,ab,id.	265891
4	(COVID or COVID-19 or COVID19 or coronavirus* or corona virus* or 2019-nCoV or 19nCoV or 2019nCoV or nCoV or n-CoV or SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or 2019-novel CoV or sarscov* or "sars cov 2" or "sars cov2" or Sars-coronavirus2 or "novel CoV" or "severe acute respiratory syndrome").ti,ab,id.	43086
5	3 and 4	2592
6	or/1-2,5 [AFTER COVID]	3932
7	Post-COVID-19 Conditions/	158
8	("postcovid condition*" or "post-covid condition*" or "postcovid syndrome*" or "post-covid syndrome*").ti,ab,id.	60
9	((longhaul or long-haul or long or longterm or long-term) adj (COVID or COVID-19 or COVID19 or coronavirus* or corona virus*)).ti,ab,id.	263

Т

10	(PASC or ((postacute or post-acute) adj2 (COVID or COVID-19 or COVID19 or coronavirus* or corona virus* or sarscov* or "sars cov 2" or "sars cov2" or "severe acute respiratory syndrome"))).ti,ab,id.	88
11	((COVID* or coronavirus* or "corona virus*" or ICD or "International Classification of Diseases" or "international statistical classification of diseases") and (B94* or U09* or RA02*)).ti,ab,id.	0
12	((late-effect* or late-onset or persist* or postrecovery or post-recovery or "after initial infection") adj3 (COVID or COVID-19 or COVID19 or coronavirus* or corona virus* or 2019-nCoV or 19nCoV or 2019nCoV or nCoV or n-CoV or SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or 2019-novel CoV or sarscov* or "sars cov 2" or "sars cov2" or Sars-coronavirus2 or "novel CoV" or "severe acute respiratory syndrome")).ti,ab,id.	117
13	(("covid* care" or longcovid* or long-covid* or longhaul* or long-haul* or PASC or "postacute covid*" or "post-acute covid*" or "postacute sars*" or "post-acute sars*" or "post severe acute respiratory syndrome" or postcovid* or post-covid*) adj3 (centre or centres or center or centers or clinic or clinics or integrative or interdisciplinary or inter-disciplinary or multidisciplinary or multi-disciplinary or program or programs or programme or programmes or rehab or rehabilitation)).ti,ab,id.	34
14	or/7-13 [PCC]	449
15	Mental Health/ or Emotional Health/	94307
16	((emotional or mental) adj (health or hygiene or wellbeing or well-being or wellness)).ti,ab.	246075
17	exp Mental Disorders/ or Psychiatric Symptoms/	1097994
18	exp Emotional Adjustment/	23216
19	exp Emotional States/	373632
20	Emotional Disturbances/ or exp Psychological Stress/ or Occupational Stress/	45883
21	(anxious* or Anxiet* or "attempted suicide*" or bereavement or bipolar* or compulsive* or compulsion* or Coping or Coronaphobia or delusion* or depressed or depressi* or dysthymi* or "Emotional regulation" or "emotional distress" or "Emotional disregulation" or "Emotional dysregulation" or fear* or grief or grieving or Hypochondriasis or hypomania or hypomanic or hypo- mania or hypo-manic or mania or manic or neuros#s or neurotic or obsession* or obsessive* or panic* or phobia* or phobic or post-trauma* or posttrauma* or PTSD or psychosis or psychoses or psychotic or selfharm* or self-harm* or self-injur* or selfinjur* or Suicidal* or worried or worries or worry*).ti,ab.	855479

22	((adjustment or affective or alcohol-induced or amnestic* or attention-deficit or ADHD or behaviour* or behavior* or conduct or compulsi* or conversion or dissociative or eating or emotional or hyperactiv* or hyper-activ* or impulse or impulsive* or mental or mood or neuro-behavio?ral or neuro- cognitive or neuro-psych* or neurobehavio?ral or neurocognitive or neuropsych* or obsessi* or personality or psychiatric or psychological or stress or trauma or somatoform or sleep or tic or tics or drug-induced or social functioning) adj1 (condition* or diagnos#s or disorder* or disturbed or disturbance* or episod* or ill or illness* or impact* or phenomena or phenomenon or sequela* or symptom*)).ti,ab.	439546
23	((alcoholism or (alcohol or anxiolytic* or drug? or hypnotic* or multi-drug? or multidrug? or nicotine or tobacco or opiate* or opioid* or poly-drug? or polydrug? or polysubstance? or poly-substance? or psychoactive* or medication or psycho-active * or sedative* or stimulant? or substance?)) adj3 (abus* or addict* or "mis-us*" or misus* or "over-us*" or overus* or "problem* use" or "use disorder*")).ti,ab.	116076
24	Cognitive Impairment/	45377
25	exp Neurocognitive Disorders/ or Perceptual Disturbances/	113502
26	((brain or cognitive or mental or mind or thinking) adj (confusion or fatigue or fog or fogg* or cloud* or fuzz*)).ti,ab.	1698
27	((cognitive or cognition) adj1 (disorder* or dysfunction or impact* or impair*)).ti,ab.	58320
28	or/15-27 [MENTAL HEALTH ISSUES]	1899794
29	(Incidence* or prevalen* or probabilit* or predict* or risk or risks or "odds ratio*").ti,ab,id.	1134039
30	((new or newly or recent) adj3 (onset or diagnos\$2 or problem\$1)).ti,ab,id.	15163
31	(declin* or deteriorat* or provok* or provocation or recur* or trigger* or worsen*).ti,ab,id.	229991
32	(rate or rates).ti,id.	53754
33	(incident adj3 (anxious* or anxiety or cogniti* or depress* or "mental health" or "mental disorder*" or "mental illness*" or mood or neurocogniti* or neuro-cogniti* or neuropsych* or neuro-psych* or psych*)).ti,ab,id.	1434
34	or/29-33 [NEW ONSET]	1340031

35	28 and 34 [NEW ONSET MH ISSUES]	617081
36	6 and 35 [NEW ONSET MH ISSUES AFTER COVID]	1383
37	14 and 28 [PCC + MH ISSUES]	305
38	36 or 37 [PCC + MH ISSUES OR NEW ONSET MH ISSUES AFTER COVID]	1580
39	Employment Status/	19141
40	Employability/ or Job loss/ or Reemployment/ or Unemployment/	8825
41	((assum* or reenter* or re-enter* or reentry or re-entry or restart* or resum* or return* or start*) adj3 (employ* or job or jobs or work* or college or school or university)).ti,ab,id.	14356
42	(back-to-work or employabilit* or workabilit*).ti,ab,id.	3041
43	((able or abilit* or capabl* or incapabl* or capacit* or incapacit* or disable* or disabilit* or inabilit* or unable* or limit*) adj5 (employ* or job or jobs or work* or college or school or university)).ti,ab,id.	65020
44	Employee Leave Benefits/	1581
45	((disabilt* or sick* or ill or illness* or unwell or "not well") adj5 (days or leave or "time off" or absenc* or absent* or presenc* or present)).ti,ab,id.	8016
46	((shortterm or short-term or longterm or long-term) adj3 (disabl* or disabilit*)).ti,ab,id.	1563
47	Employee Absenteeism/	2458
48	(absence* or absentee* or presentee* or leaveism or leavism).ti,ab,id.	93470
49	"labo?r participation".ti,ab,id.	131
50	((industrial* or occupational*) adj medicine).ti,ab,id.	368
51	exp Job Performance/	24443
52	((efficien* or productiv*) adj3 (declin* or decreas* or diminish* or less* or lose or losing or loss or losses or lost or low or lower* or reduc*)).ti,ab,id.	11202
53	((labo?r or staff*) adj1 (impact* or issue or issues or shortage*)).ti,ab,id.	954

54	("work ability index" or "work productivity and impairment questionnaire" or "occupational status item" or "symptom burden questionnaire for long covid").ti,ab,id.	179
55	or/39-54 [WORK PRODUCTIVITY]	228924
56	exp Health Care Costs/	26195
57	((disease or diseases or disabilit* or sick* or ill or illness* or unwell or "not well") adj5 (cost or costs or costly or costing or economic* or expenditure? or expens* or financ*)).ti,ab,id.	6312
58	(burden* adj1 (health or healthcare or "health care")).ti,ab,id.	1893
59	Financial Strain/	4601
60	((econom* or financ*) adj3 (challeng* or difficult* or distress* or hardship* or pressur* or problem* or strain*)).ti,ab,id.	12763
61	((econom* or financ*) adj burden*).ti,ab,id.	3561
62	or/56-61 [COST OF ILLNESS]	49845
63	Economics/	28322
64	exp "Costs and Cost Analysis"/	50239
65	exp Health Care Economics/	1237
66	Budgets/	1468
67	budget*.ti,ab,id.	10356
68	(economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or finance or finances or financed).ti,id.	87606
69	(economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or finance or finances or financed).ab. /freq=2	108818
70	(cost* adj2 (effective* or utilit* or benefit* or minimi* or analy* or outcome or outcomes)).ab,id.	30529
71	(value adj2 (money or monetary)).ti,ab,id.	1178

72	Statistical Probability/	8241
73	economic model*.ab,id.	1185
74	markov.ti,ab,id.	4850
75	monte carlo.ti,ab,id.	5627
76	Decision Theory/	1412
77	(decision* adj2 (tree* or analy* or model*)).ti,ab,id.	11291
78	or/63-77 [Economic evaluation & models - adapted from CADTH]	213469
79	((socioeconomic* or socio-economic* or economic or economical or economies or economy or societ* or labo?r or productivity or "mental health care" or "mental healthcare" or "mental health service*") adj2 (impact\$1 or effect\$1 or burden\$1 or cost\$1 or loss or losses)).ti,ab,id.	17073
80	55 or 62 or 78 or 79 [SOCIOECONOMIC IMPACT]	443596
81	38 and 80 [COVID MH ISSUES SocEc IMPACT]	197
82	6 or 14 [AFTER COVID/ PPC]	4096
83	exp Mental Health Services/ or Telepsychology/ or Digital Mental Health Resources/	59185
84	exp Psychosocial Rehabilitation/	14758
85	exp Psychotherapy/	224743
86	or/83-85	293768
87	Help Seeking Behavior/ or Professional Referral/ or Professional Consultation/	20354
88	86 and 87	3250
89	((cogniti* or "e-mental health" or "e-mentalhealth" or "emental health" or "ementalhealth" or helpline* or help-line* or hotline or hot-line or "mental health" or psycholog* or psychosocial or psycho-social or psychiatr* or suicid* or telepsychiatr* or tele-psych*) adj5 (assessment* or burden or consults or consultation* or counsel?ing or evaluation* or impact* or referral* or shortage* or seek or seeking or sought or strain* or therapy or therapies or treatment* or "use" or usage* or utilis* or utiliz* or visit or visits)) ti.ab.id.	304405

90	88 or 89 [MH SERVICES USE]	306003
91	82 and 90 [AFTER COVID/PCC + MH SERVICES USE]	708
92	81 or 91 [AFTER COVID/PCC - SOCIOEC IMPACT OR MH SERVICES USE]	844
93	(case report? or case study or case studies).ti. not (review* or trial*).ti,ab,id,hw.	37896
94	(comment or editorial or opinion).dt. [doc type]	44474
95	92 not (93 or 94) [Remove editorials, opinion pieces, etc]	833
96	remove duplicates from 95	831

Included Studies

- 1. Ahmad M, Kim K, Indorato D, Petrenko I, Diaz K, Rotatori F, et al. Post-COVID Care Center to Address Rehabilitation Needs in COVID-19 Survivors: A Model of Care. American J Medical Quality. 2022;37(3):266-71.
- 2. Anik AI, Ahmed T, Nandonik AJ, Parvez A, Das Pooja S, Kabir ZN. Evidence of mental healthrelated morbidities and its association with socio-economic status among previously hospitalized patients with symptoms of COVID-19 in Bangladesh. Frontiers in Public Health. 2023;11:1132136.
- 3. Bek LM, Hellemons ME, Berentschot JC, Visser MM, Huijts SM, van Bommel J, et al. Cognitive and psychological recovery patterns across different care pathways 12 months after hospitalization for COVID-19: A multicenter cohort study (CO-FLOW). Annals of Physical and Rehabilitation Medicine. 2023;66(5):101737.
- 4. Benzakour L, Braillard O, Mazzola V, Gex D, Nehme M, Perone SA, et al. Impact of peritraumatic dissociation in hospitalized patients with COVID-19 pneumonia: A longitudinal study. J Psychiatric Research. 2021;140:53-9.
- 5. Bonazza F, Borghi L, di San Marco EC, Piscopo K, Bai F, Monforte AA, Vegni E. Psychological outcomes after hospitalization for COVID-19: data from a multidisciplinary follow-up screening program for recovered patients. Research in Psychotherapy (Milano). 2020;23(3):491.
- Braga LW, Oliveira SB, Moreira AS, Pereira ME, Carneiro VS, Serio AS, et al. Neuropsychological manifestations of long COVID in hospitalized and non-hospitalized Brazilian Patients. NeuroRehabilitation. 2022;50(4):391-400.
- Brehon K, Niemelainen R, Hall M, Bostick GP, Brown CA, Wieler M, Gross DP. Return-to-Work Following Occupational Rehabilitation for Long COVID: Descriptive Cohort Study. JMIR Rehabilitation and Assistive Ttechnologies. 2022;9(3):e39883.
- 8. Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes Among Patients Hospitalized With COVID-19. Ann Intern Med. 2021;174(4):576-8.
- 9. Chow CM, Schleyer W, DeLisi LE. The prevalence of psychiatric symptoms and their correlates as part of the long-COVID syndrome. Psychiatry Research. 2023;323:115166.
- Danesh V, Arroliga AC, Bourgeois JA, Widmer AJ, McNeal MJ, McNeal TM. Post-acute sequelae of COVID-19 in adults referred to COVID recovery clinic services in an integrated health system in Texas. Proceedings (Baylor University Medical Center). 2021;34(6):645-8.
- Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.
- 12. Decio V, Pirard P, Pignon B, Bouaziz O, Perduca V, Chin F, et al. Hospitalization for COVID-19 is associated with a higher risk of subsequent hospitalization for psychiatric disorders: A French nationwide longitudinal study comparing hospitalizations for COVID-19 and for other reasons. European Psychiatry. 2022;65(1):e70.

- 13. Delgado-Alonso C, Cuevas C, Oliver-Mas S, Diez-Cirarda M, Delgado-Alvarez A, Gil-Moreno MJ, et al. Fatigue and Cognitive Dysfunction Are Associated with Occupational Status in Post-COVID Syndrome. International Journal of Environmental Research And Public Health. 2022;19(20).
- Diem L, Schwarzwald A, Friedli C, Hammer H, Gomes-Fregolente L, Warncke J, et al. Multidimensional phenotyping of the post-COVID-19 syndrome: A Swiss survey study. CNS Neuroscience & Therapeutics. 2022;28(12):1953-63.
- Dressing A, Bormann T, Blazhenets G, Schroeter N, Walter LI, Thurow J, et al. Neuropsychologic Profiles and Cerebral Glucose Metabolism in Neurocognitive Long COVID Syndrome. J Nuclear Medicine. 2022;63(7):1058-63.
- Farooqi M, Khan A, Jacobs A, D'Souza V, Consiglio F, Karmen CL, et al. Examining the Long-Term Sequelae of SARS-CoV2 Infection in Patients Seen in an Outpatient Psychiatric Department. Neuropsychiatric Disease and Treatment. 2022;18:1259-68.
- 17. Formoso G, Marino M, Formisano D, Grilli R. Patterns of utilisation of specialist care after SARS-Cov-2 infection: a retrospective cohort study. BMJ Open. 2023;13(3):e063493.
- Frontera JA, Thorpe LE, Simon NM, de Havenon A, Yaghi S, Sabadia SB, et al. Post-acute sequelae of COVID-19 symptom phenotypes and therapeutic strategies: A prospective, observational study. PloS one. 2022;17(9):e0275274.
- 19. Garcia-Molina A, Garcia-Carmona S, Espina-Bou M, Rodriguez-Rajo P, Sanchez-Carrion R, Ensenat-Cantallops A. Neuropsychological rehabilitation for post-COVID-19 syndrome: results of a clinical programme and six-month follow up. Neurologia. 2022.
- Gramaglia C, Gambaro E, Bellan M, Balbo PE, Baricich A, Sainaghi PP, et al. Mid-term Psychiatric Outcomes of Patients Recovered From COVID-19 From an Italian Cohort of Hospitalized Patients. Frontiers in Psychiatry. 2021;12:667385.
- 21. Green CE, Leeds JS, Leeds CM. Occupational effects in patients with post-COVID-19 syndrome. Occupational Medicine (Oxford, England). 2023.
- Heeney A, Connolly SP, Dillon R, O'Donnell A, McSweeney T, O'Kelly B, et al. Post-COVID care delivery: The experience from an Irish tertiary centre's post-COVID clinic. PLoS ONE. 2023;18(8 August):e0289245.
- 23. Hodgson CL, Higgins AM, Bailey MJ, Mather AM, Beach L, Bellomo R, et al. The impact of COVID-19 critical illness on new disability, functional outcomes and return to work at 6 months: a prospective cohort study. Crit Care. 2021;25(1):382.
- 24. Holland AE, Fineberg D, Marceau T, Chong M, Beaman J, Wilson L, et al. The Alfred Health post-COVID-19 service, Melbourne, 2020-2022: an observational cohort study. The Medical Journal of Australia. 2023.
- 25. Huang L, Li X, Gu X, Zhang H, Ren L, Guo L, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. The Lancet Respiratory medicine. 2022;10(9):863-76.

- 26. Kalyani T, Kumar BV. A Study to Analyze Potential Long-Term Post-COVID Clinical Conditions and Their Management in a Tertiary Care Hospital. International Journal of Pharmaceutical and Clinical Research. 2022;14(8):353-60.
- 27. Kerksieck P, Ballouz T, Haile SR, Schumacher C, Lacy J, Domenghino A, et al. Post COVID-19 condition, work ability and occupational changes in a population-based cohort. The Lancet Regional Health Europe. 2023:100671.
- 28. Kisiel MA, Lee S, Janols H, Faramarzi A. Absenteeism Costs Due to COVID-19 and Their Predictors in Non-Hospitalized Patients in Sweden: A Poisson Regression Analysis. International Journal of Environmental Research and Public Health. 2023;20(22).
- 29. Lazzaroni E, Tosi D, Pontiggia S, Ermolli R, Borghesi L, Rigamonti V, et al. Early psychological intervention in adult patients after hospitalization during COVID-19 pandemia. A single center observational study. Frontiers in Psychology. 2022;13:1059134.
- LeGoff DB, Lazarovic J, Kofeldt M, Peters A. Neurocognitive and Symptom Validity Testing for Post-COVID-19 Condition in a Workers Compensation Context. Journal of Occupational and Environmental Medicine. 2023;65(10):803-12.
- 31. Lemhofer C, Sturm C, Loudovici-Krug D, Guntenbrunner C, Bulow M, Reuken P, et al. Quality of life and ability to work of patients with Post-COVID syndrome in relation to the number of existing symptoms and the duration since infection up to 12 months: a cross-sectional study. Quality of Life Research. 2023;32(7):1991-2002.
- 32. Lunt J, Hemming S, Burton K, Elander J, Baraniak A. What workers can tell us about post-COVID workability. Occup Med (Lond). 2024;74(1):15-23.
- 33. Lynch ST, Dornbush R, Shahar S, Mansour R, Klepacz L, Primavera LH, Ferrando SJ. Change in Neuropsychological Test Performance Seen in a Longitudinal Study of Patients with Post-Acute Sequelae of COVID-19: A 6-Month Follow-up Study. Journal of the Academy of Consultation-Liaison Psychiatry. 2024.
- O'Sullivan O, Houston A, Ladlow P, Barker-Davies RM, Chamley R, Bennett AN, et al. Factors influencing medium- and long-term occupational impact following COVID-19. Occupational Medicine (Oxford, England). 2023.
- 35. Peter RS, Nieters A, Krausslich H-G, Brockmann SO, Gopel S, Kindle G, et al. Post-acute sequelae of covid-19 six to 12 months after infection: population based study. BMJ (Clinical research ed). 2022;379:e071050.
- Rival G, Chalbet S, Dupont C, Brun P, Letranchant L, Reynaud C, et al. Post-traumatic stress among COVID-19 survivors: A descriptive study of hospitalized first-wave survivors. Canadian Journal of Respiratory Therapy. 2023;59:20-5.
- 37. Romero-Rodriguez E, Perula-de Torres LA, Monserrat-Villatoro J, Gonzalez-Lama J, Carmona-Casado AB, Ranchal-Sanchez A. Sociodemographic and Clinical Profile of Long COVID-19 Patients, and Its Correlation with Medical Leave: A Comprehensive Descriptive and Multicenter Study. Healthcare (Basel, Switzerland). 2023;11(19).

- 38. Staples LG, Nielssen O, Dear BF, Bisby MA, Fisher A, Kayrouz R, Titov N. Prevalence and Predictors of Long COVID in Patients Accessing a National Digital Mental Health Service. International journal of environmental research and public health. 2023;20(18).
- 39. Tajer C, Martinez MJ, Mariani J, De Abreu M, Antonietti L. Post COVID-19 syndrome. Severity and evolution in 4673 health care workers. MEDICINA. 2023;83(5):669-82.
- 40. Thompson M, Ferrando SJ, Dornbush R, Lynch S, Shahar S, Klepacz L, Smiley A. Impact of COVID-19 on employment: sociodemographic, medical, psychiatric and neuropsychological correlates. Frontiers in rehabilitation sciences. 2023;4:1150734.
- 41. Tsuchida T, Yoshimura N, Ishizuka K, Katayama K, Inoue Y, Hirose M, et al. Five cluster classifications of long COVID and their background factors: A cross-sectional study in Japan. Clinical and experimental medicine. 2023;23(7):3663-70.
- 42. Umbrello M, Miori S, Sanna A, Lassola S, Baruzzo E, Penzo D, et al. High rates of impaired quality of life and social and economic problems at 6 months after COVID-19-related ARDS. Journal of Anesthesia, Analgesia and Critical Care (Online). 2022;2(1):20.
- 43. Van Wambeke E, Bezler C, Kasprowicz A-M, Charles A-L, Andres E, Geny B. Two-Years Follow-Up of Symptoms and Return to Work in Complex Post-COVID-19 Patients. Journal of Clinical Medicine. 2023;12(3).
- 44. Vanichkachorn G, Newcomb R, Cowl CT, Murad MH, Breeher L, Miller S, et al. Post-COVID-19 Syndrome (Long Haul Syndrome): Description of a Multidisciplinary Clinic at Mayo Clinic and Characteristics of the Initial Patient Cohort. Mayo Clinic Proceedings. 2021;96(7):1782-91.
- 45. Wander PL, Baraff A, Fox A, Cho K, Maripuri M, Honerlaw JP, et al. Rates of ICD-10 Code U09.9 Documentation and Clinical Characteristics of VA Patients With Post-COVID-19 Condition. JAMA Netw Open. 2023;6(12):e2346783.

Excluded Studies

Study design (n=129)

- Ahmadi N, Steinberg A, Pynoos R. The effect of reminder focused positive psychiatry suicide safety (RFPP-S) on COVID-19 related PTSD with PGD. Brain, Behavior, and Immunity. 2021;98(Supplement):1.
- Aitcheson E, Robinson V, FitzMaurice T. Exploring the holistic long-term impact on COVID-19 in a post-hospitalised patient cohort: A service improvement project. Physiotherapy (United Kingdom). 2022;114(Supplement 1):e180.
- Ajili IME, Haddar Y, Riahi A, Mhamdi S, Daboussi S, Aichaouia C, et al. Does being infected with COVID-19 have a psychological impact on healthcare workers? European Respiratory Journal. 2021;58(SUPPL 65).
- 4. Aksunger N, Janssens W, Pradhan M. The cost of a peaceful mind: Evidence from Kenya. Tropical Medicine and International Health. 2021;26(SUPPL 1):178.
- 5. Alhammad A, Aldardeer N, Alqahtani A, Alsaadon A, Alarifi M. Mental Health Assessment Among COVID-19 Patients Survivors of Critical Illness. Intensive Care Medicine Experimental. 2022;10(Supplement 29).
- 6. Andrade R, Sansone D, Farah D, Garcia R, Tannus G, Fonseca M. PRS17 What IF WE HAD NOT Done Any Isolation? Better Little THAN Nothing? Value in Health. 2020;23(Supplement 2):S719.
- Andrade R, Sansone D, Farah D, Garcia R, Tannus G, Fonseca M. PMH16 Productivity, Depression, and Measures to Reduce Social IMPACT: The Economic IMPACT of COVID-19 in Brazil. Value in Health. 2020;23(Supplement 2):S587.
- 8. Andreo Jover J, Vidal-Villegas MP, Mediavilla R, Louzao Rojas I, Cebolla Lorenzo S, Fernandez Jimenez E, et al. Mental health service requirements after hospitalization due to COVID-19: a 1-year follow-up study. European Psychiatry. 2022;65(Supplement 1):S381.
- 9. Anonymous. A longitudinal tele-follow-up study regarding predictors of post-COVID functional status amongst patients who needed hospitalization. Indian Journal of Psychiatry. 2022;64(SUPPL 3):S667.
- 10. Araja D, Berkis U, Lunga A, Murovska M. Shadow Burden of Undiagnosed Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) on Society: Retrospective and Prospective-In Light of COVID-19. Journal of clinical medicine. 2021;10(14).
- Avelino-Silva T, Garcez F, Dias M, Jacob-Filho W, Aliberti M. Fog ahead: delirium and postdischarge cognitive impairment in severe COVID-19. Journal of the American Geriatrics Society. 2022;70(SUPPL 1):S14-S5.
- 12. Ayed W, Chebbi S, Ayadi A, Ayari S, Hazem K, Magroun I. Psychological impact of the covid 19 pandemic on health care workers. European Psychiatry. 2023;66(Supplement 1):S458.
- 13. Ayed W, Chebbi S, Mosbeh M, Ayadi A, Ayari S, Magroun I. Effects of COVID-19 work circumstances on mental health. European Psychiatry. 2023;66(Supplement 1):S814.
- 14. Azevedo H, Santos N, Lafeta M, Souza V, Menezes T, Penido F, et al. Impact of COVID19 on work return after 6 months of hospitalization. European Respiratory Journal. 2022;60(Supplement 66).
- 15. Aziz R, Brode WM, Kelley MA, Alvarado NS, Melamed E. Characteristics of long COVID patients presenting to a dedicated post-COVID-19 clinic. Journal of General Internal Medicine. 2023;38(Supplement 2):S108.

- 16. Babnik K, Staresinic C, Lep Z. Some of the workforce face post COVID after the acute phase of the illness: The employer's supportive role. Human Systems Management. 2022;41(2):257-75.
- 17. Bajar E, Price O, Leitermann M, Garvin D, Oliveira C, Garavan J, Rooney C. Not for Publication A physiotherapy prospective observational study of post-intensive care COVID-19 patients in Tallaght University Hospital) 8.3 Post-Covid Assessment in a Specialist MDT Clinic: A Retrospective Review of Covid-19 Patients requiring High Dependency Oxygen Requirements or ventilation during Hospital Admission. Irish Journal of Medical Science. 2022;191(Supplement 5):S168-S9.
- 18. Bannister S. Neurological rehabilitation post Covid-19. Physiotherapy (United Kingdom). 2022;114(Supplement 1):e189-e90.
- Bates A, Cusack R, Rushbrook S, Shapiro E, Golding H, Pattison N, et al. Can eye movement desensitisation and reprocessing improve psychological recovery following COVID-19 related critical illness? the CovEMERALD feasibility trial. Journal of the Intensive Care Society. 2023;24(1 Supplement):104-5.
- 20. Biehl M, Sarin K, Bishop E, Veith JM, Holztrager M, Bash K, et al. Aiding the recovery of ICU survivors: Creation and implementation of a post-ICU recovery clinic. American Journal of Respiratory and Critical Care Medicine. 2021;203(9).
- Boparai S, Channa H, Dhaliwal L, Walter R, Motayar N. Risk factors associated with developing persistent symptoms after COVID-19: A retrospective study. Critical Care Medicine. 2022;50(1 SUPPL):88.
- 22. Borsi L, Waters A, Bodien Y, Bergin M, Boudreau N, Brown L, et al. Trajectory of Functional Recovery from 6 to 12 Months in Persons Hospitalized for Severe SARS-CoV-2 Illness. Archives of Physical Medicine and Rehabilitation. 2022;103(12):e138.
- 23. Bradley ER, Baron R, Brij SO, Khan WA. Advanced clinical practitioner (acp) hot airways clinic: a 12 month feasibility study. Thorax. 2022;77(Supplement 1):A140-A1.
- 24. Brinkley E, Mack C, Petruski-Ivleva N, Reynolds M, Bourke A, Hawaldar K, Dreyer NA. Patients tell all: Using a direct-to-patient community registry to understand patient burden of COVID-19. Pharmacoepidemiology and Drug Safety. 2021;30(SUPPL 1):98.
- 25. Brown M, Calvert S, James O. ICU follow-up clinic provides the opportunity to recognise and address symptoms post critical illness, which may otherwise have been missed. Journal of the Intensive Care Society. 2023;24(1 Supplement):59-60.
- 26. Brown M, Sanders S. Similar symptoms at 3 months post discharge in ICU, COVID-19 ICU, and COVID-19 patients that received non-invasive ventilation in high dependency areas. Journal of the Intensive Care Society. 2023;24(1 Supplement):53-4.
- Chihaoui A, Saadaoui O, Haddad A, Hammouda Z, Maatouk I, Houri F, et al. Post-traumatic stress disorder in survivors of severe covid-19 infections. Annals of Intensive Care. 2023;13(Supplement 1).
- 28. Chirouze C, Bachelet D, Hulot JS, Cervantes-Gonzalez M, Goehringer F, Lemaignen A, et al. PERSISTENT COVID-19 SYMPTOMS ARE HIGHLY PREVALENT 12 MONTHS after HOSPITALIZATION. Topics in Antiviral Medicine. 2022;30(1 SUPPL):246-7.
- Chisala E, Bahadur S. Meeting the demands of employment: the impact and rehabilitation of chronic pain and fatigue in the uk armed forces. Rheumatology (United Kingdom). 2022;61(SUPPL 1):i102.

- 30. Collins B, Humphrys M, Orford R, Ford R, Charles J. Health-related quality of life in long covid (post-covid-19 syndrome) service users in wales is much worse than the general population. Journal of Epidemiology and Community Health. 2023;77(Supplement 1):A102.
- 31. Diaz-Rodriguez C, Perez-Torres D, Canas-Perez I, Prieto-Lamo AM, Cuenca-Rubio C, Garcia-Garcia MM, et al. Referral to an inpatient rehabilitation facility evaluation of covid-19 patients after icu stay: A prospective cohort study assessing functional status 3 months after hospital discharge. Intensive Care Medicine Experimental. 2021;9(SUPPL 1).
- 32. Douglas DJ, Wolfe KS, Stutz MS, Pearson SD, Lecompte-Osorio P, Lin J, et al. One-Year Trajectories of Cognitive Impairment and Quality of Life in Critically Ill COVID-19 Survivors. American Journal of Respiratory and Critical Care Medicine. 2022;205(1).
- 33. Eilam-Stock T, George A, Lustberg M, Wolintz R, Krupp LB, Charvet LE. Telehealth transcranial direct current stimulation for recovery from Post-Acute Sequelae of SARS-CoV-2 (PASC). Brain Stimulation. 2021;14(6):1520-2.
- 34. Eltarras AM, Pan M, Chi R, Wang S, Czosnowski Q, Kruer R, et al. Post ICU Syndrome, Return to Employment, and Healthcare Utilization Among Critically Ill COVID-19 Survivors. American Journal of Respiratory and Critical Care Medicine. 2023;207(1).
- 35. Essafi F, Sdiri I, Talik I, Benismail K, Silini A, Moez K, Merhabene T. Three months post COVID: Respiratory and psychological sequelae. Intensive Care Medicine Experimental. 2021;9(SUPPL 1).
- 36. Fens T, Zon SKR, Rosmalen JGM, Brouwer S, van Asselt ADI. P4 Cost Analysis of Post-COVID-19 Healthcare Consumption in the Netherlands. Value in Health. 2022;25(12 Supplement):S1-S2.
- Fki A, Sridi C, Hafsia M, Laaroussi R, Ksibi S. Work productivity and activity limitation in healthcare workers after COVID-19 infection. Allergy: European Journal of Allergy and Clinical Immunology. 2023;78(Supplement 111):346.
- Gallegos M, Morgan ML, Burgos-Videla C, Caycho-Rodriguez T, Martino P, Cervigni M. The impact of long Covid on people's capacity to work. Annals of work exposures and health. 2023;67(7):801-4.
- 39. Ganesh A, Rosentreter R, Chen Y, Mehta R, McLeod G, Wan M, et al. Frequency, Persistence, and Patient-reported Outcomes of Neurological Symptoms in Mild COVID-19: Results from the ALBERTA HOPE COVID-19 Trial. Neurology. 2022;98(18 SUPPL).
- 40. Garner O, Kumari Narendra D, Guntupalli K. Characteristics of survivors of COVID-19 seen at a post-acute COVID-19 syndrome clinic. Chest. 2021;160(4 Supplement):A1141-A2.
- 41. Gatti S, Matteo P, Mauri F, Lucchini A, Bellin V, Bettini F, et al. Three-Months Outcome in COVID-19 Critical Care Patients: Results from a Follow-Up Study. Intensive Care Medicine Experimental. 2021;9(SUPPL 1).
- 42. Gaur A, Kukreja I, Mishra N, Roy A, Chopra A, Gupta A, et al. Risk of Psychiatric and Neurological Sequelae after the COVID-19 Infection: A Retrospective Cohort Study Using Claim Data. Value in Health. 2022;25(7 Supplement):S294.
- 43. Gilmartin M, Collins J, Mason S, McDermott G, Baily-Scanlan M, Hevey D, et al. Post-intensive care COVID survivorship clinic: a single centre experience. Critical Care. 2022;26(SUPPL 1).
- 44. Grewal S, Alismail A, Kim V, Monterroso P, Arias C, Patel P, Jeganathan N. Prevalence and characteristics of memory deficits in COVID-19 survivors. Critical Care Medicine. 2022;50(1 SUPPL):56.

- 45. Grossi MB, Liyanage-Don N, Nicholas C, Besagar S, Birger M, Freeman N, et al. COVID-19 patient needs after discharge home: A content analysis of medical records from a COVID remote care program. Journal of General Internal Medicine. 2021;36(SUPPL 1):S41.
- 46. Hamberger J, Jarczok MN, Beschoner P, Buckert D, Kersten J, Gundel H, Weimer K. Patients with functional post-covid symptoms show high utilization of the health care system. Psychosomatic Medicine. 2023;85(4):A124-A5.
- 47. Herrera E, González-Nosti M. The effect of age on cognitive impairment associated with post COVID-19 syndrome. Psychiatry Research. 2022;318.
- 48. Johns KN, Igboeli B, Ortiz-Cruzado E, Aase D, Stern S, Boxley L, et al. Ready for the Long Haul: Rapid Creation and Deployment of a Proactive, Modified Collaborative Care Program for COVID-19 Survivors with Behavioral Health Needs. Journal of the Academy of Consultation-Liaison Psychiatry. 2022;63(Supplement):S90-S1.
- 49. Kannan A, Murad A. Paediatric post covid-19 condition: experience of a northern paediatric post covid-19 assessment centre. Archives of Disease in Childhood. 2022;107(Supplement 2):A121.
- Karalasingham K, Chew D, Hira R, Siddiqui T, Ranada S, Bourne K, et al. Post-acute sequelae of COVID-19 (PASC) patients experience losses of work productivity. Clinical Autonomic Research. 2022;32(5):365-6.
- 51. Karim MA, Wadoo O, Reagu SM, Amro R, Abdulla MA. Telepsychiatry in the Arabian Gulf region-Implications beyond the COVID-19 pandemic. Asian Journal of Psychiatry. 2020;54.
- 52. Kean K, Amato C, Eskin B, Allegra JR. Shifting trends in emergency department pediatric psychiatric visits after the arrival of COVID-19. Academic Emergency Medicine. 2021;28(SUPPL 1):S128-S9.
- 53. Khan K, Hong S, Larmour K, Hussain S. Neurocognitive manifestations of post-COVID syndrome. Critical Care Medicine. 2022;50(1 SUPPL):97.
- 54. Kommaraju K, Biehl M, Bishop E, Veith J, Sarin K, O'Brien J, et al. A description of post intensive care syndrome in COVID19 survivors. American Journal of Respiratory and Critical Care Medicine. 2021;203(9).
- 55. Krotz A, Sosnowsky-Waschek N, Bechtel S, Neumann C, Lohkamp M, Kovacs G, et al. Reducing sick leave, improving work ability, and quality of life in patients with mild to moderate Long COVID through psychosocial, physiotherapeutic, and nutritive supportive digital intervention (MiLoCoDaS): study protocol for a randomized controlled trial. Trials. 2023;24(1).
- 56. Kumar P, Nyberg S, Jiwan R, Ainley A. Post-COVID and the BHRUT one-stop shop MDT approach to managing the longterm sequale of a novel disease process. European Respiratory Journal. 2021;58(SUPPL 65).
- 57. Kupferschmitt A, Hinterberger T, Montanari I, Gasche M, Hermann C, Jobges M, et al. Relevance of the post-COVID syndrome within rehabilitation (PoCoRe): study protocol of a multi-centre study with different specialisations. BMC psychology. 2022;10(1):189.
- Lagali N, Setterud H, Meijer H, Andersson G, Johansson B. Postcovid eye syndrome: ocular symptoms and anterior segment findings. Investigative Ophthalmology and Visual Science. 2023;64(8):1171.
- 59. Lee J, Sim M, Lee D, Hyun S, Kim CH, Kim W. The outcomes of mental health assessments among COVID-19 patients in South Korea. Asia-Pacific Psychiatry. 2021;13(SUPPL 1).
- 60. Lemogne C, Pitron V. Shedding light on the work burden of long COVID. The Lancet Regional Health Europe. 2023;31.

- 61. Liao Y, Tian H, He X, Chen W, Jiang W. The effect of COVID-19 on the working and psychological status of medical staffs in organ donation and transplantation. Transplantation. 2020;104(SUPPL 3):S114.
- 62. Liccari M, Furlanis G, Michelutti M, Manganotti P. Neuro-long-covid: a proposal for the management of memory impairment and cognitive deficits in a neurology ambulatory service. Neurological Sciences. 2022;43(Supplement 1):S325.
- 63. Ling J, Ilchef R. Consultation-liaison psychiatry referrals over 2 years of the covid-19 pandemic. Australian and New Zealand Journal of Psychiatry. 2022;56(SUPPL 1):242.
- 64. Lugosi S, Sanchez S, Verduzco-Gutierrez M. Letter to the Editor on "Race, ethnicity, and utilization of outpatient rehabilitation for treatment of post COVID-19 condition". PM and R. 2023;15(7):932-3.
- 65. Lunt J, Hemming S, Elander J, Burton K, Hanney B. Sustaining work ability amongst female professional workers with long COVID. Occupational Medicine. 2024;74(1):104-12.
- Makam A, Burnfield J, Prettyman E, Votto J. Recovery After Transfer to an LTCH for COVID-19 (RAFT COVID Study): A National Multicenter Cohort. Journal of the American Geriatrics Society. 2022;70(SUPPL 1):S132.
- 67. Martin A, Thomson K, LePrade A, Bertolli J, Grosse SD. PCR61 Persistent Work Limitations in Long COVID: A Cross-Sectional Analysis of Employed US Respondents to the 2022 National Health and Wellness Survey. Value in Health. 2023;26(6 Supplement):S322.
- 68. Masserini F, Pomati S, Cucumo V, Boscacci M, Scarpa C, Dell'Osso B, Pantoni L. Persistent cognitive complaints after COVID-19: a proxy for a maladaptive response to an applied stressor in the unique pandemic environment? Neurological Sciences. 2022;43(Supplement 1):S328.
- 69. Mc Closkey M, Mc Geady M, Laverty R, Khan H, King C, Kelly MG, Sharkey R. Follow up of patients discharged from a Respiratory High Dependency Unit after Covid 19 infection. Irish Journal of Medical Science. 2022;191(Supplement 5):S170.
- 70. Mera-Cordero F, Bonet-Monne S, Almeda-Ortega J, Garcia-Sangenis A, Cunillera-Puertolas O, Contreras-Martos S, et al. Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol. Trials. 2022;23(1):19.
- Millet C, Jimenez H, Racoosin E, Horani G, Shamoon Y, Narvaneni S, et al. The Racial Divide: A Follow Up Study on Racial Disparity Amongst COVID-19 Survivors in an Urban Community in New Jersey. Open Forum Infectious Diseases. 2021;8(SUPPL 1):S330-S1.
- 72. Mirin AA, Dimmock ME, Jason LA. Updated ME/CFS prevalence estimates reflecting post-COVID increases and associated economic costs and funding implications. Fatigue: Biomedicine, Health and Behavior. 2022;10(2):83-93.
- 73. Mohammadi N, Reford E, Spica NR, Tosto J, Tabacof LR, Putrino D, Kellner C. Covid-19 Associated Extreme Fatigue Effects on Activities of Daily Living in Mild and Long-Haul Infections: Patient Perspectives from a Remote Patient Monitoring Program. Neurology. 2022;98(18 SUPPL).
- 74. Monne SB, Cordero FM, Munoz GA, Ortega JA, Martos SC, Puertolas OC, et al. Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-speranza COVID-19 Project study protocol. Basic and Clinical Pharmacology and Toxicology. 2022;130(SUPPL 2):40.

- 75. Monteith T, Cocores A, Mukhtarzada M, Rincon N, Encarnacion YC, Kursewicz C, et al. Headache as an Early Symptom and Post-Acute Sequela of COVID19 in Hospitalized COVID19 Survivors. Neurology. 2022;98(18 SUPPL).
- Munblit D, Simpson F, Mabbitt J, Dunn-Galvin A, Semple C, Warner JO. Legacy of COVID-19 infection in children: Long-COVID will have a lifelong health/economic impact. Archives of Disease in Childhood. 2022;107(3):E2.
- 77. Murdock ME, Kronish IM, Cornelius T, Jurado A, Quispe K, Sullivan A, Liyanage-Don NA. Association between COVID-related psychosocial stressors and mental health outcomes among patients recovering from COVID illness. Psychosomatic Medicine. 2021;83(7):A9-A10.
- 78. Nucera A, Vazzana MR, Papa M. Post-CoViD neurological sequelae. Italian Journal of Medicine. 2021;15(3):52.
- 79. Owen R, Ashton RE, Skipper L, Phillips BE, Yates J, Thomas C, et al. Long COVID quality of life and healthcare experiences in the UK: a mixed method online survey. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2023.
- Padda K, Re'em Y, Faecher D. (PO-071) A Group Psychotherapy for Patients with Post-Acute Sequelae of COVID-19 (PASC) Experiencing Psychological Stress. Journal of the Academy of Consultation-Liaison Psychiatry. 2022;63(Supplement):S34-S5.
- 81. Palazzo M, Prodi TG, Cerioli M, Conti D, Galbassini A, Nicolini G, Dell'Osso B. Telemedicine in Psychiatry: benefits and challenges of the the Home-Hospital Care system (COD20) project. European Psychiatry. 2023;66(Supplement 1):S526-S7.
- 82. Papadopoulou A, Efstathiou V, Koliou E, Papazachos K, Barbari A, Kollia N, et al. Clinical and demographic characteristics of hospitalized patients with COVID-19 referred to a Consultation Liaison Psychiatry Unit. European Psychiatry. 2023;66(Supplement 1):S207.
- 83. Park J, Brady B. CO195 Incidence and Persistence of Post-COVID-19 Conditions in the Year Following Initial Diagnosis. Value in Health. 2023;26(6 Supplement):S51-S2.
- 84. Patel G, Dadey E, Gosal E, O'Neill T, Skyllberg EW, Calderwood CJ, et al. Clinical characteristics, mortality and short term follow up of patients admitted with covid-19 in a North East London NHS Trust: A retrospective analysis. Thorax. 2021;76(SUPPL 1):A5.
- 85. Pauwels S BI, Polli A, Mylle G, De Raeve H, Godderis L. Return to work after long COVID an evidence review. 2021.
- 86. Petry Moecke DM, Kwong E, Yao J, Turner J, McLean K, Den Breejen S, et al. Rehabilitation Needs of Adult British Columbians With Long COVID. American Journal of Respiratory and Critical Care Medicine. 2023;207(1).
- 87. Raut P, Jadhav N, Kale A. Effects of Preventive Health Interventions on COVID Positive Employees of Large Commercial Vehicle Manufacturing Company. Indian Journal of Occupational and Environmental Medicine. 2023;27(1):101.
- 88. Reford E, Mohammadi N, Spica NR, Tosto J, Tabacof LR, Putrino D, Kellner C. Post Covid-19 Neurological Impairment Effects on Activities of Daily Living: Patient Perspectives from a Remote Patient Monitoring Program. Neurology. 2022;98(18 SUPPL).
- 89. Rinaldi L, Pellizon F, Rigo S, Minonzio M, Romeo MA, Bisoglio A, et al. Relationships between autonomic symptoms and work ability in post-COVID19 autonomic syndrome. Clinical Autonomic Research. 2022;32(5):367.
- 90. Roberts L, Kozlowska W. The difficult asthma multi-disciplinary clinic: Silver linings of the COVID cloud. Archives of Disease in Childhood. 2021;106(SUPPL 1):A85.

- 91. Roesch Ely D, Kramer B, Jaehn A, Merle U, Weisbrod M. Post-Covid Syndrome: A standardized assessment on subjective psychiatric and neuropsychological symptoms. European Psychiatry. 2022;65(Supplement 1):S530-S1.
- 92. Rohde G, Helseth S, Smastuen MC, Mikkelsen HET, Skarstein S, Haraldstad K. Changes in healthrelated quality of life in parents of adolescents, and the impact of gender, sociodemographic and psychological factors, and pain on the changes: A two-year longitudinal study. Quality of Life Research. 2022;31(Supplement 2):S89-S90.
- Roseanne MJ, Thant T, Murray HJ, Dillon J, Golub M. (PO-013) Creating an Effective Clinic Model for Post-COVID Mental Health Treatment. Journal of the Academy of Consultation-Liaison Psychiatry. 2022;63(Supplement):S7.
- 94. Saigal A, Naidu SB, Shah AJ, Brill SE, Jarvis H, Goldring JG, et al. 'Long-COVID': The need for multi-disciplinary working. Thorax. 2021;76(SUPPL 1):A33-A4.
- 95. Saigal A, Shah AJ, Naidu SB, Brown J, Goldring JG, Sood T, et al. Ward vs. Emergency department discharge in patients with COVID-19: Does it make a difference to symptom burden and radiological severity at follow up? Thorax. 2021;76(SUPPL 1):A182.
- 96. Salvador G, Nogueira M, Silva L, Aventurado I, Cendes F, Bandini M, et al. The Analysis of 607 Volunteers Shows a Reduction of Workability in Individuals With LONG-COVID Syndrome Associated With Neuropsychiatric Symptoms. Neurology. 2023;100(17 Supplement 2).
- Santos RAG, Rodriguez Rodriguez M. Cognitive impairment detected by MoCA (Montreal Cognitive Assessment) test after COVID-19 in Mexico. European Journal of Neurology. 2021;28(SUPPL 1):450-1.
- 98. Schamess A, Woschkolup K, Rush LJ, McConnell E, Friedberg A, Saigal T, et al. Three-month outcomes for patients treated in an academic medical center long COVID clinic for cognitive symptoms. Journal of General Internal Medicine. 2023;38(Supplement 2):S132-S3.
- 99. Seyffert SA, Khan SH, Jamil Y, Lindroth HL, Wang S, Khan BA. Beyond the ICU: The association between post intensive care syndrome and survivors of severe COVID-19. American Journal of Respiratory and Critical Care Medicine. 2021;203(9).
- 100. Shadwell C, Vardy E. Follow-up of older people hospitalised with COVID-19 infection: A single centre study. European Geriatric Medicine. 2022;13(Supplement 1):S172.
- 101. Shams-Khan H, Nwosu N, Watkins L, Tack G. Employment status of referrals to a regional Long COVID service in the United Kingdom. European Respiratory Journal. 2022;60(Supplement 66).
- 102. Shamsutdinova N, Lapshina S, Mukhamadieva V, Abdrakipov R, Sukhorukova E, Kupkenova L, Abdulganieva D. Clinical characteristics of post-COVID syndrome in patients with rheumatic diseases in the Republic of Tatarstan. Annals of the Rheumatic Diseases. 2022;81(Supplement 1):1695-6.
- Shechter A, Abdalla M, Raju D, Kronish I, Liyanage-Don N. COVID-19 related worries and sleep disturbances in patients previously hospitalized with COVID-19 illness. Sleep. 2021;44(SUPPL 2):A93.
- 104. Shinde V, Master M, Rajesh R. Post COVID Syndrome in patients with COVID -19 : A Cross-Sectional study. Safety and Health at Work. 2022;13(Supplement):S121.
- 105. Siebler M, Moessinger B, Schmalenbach M, Bonnert J, Waldmann G, Lammers M, et al. Beneficial effects of interdisciplinary stationary rehabilitation in employed and retired patients with the Post-Covid-Syndrome. Neurologie und Rehabilitation. 2022;28(Supplement 1):S43.

- Stolyarova A, Tyvina N, Golovkina D, Vysokova V, Zhao J, Zhang K, Kinkulkina M. Anxiety and depressive disorders in patients with Covid-19. European Psychiatry. 2023;66(Supplement 1):S339-S40.
- Stufano A, Bonfrate L, Portincasa P, Dell'Erba A, Lovreglio P. Long covid and gender differences: implications for return to work. European Journal of Clinical Investigation. 2022;52(Supplement 1):175.
- 108. Tak CR, Landgren K, Hughes P, Ramage M. Long COVID and Mental Health: An Assessment of Health Status and Service Utilization. Journal of Mental Health Policy and Economics. 2023;26(Supplement 1):S31.
- 109. Thiery G, Laurent R, Correia P, Ezingeard E, Eric D, Lachand R, et al. One-year follow-up of patients and relatives after severe COVID-19 related ARDS treated in the intensive care unit. Annals of Intensive Care. 2022;12(Supplement 1).
- 110. Thomas S, Frater J, Davies-Cotter D, Watters A, Lane A. Screening and referral patterns for raised edinburgh postnatal depression scores at mater mother's hospital: current practices and impact of the SARS COVID-19 pandemic on routine care. Australian and New Zealand Journal of Psychiatry. 2022;56(SUPPL 1):95-6.
- 111. Tileubek N, Shamsutdinova N, Mukhamadieva V, Abdulganieva D, Abdrakipov R, Lapshina S. The incidence of post-COVID syndrome in patients with rheumatic diseases. Annals of the Rheumatic Diseases. 2023;82(Supplement 1):1879.
- 112. Topeli A, Halacli B, Ortac Ersoy E, Kilic S, S OC. Short-term physical and mental health outcome of critically-ill COVID-19 patients after discharge from intensive care unit. Intensive Care Medicine Experimental. 2020;8(SUPPL 2).
- 113. Van Voorthuizen E, Peters J, Vercoulen J, Van Den Heuvel M, Van Helvoort H, Van Hees J, Van Den Borst B. Recovering after COVID-19: 10- month follow-up data from a multidisciplinary outpatient clinic. European Respiratory Journal. 2021;58(SUPPL 65).
- 114. Vink M, Vink-Niese F. Is It Useful to Question the Recovery Behaviour of Patients with ME/CFS or Long COVID? Healthcare (Basel, Switzerland). 2022;10(2).
- 115. Weakley KE, Schikler A, Green JV, Blatt DB, Barton SM, Statler VA, Marshall GS. Clinical Features and Long-Term Follow-up of Children Evaluated for Persistent Unwellness Following Acute COVID-19. Open Forum Infectious Diseases. 2022;9(Supplement 2):S459-S60.
- 116. Weidemann DK, Redpath AC, Ashoor I. COVID-19 financial ramifications on the pediatric nephrology workforce. Journal of the American Society of Nephrology. 2020;31:808.
- 117. Weimer K, Hamberger J, Beschoner P, Buckert D, Kersten J, Gundel H, Jarczok MN. Patients with functional post-COVID symptoms show relevant scores and prevalence in psychological screening questionnaires. Psychosomatic Medicine. 2023;85(4):A42.
- 118. White KR, Osman F, Piscitello G, Gerhart J, Greenberg JA. Associations Between COVID-19, Unexpectedness of Death, and Symptoms of PTSD Among Bereaved ICU Surrogates. American Journal of Respiratory and Critical Care Medicine. 2023;207(1).
- 119. Wildi K, LiBassi G, McNicholas B, Rainieri F, Forsyth S, Cho S, et al. Long-Term Impact in Intensive Care Survivors of Coronavirus Disease- 19 (AFTERCOR Study): Preliminary 3-Month Analysis After ICU Discharge. American Journal of Respiratory and Critical Care Medicine. 2022;205(1).

- Williams MK, Crawford CA, Zapolski TC, Hirsh AT, Stewart JC. Longer-term mental health consequences of COVID-19 infection: moderation by race and socioeconomic status. Psychosomatic Medicine. 2023;85(4):A123-A4.
- 121. Wolfe KS, Douglas DJ, Pearson SD, Stutz MR, Lecompte-Osorio PA, Lin J, et al. Functional and quality of life outcomes of critically ill covid-19 survivors at hospital discharge and six months. American Journal of Respiratory and Critical Care Medicine. 2021;203(9).
- 122. Womer J, Sarma N, Hauschildt K, Caldwell E, Admon AJ, Hough CL, Iwashyna TJ. Financial Toxicity Is Associated With Impaired Recovery After Severe COVID-19: Results From the BLUE-CORAL Study. American Journal of Respiratory and Critical Care Medicine. 2023;207(1).
- 123. Wu Q. Understanding the burden of post-covid-19 condition. BMJ. 2023.
- 124. Wynne-Jones G, Chew-Graham C. Why GPs must not lose their role in supporting people back to work. British Journal of General Practice. 2022;72(717):174.
- 125. Yus-Fuertes M, Diez-Cirarda M, Matias-Guiu JA, Gil-Martinez L, Gomez-Ruiz N, Polidura-Arruga C, et al. MR assessment of brain alterations in post-COVID cognitive syndrome. Neuroradiology. 2022;64(Supplement 1):S84.
- 126. Zaidan MF, A PND, Polychronopoulou E, P. Nishi S, G DA, Kuo Yongfang, Sharma G. Health care utilization among patients discharged alive post-COVID-19 hospitalization. Chest. 2022;162(4 Supplement):A519.
- 127. Zhong Y, Ji Q, Zhou L. Sleep disorders of post-COVID-19 conditions. Sleep and Breathing. 2023;27(6):2435-6.
- 128. Ziauddeen N, Gurdasani D, O'Hara ME, Hastie C, Roderick P, Yao G, Alwan NA. Characteristics of long COVID: findings from a social media survey. Journal of Epidemiology and Community Health. 2021;75(Supplement 1):A90.
- 129. Zima BT, Bussing R. The early impact of the COVID-19 pandemic on child mental health service utilization and disparities in care. Journal of the American Academy of Child and Adolescent Psychiatry. 2021;60(10 Supplement):S295-S6.

No outcome of interest (n=70)

- 1. Abd El-Khalik DM, Eltohamy M. Post-COVID-19 depression and anxiety in patients with systemic lupus erythematosus. Lupus. 2023;32(8):974-82.
- Abramoff BA, Dillingham TR, Brown LA, Caldera F, Caldwell KM, McLarney M, et al. Psychological and Cognitive Functioning Among Patients Receiving Outpatient Rehabilitation for Post-COVID Sequelae: An Observational Study. Archives of Physical Medicine and Rehabilitation. 2023;104(1):11-7.
- 3. Ali ST, Kang AK, Patel TR, Clark JR, Perez-Giraldo GS, Orban ZS, et al. Evolution of neurologic symptoms in non-hospitalized COVID-19 "long haulers". Annals of clinical and translational neurology. 2022;9(7):950-61.
- 4. Alqutub S, Mahmoud M, Baksh T. Psychological Impact of COVID-19 on Frontline Healthcare Workers in Saudi Arabia. Cureus. 2021;13(5):e15300.
- Angeles MR, Wanni Arachchige Dona S, Nguyen HD, Le LK-D, Hensher M. Modelling the potential acute and post-acute burden of COVID-19 under the Australian border re-opening plan. BMC public health. 2022;22(1):757.
- 6. Ashktorab H, Challa SR, Singh G, Nanduri S, Ibrahim M, Martirosyan Z, et al. Gastrointestinal Manifestations and Their Association with Neurologic and Sleep Problems in Long COVID-19 Minority Patients: A Prospective Follow-Up Study. Digestive diseases and sciences. 2023.
- 7. Bahmer T, Borzikowsky C, Lieb W, Horn A, Krist L, Fricke J, et al. Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study. EClinicalMedicine. 2022;51:101549.
- Becker JH, Lin JJ, Doernberg M, Stone K, Navis A, Festa JR, Wisnivesky JP. Assessment of Cognitive Function in Patients After COVID-19 Infection. JAMA network open. 2021;4(10):e2130645.
- 9. Bek LM, Berentschot JC, Hellemons ME, Remerie SC, van Bommel J, Aerts JGJV, et al. Return to work and health-related quality of life up to 1 year in patients hospitalized for COVID-19: the CO-FLOW study. BMC medicine. 2023;21(1):380.
- 10. Bernacki EJ, Hunt DL, Tsourmas NF, Yuspeh L, Lavin RA, Kalia N, et al. Attributes of Long Duration COVID-19 Workers' Compensation Claims. J Occup Environ Med. 2022;64(5):e327-e32.
- Boesl F, Audebert H, Endres M, Pruss H, Franke C. A Neurological Outpatient Clinic for Patients With Post-COVID-19 Syndrome - A Report on the Clinical Presentations of the First 100 Patients. Frontiers in neurology. 2021;12:738405.
- 12. Braig S PR, Nieters A, Kräusslich HG, Brockmann SO, Göpel S, Kindle G, Merle U, Steinacker JM, Kern WV, Rothenbacher D. Post-COVID syndrome and work ability 9-12 months after a SARS-CoV-2 infection among over 9000 employees from the general population. IJID Regions. 2024;10:67-74.
- 13. Buonsenso D, Gualano MR, Rossi MF, Valz Gris A, Sisti LG, Borrelli I, et al. Post-Acute COVID-19 Sequelae in a Working Population at One Year Follow-Up: A Wide Range of Impacts from an Italian Sample. International journal of environmental research and public health. 2022;19(17).
- Calabria M, Garcia-Sanchez C, Grunden N, Pons C, Arroyo JA, Gomez-Anson B, et al. Post-COVID-19 fatigue: the contribution of cognitive and neuropsychiatric symptoms. Journal of neurology. 2022;269(8):3990-9.
- Chieffo DPR, Delle Donne V, Massaroni V, Mastrilli L, Belella D, Monti L, et al. Psychopathological profile in COVID-19 patients including healthcare workers: the implications. European review for medical and pharmacological sciences. 2020;24(22):11964-70.
- 16. Cohen K, Ren S, Heath K, Dasmarinas MC, Jubilo KG, Guo Y, et al. Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: Retrospective cohort study. The BMJ. 2022;376:e068414.
- 17. Crivelli L, Calandri I, Corvalan N, Carello MA, Keller G, Martinez C, et al. Cognitive consequences of COVID-19: results of a cohort study from South America. Arquivos de neuro-psiquiatria. 2022;80(3):240-7.
- Davisse-Paturet C, Orri M, Legleye S, Florence AM, Hazo JB, Warszawski J, et al. Suicidal ideation following self-reported COVID-19-like symptoms or serology-confirmed SARS-CoV-2 infection in France: A propensity score weighted analysis from a cohort study. PLoS Medicine. 2023;20(2):e1004171.
- 19. Dawra S, Shrivastava S, Chauhan VS, Asturkar V, Ahmad F, Kumar A, et al. The psychological impact of COVID-19 among newly diagnosed patients: COVID Impact study. Medical journal, Armed Forces India. 2021;77:S333-S7.

- 20. Diez-Cirarda M, Yus M, Gomez-Ruiz N, Polidura C, Gil-Martinez L, Delgado-Alonso C, et al. Multimodal neuroimaging in post-COVID syndrome and correlation with cognition. Brain : a journal of neurology. 2023;146(5):2142-52.
- 21. Efgan MG, Cinaroglu OS, Payza U, Kanter E, Bilgin S. Comparison of suicide attempt cases admitted to emergency services during COVID-19 and before Comparison of suicide attempts during and before COVID-19. Annals of Clinical and Analytical Medicine. 2023;14(Supplement 2):S165-S70.
- 22. Faghy MA, Maden-Wilkinson T, Arena R, Copeland RJ, Owen R, Hodgkins H, Willmott A. COVID-19 patients require multi-disciplinary rehabilitation approaches to address persisting symptom profiles and restore pre-COVID quality of life. Expert review of respiratory medicine. 2022;16(5):595-600.
- Ferrando SJ, Dornbush R, Lynch S, Shahar S, Klepacz L, Karmen CL, et al. Neuropsychological, Medical, and Psychiatric Findings After Recovery From Acute COVID-19: A Cross-sectional Study. Journal of the Academy of Consultation-Liaison Psychiatry. 2022;63(5):474-84.
- 24. Frontera JA, Sabadia S, Lalchan R, Fang T, Flusty B, Millar-Vernetti P, et al. A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City. Neurology. 2021;96(4):e575-e86.
- 25. Fung KW, Baye F, Baik SH, Zheng Z, McDonald CJ. Prevalence and characteristics of long COVID in elderly patients: An observational cohort study of over 2 million adults in the US. PLoS Medicine. 2023;20(4):e1004194.
- 26. Furlanis G, Buoite Stella A, Biaduzzini F, Bellavita G, Frezza NA, Olivo S, et al. Cognitive deficit in post-acute COVID-19: an opportunity for EEG evaluation? Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2023;44(5):1491-8.
- 27. Gaber TAZK, Ashish A, Unsworth A. Persistent post-covid symptoms in healthcare workers. Occupational medicine (Oxford, England). 2021;71(3):144-6.
- 28. Ganesh A, Rosentreter RE, Chen Y, Mehta R, McLeod GA, Wan MW, et al. Patient-reported outcomes of neurologic and neuropsychiatric symptoms in mild COVID-19: a prospective cohort study. CMAJ open. 2023;11(4):E696-E705.
- 29. Garg A, Subramain M, Barlow PB, Garvin L, Hoth KF, Dukes K, et al. Patient experience with healthcare: Feedback for a 'post COVID-19 clinic' at a tertiary care center in rural area. medRxiv. 2021.
- 30. Goodman ML, Molldrem S, Elliott A, Robertson D, Keiser P. Long COVID and mental health correlates: a new chronic condition fits existing patterns. Health psychology and behavioral medicine. 2023;11(1):2164498.
- 31. Graham EL, Clark JR, Orban ZS, Lim PH, Szymanski AL, Taylor C, et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers". Annals of clinical and translational neurology. 2021;8(5):1073-85.
- 32. Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol. 2021;93(2):1013-22.
- 33. Hirahata K, Nawa N, Fujiwara T. Characteristics of Long COVID: Cases from the First to the Fifth Wave in Greater Tokyo, Japan. Journal of Clinical Medicine. 2022;11(21):6457.

- 34. Iob E, Steptoe A, Zaninotto P. Mental health, financial, and social outcomes among older adults with probable COVID-19 infection: A longitudinal cohort study. PNAS Proceedings of the National Academy of Sciences of the United States of America. 2022;119(27):1-9.
- 35. Jacob L, Koyanagi A, Smith L, Tanislav C, Konrad M, van der Beck S, Kostev K. Prevalence of, and factors associated with, long-term COVID-19 sick leave in working-age patients followed in general practices in Germany. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2021;109:203-8.
- Jain A, Gupta P, Mittal AA, Sengar NS, Chaurasia R, Banoria N, et al. Long-term quality of life and work ability among severe COVID-19 survivors: A multicenter study. Dialogues in health. 2023;2:100124.
- 37. Jakobsen KD, O'Regan E, Svalgaard IB, Hviid A. Machine learning identifies risk factors associated with long-term sick leave following COVID-19 in Danish population. Communications medicine. 2023;3(1):188.
- 38. Jaquet P, Legouy C, Le Fevre L, Grinea A, Sinnah F, Franchineau G, et al. Neurologic Outcomes of Survivors of COVID-19-Associated Acute Respiratory Distress Syndrome Requiring Intubation. Critical care medicine. 2022;50(8):e674-e82.
- Kaplan M, Çamurcu AA, Erol S. Post-Coronavirus Disease-2019 Syndrome in Healthcare Workers COVID-19 Enfeksiyonu Geçiren Sağlık Çalışanlarında Post-COVID-19 Sendromunun İncelenmesi. Mediterranean Journal of Infection, Microbes and Antimicrobials. 2022;11.
- 40. Khan M, Majeed S, Ain QT, Nawaz A, Sumra KA, Lammi V, et al. Analysing the psychosocial and health impacts of Long COVID in Pakistan: A cross sectional study. medRxiv. 2023.
- 41. Khanna SK, Khanna N, Malav MK, Bayad HC, Sood A, Abraham L. Profiling Cognitive Impairment in Mild COVID-19 Patients: A Case-Control Study at a Secondary Healthcare Centre in the Hilly Region of North India. Annals of Indian Academy of Neurology. 2022;25(6):1099-103.
- 42. Kikkenborg Berg S, Dam Nielsen S, Nygaard U, Bundgaard H, Palm P, Rotvig C, Vinggaard Christensen A. Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study. The Lancet Child and Adolescent Health. 2022;6(4):240-8.
- 43. Kim S-G, Kwon HC, Kang TK, Kwak MY, Lee S, Lee K, Ko K. COVID-19 Sequelae and Their Implications on Social Services. Journal of Korean medical science. 2022;37(48):e342.
- 44. Kitsios GD, Blacka S, Jacobs J, Mirza T, Naqvi A, Gentry H, et al. Subphenotypes of Self-Reported Symptoms and Outcomes in Long COVID: a prospective cohort study with latent class analysis. medRxiv. 2023.
- 45. Kumar NS, Rose D, Amrutha MK, Babu S, Almeda ND, Dileep R. A retrospective observational study to assess the clinical manifestations and functioning status among covid-19 survivors with and without post-covid syndrome. International Journal of Pharmaceutical Sciences and Research. 2023;14(8):3972-7.
- 46. Kwon J, Milne R, Rayner C, Rocha Lawrence R, Mullard J, Mir G, et al. Impact of Long COVID on productivity and informal caregiving. European Journal of Health Economics. 2023.
- 47. Lear-Claveras A, Aguilar-Latorre A, Olivan-Blazquez B, Couso-Viana S, Claveria-Fontan A. Evolution of Anxiety and Depression in Men during the First Six Months of the COVID-19 Pandemic and Factors Associated with Worsening of Mental Health: Retrospective Longitudinal Study. Journal of Men's Health. 2022;18(9):jomh1809182.

- 48. Miraglia Del Giudice M, Klain A, Dinardo G, D'Addio E, Bencivenga CL, Fontanella C, et al. Behavioral and Sleep Disorders in Children and Adolescents following COVID-19 Disease: A Case-Control Study. Children (Basel, Switzerland). 2023;10(7).
- 49. Nielsen TB, Leth S, Pedersen M, Harbo HD, Nielsen CV, Laursen CH, et al. Mental Fatigue, Activities of Daily Living, Sick Leave and Functional Status among Patients with Long COVID: A Cross-Sectional Study. International journal of environmental research and public health. 2022;19(22).
- 50. Nishimi K, Neylan TC, Bertenthal D, Seal KH, O'Donovan A. Association of psychiatric disorders with clinical diagnosis of long COVID in US veterans. Psychol Med. 2024:1-9.
- 51. O'Brien K, Townsend L, Dowds J, Bannan C, Nadarajan P, Kent B, et al. 1-year quality of life and health-outcomes in patients hospitalised with COVID-19: a longitudinal cohort study. Respir Res. 2022;23(1):115.
- 52. O'Keefe JB, Minton HC, Morrow M, Johnson C, Moore MA, O'Keefe GAD, et al. Postacute Sequelae of SARS-CoV-2 Infection and Impact on Quality of Life 1-6 Months After Illness and Association With Initial Symptom Severity. Open forum infectious diseases. 2021;8(8):ofab352.
- 53. Palladini M, Bravi B, Colombo F, Caselani E, Di Pasquasio C, D'Orsi G, et al. Cognitive remediation therapy for post-acute persistent cognitive deficits in COVID-19 survivors: A proof-of-concept study. Neuropsychological rehabilitation. 2023;33(7):1207-24.
- 54. Pihlaja RE, Kauhanen L-LS, Ollila HS, Tuulio-Henriksson AS, Koskinen SK, Tiainen M, et al. Associations of subjective and objective cognitive functioning after COVID-19: A six-month follow-up of ICU, ward, and home-isolated patients. Brain, behavior, & immunity health. 2023;27:100587.
- 55. Price E, Hollis N, Salganik J, Lykke M, Paolinelli C, Chamovitz S, et al. Implementing a Multidisciplinary Post-COVID Clinic in a Small Community Environment. Archives of rehabilitation research and clinical translation. 2023;5(3):100270.
- 56. Rabaiotti P, Ciraci C, Donelli D, Oggioni C, Rizzi B, Savi F, et al. Effects of Multidisciplinary Rehabilitation Enhanced with Neuropsychological Treatment on Post-Acute SARS-CoV-2 Cognitive Impairment (Brain Fog): An Observational Study. Brain sciences. 2023;13(5).
- 57. Shahar S, Lynch S, Dornbush R, Klepacz L, Smiley A, Ferrando SJ. Frequency and Characteristics of Depression and Its Association with Diminished Quality of Life in a Cohort of Individuals with Post-Acute Sequelae of COVID-19. Neuropsychiatric disease and treatment. 2023;19:2069-79.
- 58. Shanley JE, Valenciano AF, Timmons G, Miner AE, Kakarla V, Rempe T, et al. Longitudinal evaluation of neurologic-post acute sequelae SARS-CoV-2 infection symptoms. Annals of clinical and translational neurology. 2022;9(7):995-1010.
- 59. Simonetti A, Bernardi E, Janiri D, Mazza M, Montanari S, Catinari A, et al. Suicide Risk in Post-COVID-19 Syndrome. Journal of personalized medicine. 2022;12(12).
- 60. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416-27.
- 61. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8(2):130-40.

- 62. Thiruvalluru RK, Sharma MM, Olfson M, Keyes KM, Weissman MM, Pathak J, Xiao Y. Trends in Healthcare Service Disruptions and Associations with COVID-19 Outcomes among Patients with SMI vs. Non-SMI during COVID-19. medRxiv : the preprint server for health sciences. 2023.
- 63. Van Veenendaal VdMI, Onrust M, Paans W, Dieperink W, Van der Voort P. Long-Term Outcomes in COVID-19 ICU Patients: A Prospective Cohort Study. Research square. 2021.
- 64. Vlake JH, Van Bommel J, Hellemons ME, Wils E-J, Bienvenu OJ, Schut AFC, et al. Psychologic Distress and Quality of Life After ICU Treatment for Coronavirus Disease 2019: A Multicenter, Observational Cohort Study. Critical care explorations. 2021;3(8):e0497.
- 65. Vlake JH, van Bommel J, Wils E-J, Bienvenu J, Hellemons ME, Korevaar TI, et al. Intensive Care Unit-Specific Virtual Reality for Critically Ill Patients With COVID-19: Multicenter Randomized Controlled Trial. Journal of medical Internet research. 2022;24(1):e32368.
- 66. Walker S, Goodfellow H, Pookarnjanamorakot P, Murray E, Bindman J, Blandford A, et al. Impact of fatigue as the primary determinant of functional limitations among patients with post-COVID-19 syndrome: a cross-sectional observational study. BMJ open. 2023;13(6):e069217.
- 67. Whittaker HR, Gulea C, Koteci A, Kallis C, Morgan AD, Iwundu C, et al. GP consultation rates for sequelae after acute covid-19 in patients managed in the community or hospital in the UK: population-based study. BMJ (Clinical research ed). 2021;375:e065834.
- 68. Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with covid-19: cohort study. Bmj. 2022;376:e068993.
- 69. Yang X, Yang X, Kumar P, Cao B, Ma X, Li T. Social support and clinical improvement in COVID-19 positive patients in China. Nursing outlook. 2020;68(6):830-7.
- 70. Zhang S, Liu Q, Yang F, Zhang J, Fu Y, Zhu Z, et al. Associations between COVID-19 infection experiences and mental health problems among Chinese adults: A large cross-section study. Journal of Affective Disorders. 2023;340:719-27.

Wrong population for labour force outcome (n=70)

- Admon AJ, Iwashyna TJ, Kamphuis LA, Gundel SJ, Sahetya SK, Peltan ID, et al. Assessment of Symptom, Disability, and Financial Trajectories in Patients Hospitalized for COVID-19 at 6 Months. JAMA network open. 2023;6(2):e2255795.
- 2. Al Dweik R, Rahman MA, Ahamed FM, Ramada H, Al Sheble Y, ElTaher S, et al. COVID-19: Psychological distress, fear, and coping strategies among community members across the United Arab Emirates. PloS one. 2023;18(3):e0282479.
- 3. Ariza M, Cano N, Segura B, Bejar J, Barrue C, Cortes CU, et al. Cognitive and emotional predictors of quality of life and functioning after COVID-19. Annals of clinical and translational neurology. 2023.
- 4. Benoit-Piau J, Tremblay K, Piche A, Dallaire F, Belanger M, d'Entremont M-A, et al. Long-Term Consequences of COVID-19 in Predominantly Immunonaive Patients: A Canadian Prospective Population-Based Study. Journal of clinical medicine. 2023;12(18).
- 5. Bonner C, Ghouralal S-L. Long COVID and Chronic Conditions in the U.S. Workforce: Prevalence, Productivity Loss, and Disability. Journal of occupational and environmental medicine. 2024.

- 6. Cheng D, Calderwood C, Skyllberg E, Ainley A. Clinical characteristics and outcomes of adult patients admitted with COVID-19 in East London: a retrospective cohort analysis. BMJ open respiratory research. 2021;8(1).
- 7. Chommeloux J, Valentin S, Winiszewski H, Adda M, Pineton de Chambrun M, Moyon Q, et al. One-Year Mental and Physical Health Assessment in Survivors after Extracorporeal Membrane Oxygenation for COVID-19-related Acute Respiratory Distress Syndrome. American journal of respiratory and critical care medicine. 2023;207(2):150-9.
- Damant RW, Rourke L, Cui Y, Lam GY, Smith MP, Fuhr DP, et al. Reliability and validity of the post COVID-19 condition stigma questionnaire: A prospective cohort study. EClinicalMedicine. 2023;55:101755.
- 9. Datta BK, Coughlin SS, Fazlul I, Pandey A. COVID-19 and health care-related financial toxicity in the United States: Evidence from the 2022 National Health Interview Survey. American Journal of Infection Control. 2023.
- de Azevedo HMJ, Dos Santos NWF, Lafetá ML, de Albuquerque ALP, Tanni SE, Sperandio PA, Ferreira EVM. Persistence of symptoms and return to work after hospitalization for COVID-19. Jornal Brasileiro de Pneumologia. 2022;48(6).
- 11. Demoule A, Morawiec E, Decavele M, Ohayon R, Malrin R, Galarza-Jimenez MA, et al. Healthrelated quality of life of COVID-19 two and 12 months after intensive care unit admission. Annals of Intensive Care. 2022;12(1):16.
- 12. Ekstrand E, Brogardh C, Axen I, Fange AM, Stigmar K, Hansson EE. Perceived Consequences of Post-COVID-19 and Factors Associated with Low Life Satisfaction. International journal of environmental research and public health. 2022;19(22).
- 13. Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, Sereno M, et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. The Lancet Respiratory medicine. 2021;9(11):1275-87.
- 14. Fitzgerald KC, Mecoli CA, Douglas M, Harris S, Aravidis B, Albayda J, et al. Risk factors for infection and health impacts of the COVID-19 pandemic in people with autoimmune diseases. medRxiv : the preprint server for health sciences. 2021.
- 15. Frontera JA, Yang D, Lewis A, Patel P, Medicherla C, Arena V, et al. A prospective study of longterm outcomes among hospitalized COVID-19 patients with and without neurological complications. Journal of the neurological sciences. 2021;426:117486.
- 16. Galas FRBG, Fernandes HM, Franci A, Rosario AL, Saretta R, Patore L, Jr., et al. In-hospital and Post-discharge Status in COVID-19 Patients with Acute Respiratory Failure Supported With Extracorporeal Membrane Oxygenation. ASAIO journal (American Society for Artificial Internal Organs : 1992). 2023;69(5):e181-e7.
- 17. Harari S, Mannucci PM, Nobili A, Galbussera AA, Fortino I, Leoni O, et al. Post-recovery impact of the second and third SARS-CoV-2 infection waves on healthcare resource utilization in Lombardy, Italy. Internal and Emergency Medicine. 2023;18(7):2011-8.
- Ida FS, Ferreira HP, Vasconcelos AKM, Furtado IAB, Fontenele CJPM, Pereira AC. Post-COVID-19 syndrome: persistent symptoms, functional impact, quality of life, return to work, and indirect costs - a prospective case study 12 months after COVID-19 infection. Cadernos de Saude Publica. 2024;40(2).
- 19. Iwashyna TJ, Kamphuis LA, Gundel SJ, Hope AA, Jolley S, Admon AJ, et al. Continuing Cardiopulmonary Symptoms, Disability, and Financial Toxicity 1 Month After Hospitalization for

Third-Wave COVID-19: Early Results From a US Nationwide Cohort. Journal of Hospital Medicine. 2021;16(9):531-7.

- 20. Izadi N, Najafi A, Sadeghniiat-Haghighi K, Mohammadi H. Characterization of Long COVID and Its Contributing Factors among a Population of Health Care Workers in a 6-Month Follow-up. Medical journal of the Islamic Republic of Iran. 2023;37:29.
- Jaywant A, Gunning FM, Oberlin LE, Santillana M, Ognyanova K, Druckman JN, et al. Cognitive Symptoms of Post-COVID-19 Condition and Daily Functioning. JAMA Network Open. 2024;7(2):E2356098.
- 22. Jacobsen PA, Andersen MP, Gislason G, Phelps M, Butt JH, Kober L, et al. Return to work after COVID-19 infection A Danish nationwide registry study. Public Health. 2022;203:116-22.
- 23. Jamoulle M, Kazeneza-Mugisha G, Zayane A. Follow-Up of a Cohort of Patients with Post-Acute COVID-19 Syndrome in a Belgian Family Practice. Viruses. 2022;14(9).
- 24. Kisiel MA, Lee S, Malmquist S, Rykatkin O, Holgert S, Janols H, et al. Clustering Analysis Identified Three Long COVID Phenotypes and Their Association with General Health Status and Working Ability. Journal of clinical medicine. 2023;12(11).
- 25. Kisiel MA, Nordqvist T, Westman G, Svartengren M, Malinovschi A, Janols H. Patterns and predictors of sick leave among Swedish non-hospitalized healthcare and residential care workers with Covid-19 during the early phase of the pandemic. PloS one. 2021;16(12):e0260652.
- 26. Knight DRT, Munipalli B, Logvinov II, Halkar MG, Mitri G, Dabrh AMA, Hines SL. Perception, Prevalence, and Prediction of Severe Infection and Post-acute Sequelae of COVID-19. The American journal of the medical sciences. 2022;363(4):295-304.
- 27. Kumar M, Ali K, Sharma N, Sharma A, Jain M, Vats S, et al. Evaluation of Mental Health and Quality of Life among Indian Professionals Embarked as COVID-19 Survivors. Journal of lifestyle medicine. 2023;13(1):66-72.
- Ladlow P, Holdsworth DA, O'Sullivan O, Barker-Davies RM, Houston A, Chamley R, et al. Exercise tolerance, fatigue, mental health, and employment status at 5 and 12 months following COVID-19 illness in a physically trained population. Journal of applied physiology (Bethesda, Md : 1985). 2023;134(3):622-37.
- 29. Lemhofer C, Sturm C, Loudovici-Krug D, Best N, Gutenbrunner C. The impact of Post-COVID-Syndrome on functioning - results from a community survey in patients after mild and moderate SARS-CoV-2-infections in Germany. Journal of occupational medicine and toxicology (London, England). 2021;16(1):45.
- Lemhöfer C, Best N, Gutenbrunner C, Loudovici-Krug D, Teixido L, Sturm C. Perceived and Real Work Capacity of Patients with Post-COVID Symptoms after Mild Acute Course: A Analysis of the Rehabilitation Needs Questionnaire (RehabNeQ). Physikalische Medizin Rehabilitationsmedizin Kurortmedizin. 2022;54(3):151-8.
- 31. León-Herrera S, Samper-Pardo M, Oliván-Blázquez B, Sánchez-Recio R, Magallón-Botaya R, Sánchez-Arizcuren R. Loss of socioemotional and occupational roles in individuals with Long COVID according to sociodemographic and clinical factors: Secondary data from a randomized clinical trial. PLoS ONE. 2024;19(2 February).
- 32. Machado FVC, Meys R, Delbressine JM, Vaes AW, Goertz YMJ, van Herck M, et al. Construct validity of the Post-COVID-19 Functional Status Scale in adult subjects with COVID-19. Health and Quality of Life Outcomes. 2021;19(1):40.

- Magnavita N, Arnesano G, Di Prinzio RR, Gasbarri M, Meraglia I, Merella M, Vacca ME. Post-COVID Symptoms in Occupational Cohorts: Effects on Health and Work Ability. International journal of environmental research and public health. 2023;20(9).
- 34. Mendola M, Leoni M, Cozzi Y, Manzari A, Tonelli F, Metruccio F, et al. Long-term COVID symptoms, work ability and fitness to work in healthcare workers hospitalized for Sars-CoV-2 infection. La Medicina del lavoro. 2022;113(5):e2022040.
- 35. Mirin AA. A preliminary estimate of the economic impact of long COVID in the United States. Fatigue: Biomedicine, Health and Behavior. 2022;10(4):190-9.
- 36. Miskowiak KW, Johnsen S, Sattler SM, Nielsen S, Kunalan K, Rungby J, et al. Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2021;46:39-48.
- 37. Miskowiak KW, Pedersen JK, Gunnarsson DV, Roikjer TK, Podlekareva D, Hansen H, et al. Cognitive impairments among patients in a long-COVID clinic: Prevalence, pattern and relation to illness severity, work function and quality of life. Journal of Affective Disorders. 2023;324:162-9.
- 38. Monti G, Leggieri C, Fominskiy E, Scandroglio AM, Colombo S, Tozzi M, et al. Two-months quality of life of COVID-19 invasively ventilated survivors; an Italian single-center study. Acta anaesthesiologica Scandinavica. 2021;65(7):912-20.
- Moy FM, Hairi NN, Lim ERJ, Bulgiba A. Long COVID and its associated factors among COVID survivors in the community from a middle-income country-An online crosssectional study. PLoS ONE. 2022;17(8 August):e0273364.
- 40. Muller K, Poppele I, Ottiger M, Zwingmann K, Berger I, Thomas A, et al. Impact of Rehabilitation on Physical and Neuropsychological Health of Patients Who Acquired COVID-19 in the Workplace. International journal of environmental research and public health. 2023;20(2).
- 41. Nagata T, Nagata M, Hino A, Tateishi S, Ogami A, Tsuji M, et al. Prospective cohort study of workers diagnosed with COVID-19 and subsequent unemployment. Journal of Occupational Health. 2022;64(1).
- 42. Nanwani-Nanwani K, Lopez-Perez L, Gimenez-Esparza C, Ruiz-Barranco I, Carrillo E, Arellano MS, et al. Prevalence of post-intensive care syndrome in mechanically ventilated patients with COVID-19. Scientific reports. 2022;12(1):7977.
- 43. Nehme M, Braillard O, Chappuis F, Courvoisier DS, Kaiser L, Soccal PM, et al. One-year persistent symptoms and functional impairment in SARS-CoV-2 positive and negative individuals. Journal of Internal Medicine. 2022;292(1):103-15.
- 44. Nowak-Kiczmer M, Kubicka-Baczyk K, Niedziela N, Adamczyk B, Wierzbicki K, Bartman W, Adamczyk-Sowa M. The course of COVID-19 infection in patients with multiple sclerosis-The experience of one center based on the population of Upper Silesia. Multiple sclerosis and related disorders. 2021;52:102984.
- 45. O' Mahony L, Buwalda T, Blair M, Forde B, Lunjani N, Ambikan A, et al. Impact of Long COVID on health and quality of life. HRB open research. 2022;5:31.
- 46. O'Regan E, Svalgaard IB, Sorensen AIV, Spiliopoulos L, Bager P, Nielsen NM, et al. A hybrid register and questionnaire study of Covid-19 and post-acute sick leave in Denmark. Nature Communications. 2023;14(1):6266.

- 47. Okawara M, Hirashima K, Igarashi Y, Mafune K, Muramatsu K, Nagata T, et al. Impact of COVID-19 Infection on Work Functioning in Japanese Workers: A Prospective Cohort Study. Safety and Health at Work. 2023;14(4):445-50.
- 48. Oravec MJ. Incidence of post-acute COVID-19 sequelae and predictors for post-COVID infection health care utilization in an integrated health system patient population. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2024;85(2-B):No-Specified.
- 49. Perlis RH, Trujillo KL, Safarpour A, Santillana M, Ognyanova K, Druckman J, Lazer D. Research Letter: Association between long COVID symptoms and employment status. medRxiv. 2022.
- 50. Peter RS, Nieters A, Brockmann SO, Gopel S, Kindle G, Merle U, et al. Association of BMI with general health, working capacity recovered, and post-acute sequelae of COVID-19. Obesity (Silver Spring, Md). 2023;31(1):43-8.
- Potter R, Eisenberg E, Mock V, Bose S. Impact of CIVUD-19 pandemic on identified psychosocial needs of specialty social worker embedded in pulmonary practice. Chest. 2023;164(4 Supplement):A3827.
- 52. Rhead RD, Wels J, Moltrecht B, Shaw RJ, Silverwood RJ, Zhu J, et al. Long COVID and financial outcomes: Evidence from four longitudinal population surveys. medRxiv. 2023.
- 53. Robinson-Lane SG, Sutton NR, Chubb H, Yeow RY, Mazzara N, DeMarco K, et al. Race, Ethnicity, and 60-Day Outcomes After Hospitalization With COVID-19. Journal of the American Medical Directors Association. 2021;22(11):2245-50.
- 54. Salmon D, Slama D, Linard F, Dumesges N, Lebaut V, Hakim F, et al. Factors associated with release relief of Long COVID symptoms at 12-Months and their impact on daily life. medRxiv. 2022.
- 55. Salmon D, Slama D, Linard F, Dumesges N, Lebaut V, Hakim F, et al. Long COVID patients continue to experience significant symptoms at 12 months and factors associated with improvement: a prospective cohort study in France (PERSICOR). International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2023.
- 56. Sansone D, Tassinari A, Valentinotti R, Kontogiannis D, Ronchese F, Centonze S, et al. Persistence of Symptoms 15 Months since COVID-19 Diagnosis: Prevalence, Risk Factors and Residual Work Ability. Life (Basel, Switzerland). 2022;13(1).
- Schilling C, Nieters A, Schredl M, Peter RS, Rothenbacher D, Brockmann SO, et al. Pre-existing sleep problems as a predictor of post-acute sequelae of COVID-19. Journal of sleep research. 2023:e13949.
- 58. Singh P, Mohanti BK, Mohapatra SK, Deep A, Harsha B, Pathak M, Patro S. Post-COVID-19 Assessment of Physical, Psychological, and Socio-Economic Impact on a General Population of Patients From Odisha, India. Cureus. 2022;14(10):e30636.
- 59. Smith JL, Deighton K, Innes AQ, Holl M, Mould L, Liao Z, et al. Improved clinical outcomes in response to a 12-week blended digital and community-based long-COVID-19 rehabilitation programme. Frontiers in medicine. 2023;10:1149922.
- 60. Sorensen AIV, Spiliopoulos L, Bager P, Nielsen NM, Hansen JV, Koch A, et al. Post-acute symptoms, new onset diagnoses and health problems 6 to 12 months after SARS-CoV-2 infection: a nationwide questionnaire study in the adult Danish population. medRxiv. 2022.

- 61. Strasburger C, Hieber D, Karthan M, Juster M, Schobel J. Return to work after Post-COVID: describing affected employees' perceptions of personal resources, organizational offerings and care pathways. Frontiers in public health. 2023;11:1282507.
- 62. Tang S, Horter L, Bosh K, Kassem AM, Kahn EB, Ricaldi JN, et al. Change in unemployment by social vulnerability among United States counties with rapid increases in COVID-19 incidence-July 1-October 31, 2020. PLoS ONE. 2022;17(4 April):e0265888.
- 63. Vandersmissen G, Verbeeck J, Henckens P, Van Dyck J, Wuytens C, Molenberghs G, Godderis L. Sick leave due to SARS-CoV-2 infection. Occupational medicine (Oxford, England). 2023.
- 64. Visconti NRGDR, Cailleaux-Cezar M, Capone D, Dos Santos MIV, Graca NP, Loivos LPP, et al. Long-term respiratory outcomes after COVID-19: a Brazilian cohort study. Revista panamericana de salud publica = Pan American journal of public health. 2022;46:e187.
- 65. Wahlgren C, Divanoglou A, Larsson M, Nilsson E, Ostholm Balkhed A, Niward K, et al. Rehabilitation needs following COVID-19: Five-month post-discharge clinical follow-up of individuals with concerning self-reported symptoms. EClinicalMedicine. 2022;43:101219.
- 66. Wahlgren C, Forsberg G, Divanoglou A, Ostholm Balkhed A, Niward K, Berg S, Levi R. Two-year follow-up of patients with post-COVID-19 condition in Sweden: a prospective cohort study. The Lancet Regional Health Europe. 2023;28:100595.
- 67. Wallin E, Hultstrom M, Lipcsey M, Frithiof R, Rubertsson S, Larsson IM. Intensive care-treated COVID-19 patients' perception of their illness and remaining symptoms. Acta Anaesthesiologica Scandinavica. 2022;66(2):240-7.
- 68. Wiertz CMH, Hemmen B, Sep SJS, Van Santen S, Van Horn YY, Van Kuijk SMJ, Verbunt JA. Life after COVID-19: the road from intensive care back to living a prospective cohort study. BMJ Open. 2022;12(11):e062332.
- 69. Wolff Sagy Y, Feldhamer I, Brammli-Greenberg S, Lavie G. Estimating the economic burden of long-Covid: the additive cost of healthcare utilisation among COVID-19 recoverees in Israel. BMJ global health. 2023;8(7).
- 70. Ziauddeen N, Gurdasani D, O'Hara ME, Hastie C, Roderick P, Yao G, Alwan NA. Characteristics and impact of Long Covid: Findings from an online survey. PloS one. 2022;17(3):e0264331.

Population not post-COVID (n=52)

- 1. Afsharnejad B, Milbourn B, Brown C, Clifford R, Foley K-R, Logan A, et al. Understanding the utility of "Talk-to-Me" an online suicide prevention program for Australian university students. Suicide & life-threatening behavior. 2023;53(5):725-38.
- 2. Alyahya MA, Elshaer IA, Sobaih AEE. The Impact of Job Insecurity and Distributive Injustice Post COVID-19 on Social Loafing Behavior among Hotel Workers: Mediating Role of Turnover Intention. International journal of environmental research and public health. 2021;19(1).
- 3. Ambrosetti J, Macheret L, Folliet A, Wullschleger A, Amerio A, Aguglia A, et al. Psychiatric emergency admissions during and after COVID-19 lockdown: short-term impact and long-term implications on mental health. BMC psychiatry. 2021;21(1):465.
- 4. Antar AAR, Yu T, Demko ZO, Hu C, Tornheim JA, Blair PW, et al. Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection. medRxiv : the preprint server for health sciences. 2023.

- 5. Asiamah N, Muhonja F, Omisore A, Opuni FF, Mensah HK, Danquah E, et al. The association between core job components, physical activity, and mental health in African academics in a post-COVID-19 context. Current psychology (New Brunswick, NJ). 2023;42(9):7235-51.
- 6. Atalla E, Kalligeros M, Giampaolo G, Mylona EK, Shehadeh F, Mylonakis E. Readmissions among patients with COVID-19. Int J Clin Pract. 2021;75(3):e13700.
- 7. Aubouin-Bonnaventure J, Chevalier S, Lahiani F-J, Fouquereau E. Preventing workers' need for recovery and turnover intentions: The protective effect of virtuous organizational practices through work ability. Journal of Workplace Behavioral Health. 2023:No-Specified.
- 8. Baumgartner TJ, Sanborn K, Reta M, Lenards N, Hunzeker A, Zeiler S. Perceptions of burnout in medical dosimetry within a postpandemic work environment. Medical dosimetry : official journal of the American Association of Medical Dosimetrists. 2023;48(2):77-81.
- 9. Bou Sanayeh E, El Chamieh C, Saade MC, Maalouf RG, Bizri M. Post-traumatic stress symptoms experienced by healthcare workers in Lebanon four months following Beirut's ammonium nitrate explosion: a survey-based study. Archives of public health = Archives belges de sante publique. 2022;80(1):156.
- Flament J, Scius N, Zdanowicz N, Regnier M, De Canniere L, Thonon H. Influence of post-COVID-19 deconfinement on psychiatric visits to the emergency department. The American journal of emergency medicine. 2021;48:238-42.
- 11. Goldsmith LP, Anderson K, Clarke G, Crowe C, Jarman H, Johnson S, et al. Service use preceding and following first referral for psychiatric emergency care at a short-stay crisis unit: A cohort study across three cities and one rural area in England. The International journal of social psychiatry. 2023;69(4):928-41.
- 12. Grandey AA, Sayre GM, French KA. "A blessing and a curse": Work loss during coronavirus lockdown on short-term health changes via threat and recovery. Journal of occupational health psychology. 2021;26(4):261-75.
- Ham E, Hilton NZ, Crawford J, Kim S. Psychiatric inpatient services in Ontario, 2019-2021: a crosssectional comparison of admissions, diagnoses and acuity during the COVID-19 prerestriction, restriction and postrestriction periods. CMAJ open. 2023;11(5):E988-E94.
- 14. Harvey-Dunstan TC, Jenkins AR, Gupta A, Hall IP, Bolton CE. Patient-related outcomes in patients referred to a respiratory clinic with persisting symptoms following non-hospitalised COVID-19. Chronic Respiratory Disease. 2022;19.
- 15. Hertz-Palmor N, Moore TM, Gothelf D, DiDomenico GE, Dekel I, Greenberg DM, et al. Association among income loss, financial strain and depressive symptoms during COVID-19: Evidence from two longitudinal studies. Journal of affective disorders. 2021;291:1-8.
- 16. Iasevoli F, Fornaro M, D'Urso G, Galletta D, Casella C, Paternoster M, et al. Psychological distress in patients with serious mental illness during the COVID-19 outbreak and one-month mass quarantine in Italy. Psychological Medicine. 2021;51(6):1054-6.
- Iverson KM, Stolzmann KL, Brady JE, Adjognon OL, Dichter ME, Lew RA, et al. Integrating Intimate Partner Violence Screening Programs in Primary Care: Results from a Hybrid-II Implementation-Effectiveness RCT. American journal of preventive medicine. 2023;65(2):251-60.
- Jacquet LH. Major mental health referral quality improvement project for castle high school staff. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2023;84(1-B):No-Specified.

- 19. Jayawardana D, Gannon B. Use of telehealth mental health services during the COVID-19 pandemic. Australian health review : a publication of the Australian Hospital Association. 2021;45(4):442-6.
- 20. Kameyama K, Mizutani K, Miyake Y, Iwase T, Mizutani Y, Yamada M, et al. Evaluation of physical and psychological status of health care workers infected with COVID-19 during a hospital outbreak in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2023;29(2):126-30.
- 21. Kandiah S, Chamberlain R. Does Implementation of Patient Health Questionnaire Increase Referrals to Behavioral Health Services. Clinical Journal of Sport Medicine. 2023;33(3):328.
- 22. Kim J, Rim SJ, Jo M, Lee MG, Park S. The Trend of Psychiatric Visits and Psychiatric Medication Prescription Among People Tested for SARS-CoV-2 During the Initial Phase of COVID-19 Pandemic in South Korea. Psychiatry Investig. 2022;19(1):61-71.
- 23. Kupferschmitt A, Langheim E, Tuter H, Etzrodt F, Loew TH, Kollner V. First results from post-COVID inpatient rehabilitation. Frontiers in rehabilitation sciences. 2022;3:1093871.
- 24. Lam MH-B, Wing Y-K, Yu MW-M, Leung C-M, Ma RCW, Kong APS, et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Archives of internal medicine. 2009;169(22):2142-7.
- 25. Lee ATC, Mo FYM, Lam LCW. Higher psychogeriatric admissions in COVID-19 than in severe acute respiratory syndrome. International journal of geriatric psychiatry. 2020;35(12):1449-57.
- Leeds LW, Powers J. Implementation of a bystander intervention model to promote referrals to and enhance utilization of mental health resources by students in a community college setting. Dissertation Abstracts International Section A: Humanities and Social Sciences. 2023;84(3-A):No-Specified.
- 27. Lerminiaux D, Somers L. [An analysis of child psychiatric emergency department consultations from 2019 to 2022 in the context of COVID-19]. Face a la COVID-19 Une analyse des consultations aux urgences pedopsychiatriques de 2019 a 2022 dans le contexte de la COVID-19. 2023;78(11):614-8.
- 28. Liu J, Tong Y, Li S, Tian Z, He L, Zheng J. Compliance with COVID-19-preventive behaviours among employees returning to work in the post-epidemic period. BMC public health. 2022;22(1):369.
- 29. Lynch DA, Stefancic A, Cabassa LJ, Medalia A. Client, clinician, and administrator factors associated with the successful acceptance of a telehealth comprehensive recovery service: A mixed methods study. Psychiatry research. 2021;300:113871.
- Mantero V, Basilico P, Balgera R, Rigamonti A, Sozzi M, Salmaggi A, Cordano C. Flu-like syndrome due to interferon-beta injections does not increase anxiety, depression, and lost working days in multiple sclerosis patients during the Sars-CoV-2 pandemic. Clinical Neurology and Neurosurgery. 2023;232:107892.
- McNicholas F, Kelleher I, Hedderman E, Lynch F, Healy E, Thornton T, et al. Referral patterns for specialist child and adolescent mental health services in the Republic of Ireland during the COVID-19 pandemic compared with 2019 and 2018. BJPsych open. 2021;7(3):e91.
- 32. Meirun T, Bano S, Javaid MU, Arshad MZ, Shah MU, Rehman U, et al. Nuances of COVID-19 and Psychosocial Work Environment on Nurses' Wellbeing: The Mediating Role of Stress and Eustress in Lieu to JD-R Theory. Frontiers in psychology. 2020;11:570236.
- 33. Modarres MH, Kalafatis C, Apostolou P, Tabet N, Khaligh-Razavi S-M. The use of the integrated cognitive assessment to improve the efficiency of primary care referrals to memory services in the

accelerating dementia pathway technologies study. Frontiers in aging neuroscience. 2023;15:1243316.

- Monier D, Bonjean P, Carcasset P, Moulin M, Pozzetto B, Botelho-Nevers E, et al. Factors Contributing to Delayed Return to Work among French Healthcare Professionals Afflicted by COVID-19 at a Hospital in the Rhone-Alpes Region, 2021. International journal of environmental research and public health. 2023;20(21).
- 35. Muthumuni N, Sommer JL, El-Gabalawy R, Reynolds KA, Mota NP. Evaluating the mental health status, help-seeking behaviors, and coping strategies of Canadian essential workers versus non-essential workers during COVID-19: a longitudinal study. Anxiety, stress, and coping. 2023:1-14.
- 36. Purrington J, Beail N. The impact of Covid-19 on access to psychological services. Advances in Mental Health and Intellectual Disabilities. 2021;15(4):119-31.
- 37. Puthucheary Z, Brown C, Corner E, Wallace S, Highfield J, Bear D, et al. The Post-ICU presentation screen (PICUPS) and rehabilitation prescription (RP) for intensive care survivors part II: Clinical engagement and future directions for the national Post-Intensive care Rehabilitation Collaborative. Journal of the Intensive Care Society. 2022;23(3):264-72.
- 38. Qiu X, Lan Y, Miao J, Wang H, Wang H, Wu J, et al. A Comparative Study on the Psychological Health of Frontline Health Workers in Wuhan Under and After the Lockdown. Frontiers in psychiatry. 2021;12:701032.
- 39. Sawant N, Ingawale S, Lokhande U, Patil S, Ayub EFM, Rathi V. Psychiatric Sequelae and COVID Experiences of Post COVID -19 Recovered Resident Doctors and Interns of a Tertiary General Hospital in Mumbai. The Journal of the Association of Physicians of India. 2021;69(4):22-6.
- 40. Sonney J, Peck JL. The Cost of Caring During COVID-19: A Clarion Call to Action to Support the Pediatric Advanced Practice Nursing Workforce. Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners. 2023;37(6):658-72.
- 41. Takeuchi E, Katanoda K, Cheli S, Goldzweig G, Tabuchi T. Restrictions on healthcare utilization and psychological distress among patients with diseases potentially vulnerable to COVID-19; the JACSIS 2020 study. Health psychology and behavioral medicine. 2022;10(1):229-40.
- 42. Taylor JL, Adams RE, Pezzimenti F, Zheng S, Bishop SL. Job loss predicts worsening depressive symptoms for young adults with autism: A COVID-19 natural experiment. Autism Research. 2022;15(1):93-102.
- 43. Turan Ş, Poyraz B, Aksoy Poyraz C, Demirel Ö F, Tanrıöver Aydın E, Uçar Bostan B, et al. Characteristics and outcomes of COVID-19 inpatients who underwent psychiatric consultations. Asian J Psychiatr. 2021;57:102563.
- 44. Wang CC, Lo J, Saunders R, Adama E, Bulsara C, Etherton-Beer C, Yang AWH. Light acupuncture and five-element music therapy for nurses' mental health and well-being during and post-COVID-19: protocol for a randomised cross-over feasibility study. BMJ open. 2022;12(4):e057106.
- 45. Wang PR, Anand A, Bena J, Morrison S, Weleff J. Changes in emergency department utilization in vulnerable populations after COVID-19 shelter in place orders. medRxiv. 2023.
- 46. Werling AM, Walitza S, Drechsler R. Impact of the COVID-19 lockdown on screen media use in patients referred for ADHD to child and adolescent psychiatry: an introduction to problematic use of the internet in ADHD and results of a survey. Journal of neural transmission (Vienna, Austria : 1996). 2021;128(7):1033-43.

- 47. Werling AM, Walitza S, Grunblatt E, Drechsler R. Media use before, during and after COVID-19 lockdown according to parents in a clinically referred sample in child and adolescent psychiatry: Results of an online survey in Switzerland. Comprehensive psychiatry. 2021;109:152260.
- 48. Yang Q, Huo J, Li J, Jiang Y. Research on the influence of the COVID-19 epidemic on work stress of returning workers in China: A study based on empirical analyses of industrial enterprises. Work (Reading, Mass). 2020;67(1):67-79.
- 49. Yu X, Langa KM, Cho T-C, Kobayashi LC. Association of Perceived Job Insecurity With Subsequent Memory Function and Decline Among Adults 55 Years or Older in England and the US, 2006 to 2016. JAMA network open. 2022;5(4):e227060.
- 50. Zahedifar F, Nejatifar Z, Rafiei S, Hashemi F. The effect of educational intervention on anxiety and quality of life among individuals referring to healthcare centers in the face of covid-19. Acta Medica Iranica. 2021;59(8):484-90.
- 51. Zhu Z, Xu S, Wang H, Liu Z, Wu J, Li G, et al. COVID-19 in Wuhan: Sociodemographic characteristics and hospital support measures associated with the immediate psychological impact on healthcare workers. EClinicalMedicine. 2020;24:100443.
- 52. Zielasek J, Lehmann I, Vrinssen J, Gouzoulis-Mayfrank E. Analysis of the utilization, processes, and outcomes of inpatient mental healthcare during the first three waves of the COVID-19 pandemic in the federal state of North Rhine-Westphalia, Germany. Frontiers in psychiatry. 2022;13:957951.

Language (n=15)

- August D, Stete K, Hilger H, Gotz V, Biever P, Hosp J, et al. [Complaints and clinical findings six months after COVID-19: outpatient follow-up at the University Medical Center Freiburg]. Persistierende Beschwerden 6 Monate nach COVID-19 - Erfahrungen aus der COVID-19-Nachsorgeambulanz des Universitatsklinikums Freiburg. 2021;146(17):e65-e73.
- 2. Bogolepova AN, Osinovskaya NA, Kovalenko EA, Makhnovich EV. Fatigue and cognitive impairment in post-COVID syndrome: possible treatment approaches. Nevrologiya, Neiropsikhiatriya, Psikhosomatika. 2021;13(4):88-93.
- 3. Delevaux I, Duquenne C, Kokkinakis I, Favrat B. [Neuropsychiatric manifestations of post COVID-19 Syndrome and Disability Insurance (DI)]. Covid long neuropsychiatrique et assurance invalidite (AI). 2023;19(827):992-3.
- 4. Dresing H, Meyer-Lindenberg A. [Future issues in "long COVID" psychiatric assessment]. Kunftige Aufgaben der psychiatrischen Begutachtung bei Long-COVID". 2022;93(3):309-12.
- 5. Gulyaev SA. Dynamic electroencephalographic study of persons mild COVID-19 convalescents. Russkii Zhunal Detskoi Nevrologii. 2022;17(4):44-53.
- 6. Haller J, Kocalevent R-D, Nienhaus A, Peters C, Bergelt C, Koch-Gromus U. [Persistent fatigue symptoms following COVID-19 infection in healthcare workers: risk factors and impact on quality of life]. Anhaltende Fatigue als Folge einer COVID-19-Infektion bei Beschaftigten im Gesundheitswesen: Risikofaktoren und Auswirkungen auf die Lebensqualitat. 2022;65(4):471-80.
- Meskina ER, Khadisova MK, Stashko TV, Galkina LA, Tselipanova EE, Shilkina IM. Efficiency of application of sorbed probiotics in the complex therapy of pneumonia caused by SARS-CoV-2. Quality of life in the short term COVID-19. Infectious Diseases: News, Opinions, Training. 2022;11(3):69-80.

- Petrova NN, Pryanikova EV, Pustotin Yu L, Yakusheva NV, Dorofeikova MV. Post-COVID syndrome in psychiatric practice. Nevrologiya, Neiropsikhiatriya, Psikhosomatika. 2022;14(6):49-54.
- Rover MM, Trott G, Scolari FL, Silva MMDd, Souza Dd, Santos RdRMD, et al. Health-Related Quality of Life and Long-Term Outcomes after Mildly Symptomatic COVID-19: The Post-COVID Brazil Study 2 Protocol. Qualidade de Vida Relacionada a Saude e Desfechos em Longo Prazo apos COVID-19 Sintomatica Leve: Protocolo do Estudo Pos-COVID Brasil 2. 2023;120(9):e20220835.
- Rusinova DS, Vasil'eva TM, Bezymyanny AS, Starshinin AV. Analysis of Employee's Working Capacity in Children's City Outpatient's Clinic 133 of Moscow City Health Department after COVID-19. Pediatricheskaya Farmakologiya. 2021;18(6):507-14.
- 11. Rutsch M, Deck R. [Occupational Stress of Long Covid Rehabilitants and Return to Work After Pneumological Rehabilitation]. Berufliche Belastungen von Long-Covid-Rehabilitand*innen und Ruckkehr zur Arbeit nach einer pneumologischen Rehabilitation. 2023;62(6):369-78.
- 12. Rutsch M, Frommhold J, Buhr-Schinner H, Gross T, Schuller PO, Deck R. [Pneumological Rehabilitation in Patients with Long Covid Health Changes at the End of the Inpatient Rehabilitation Measure]. Pneumologische Rehabilitation bei Long Covid Gesundheitliche Veranderungen am Ende der stationaren Rehabilitationsmasnahme. 2023;62(6):359-68.
- 13. Tamasi J, Kalabay L. Monitoring the development of post-COVID-19 syndrome. Poszt-COVID-19szindromas esetek kialakulasanak követese. 2022;163(9):335-42.
- 14. Trott G, Scolari FL, Rover MM, Silva MMDd, Souza Dd, Santos RdRMD, et al. Long-term Health-Related Quality of Life and Outcomes after Hospitalization for COVID-19 in Brazil: Post-COVID Brazil 1 Study Protocol. Qualidade de Vida em Longo Prazo e Desfechos apos Internacao por COVID-19 no Brasil: Protocolo do Estudo Pos-COVID Brasil 1. 2023;120(11):e20230378.
- 15. Vysokova VO, Tyuvina NA, Maksimova TN, Prokhorova SV. Mental disorders during the pandemic of a new coronavirus infection: clinical features. Nevrologiya, Neiropsikhiatriya, Psikhosomatika. 2023;15(3):60-7.

Author contact, unsuccessful (n=8)

- 1. Adjorlolo S, Adjorlolo P, Andoh-Arthur J, Ahiable EK, Kretchy IA, Osafo J. Post-Traumatic Growth and Resilience among Hospitalized COVID-19 Survivors: A Gendered Analysis. International journal of environmental research and public health. 2022;19(16).
- Bozzani A, Arici V, Tavazzi G, Ragni F, Mojoli F, Cavallini E, et al. Trends (2020-2022) toward Reduced Prevalence of Postcoronavirus Disease Syndrome and Improved Quality of Life for Hospitalized Coronavirus Disease 2019 Patients with Severe Infection and Venous Thromboembolism. Seminars in thrombosis and hemostasis. 2023.
- 3. Liu EN, Yang JH, Patel L, Arora J, Gooding A, Ellis R, Graves JS. Longitudinal analysis and treatment of neuropsychiatric symptoms in post-acute sequelae of COVID-19. Journal of neurology. 2023;270(10):4661-72.
- 4. McLaughlin M, Cerexhe L, Macdonald E, Ingram J, Sanal-Hayes NEM, Hayes LD, et al. A Cross-Sectional Study of Symptom Prevalence, Frequency, Severity, and Impact of Long COVID in Scotland: Part II. The American journal of medicine. 2023.
- 5. Nehme M, Vieux L, Kaiser L, Chappuis F, Chenaud C, Guessous I. The longitudinal study of subjective wellbeing and absenteeism of healthcare workers considering post-COVID condition and the COVID-19 pandemic toll. Scientific reports. 2023;13(1):10759.

- 6. Price JK, de Avila L, Stepanova M, Weinstein AA, Pham H, Keo Wo, et al. Severe, Persistent, Disruptive Fatigue Post-SARS-CoV-2 Disproportionately Affects Young Women. International journal of general medicine. 2023;16:4393-404.
- Romer V, Sivapalan P, Eklof J, Nielsen SD, Harboe ZB, Biering-Sorensen T, et al. SARS-CoV-2 and risk of psychiatric hospital admission and use of psychopharmaceuticals: A nationwide registry study of 4,585,083 adult Danish citizens. European psychiatry : the journal of the Association of European Psychiatrists. 2023;66(1):e50.
- Simkovich SM, Ahmed N, Chou J, McCullers A, Wisotzky EM, Semel J, et al. Health, social, and economic characteristics of patients enrolled in a COVID-19 recovery program. PLoS ONE. 2022;17(11 November):e0278154.

No usable data (n=7)

- 1. Bonham C, Juarez R, Siegal N. Long COVID and Unemployment in Hawaii. Int J Environ Res Public Health. 2023;20(13).
- 2. Galanis P, Katsiroumpa A, Vraka I, Kosiara K, Siskou O, Konstantakopoulou O, et al. Post-COVID-19 syndrome and related dysautonomia affect patients' life and work productivity. medRxiv. 2023.
- 3. Kennedy J, Parker M, Seaborne M, Mhereeg M, Walker A, Walker V, et al. Health care use attributable to COVID-19: A propensity matched national electronic health records cohort study of 249,390 people in Wales, UK. medRxiv. 2022.
- 4. Miskowiak KW, Fugledalen L, Jespersen AE, Sattler SM, Podlekareva D, Rungby J, et al. Trajectory of cognitive impairments over 1 year after COVID-19 hospitalisation: Pattern, severity, and functional implications. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2022;59:82-92.
- Perlis RH, Lunz Trujillo K, Safarpour A, Santillana M, Ognyanova K, Druckman J, Lazer D. Association of Post-COVID-19 Condition Symptoms and Employment Status. JAMA network open. 2023;6(2):e2256152.
- 6. Rafferty E, Unsal A, Kirwin E, Kingdom U. Healthcare costs and effects of post-COVID-19 condition in Canada. Can Commun Dis Rep. 2023;49(10):425-32.
- Yelin D, Margalit I, Nehme M, Bordas-Martinez J, Pistelli F, Yahav D, et al. Patterns of Long COVID Symptoms: A Multi-Center Cross Sectional Study. Journal of Clinical Medicine. 2022;11(4):898.

N <30 with MH for labour force (n=7)

- 1. Dimitrova M, Marinova Y, Dilkov D. Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome. Diagnostics. 2023;13(16).
- Ghosn J, Bachelet D, Livrozet M, Cervantes-Gonzalez M, Poissy J, Goehringer F, et al. Prevalence of post-acute coronavirus disease 2019 symptoms twelve months after hospitalization in participants retained in follow-up: analyses stratified by gender from a large prospective cohort. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2023;29(2):254.e7-.e13.

- Gilmartin M, Collins J, Mason S, Horgan A, Cuadrado E, Ryberg M, et al. Post-Intensive Care COVID Survivorship Clinic: A Single-Center Experience. Critical care explorations. 2022;4(5):e0700.
- 4. Larsson I-M, Hultstrom M, Lipcsey M, Frithiof R, Rubertsson S, Wallin E. Poor long-term recovery after critical COVID-19 during 12 months longitudinal follow-up. Intensive & critical care nursing. 2023;74:103311.
- 5. Park N, Oberlin L, Cherestal S, Bueno Castellano C, Dargis M, Wyka KE, et al. Trajectory and outcomes of psychiatric symptoms in first-wave COVID-19 survivors referred for telepsychotherapy. General Hospital Psychiatry. 2023;81:86-8.
- Rajajee V, Fung CM-C, Seagly KS, Park PK, Raghavendran K, Machado-Aranda DA, et al. One-Year Functional, Cognitive, and Psychological Outcomes Following the Use of Extracorporeal Membrane Oxygenation in Coronavirus Disease 2019: A Prospective Study. Critical care explorations. 2021;3(9):e0537.
- Scherlinger M, Felten R, Gallais F, Nazon C, Chatelus E, Pijnenburg L, et al. Refining "Long-COVID" by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection. Infectious diseases and therapy. 2021;10(3):1747-63.

Duplicates (n=4)

- 1. Benzakour L, Braillard O, Mazzola V, Gex D, Nehme M, Perone SA, et al. P.0805 Impact of peritraumatic dissociation in hospitalized patients with COVID-19 pneumonia: a longitudinal study. European Neuropsychopharmacology. 2021;53(Supplement 1):S589.
- 2. Bonazza F, Luridiana Battistini C, Fior G, Bergamelli E, Wiedenmann F, D'Agostino A, et al. Recovering from COVID-19: psychological sequelae and post-traumatic growth six months after discharge. European journal of psychotraumatology. 2022;13(1):2095133.
- 3. Ferrando SJ, Lynch S, Ferrando N, Dornbush R, Shahar S, Klepacz L. Anxiety and posttraumatic stress in post-acute sequelae of COVID-19: prevalence, characteristics, comorbidity, and clinical correlates. Frontiers in psychiatry. 2023;14:1160852.
- 4. Peter RS, Nieters A, Krausslich HG, Brockmann SO, Gopel S, Kindle G, et al. Prevalence, determinants, and impact on general health and working capacity of post-acute sequelae of COVID-19 six to 12 months after infection: a population-based retrospective cohort study from southern Germany. medRxiv. 2022.

Other (n=2)

- 1. Chen H, Ma Q, Du B, Huang Y, Zhu S-G, Li S-L, et al. Psychotherapy and Follow-Up in Health Care Workers After the COVID-19 Epidemic: A Single Center's Experience. Psychology research and behavior management. 2022;15:2245-58.
- No authorship. Psychotherapy and follow-up in health care workers after the COVID-19 epidemic: A single center's experience [Retraction]. Psychology Research and Behavior Management. 2022;15:3409.

Table S2: Risk of Bias Assessments

Author, year	Were the two groups similar and recruited from the same population?	Were the exposures measured similarly to assign people to both exposed and unexposed groups?	Were the exposures measured in a valid and reliable way?	Were confounding factors identified?	Were strategies to deal with confounding factors stated?	Were the participants free of the outcome at the start of the study or exposure?	Were the outcomes measured in a valid and reliable way?	Was the follow up time reported and sufficient to be long enough for outcomes to occur?	Was follow up complete, and if not, were the reasons to loss to follow up described and explored?	Were strategies to address incomplete follow up utilized?	Was appropriate statistical analysis used (i.e. age, sex, severity)?	Overall assessment*
Labour Force Out	tcomes							-				
Anik, 2023	+	+	+	?	-	-	?	+	+	NA	No	High
Danesh, 2021	+	+	?	-	-	?	?	+	+	NA	No	High
Diem, 2022	+	+	+	?	+	?	+	+	+	NA	No	Low/ Moderate
Garcia-Molina, 2022	+	+	+	+	-	+	?	+	+	NA	-	Low/ Moderate
Green, 2023	+	+	-	?	-	?	?	+	+	NA	-	High
Kerksieck, 1001	+	+	+	+	-	+	+	-	+	NA	-	Low/ Moderate
Lemhofer, 2023	+	+	+	?	-	+	?	?	+	NA	-	Low/ Moderate
O'Sullivan, 2023	+	+	+	+	?	+	+	+	+	NA	-	Low/ Moderate
Romero- Rodrique, 2023	+	+	-	-	-	+	?	?	+	NA	-	High
Thompson, 2023	+	+	+	+	-	+	+	+	+	NA	-	Low/ Moderate
Tsuchida, 2023	+	+	?	?	-	?	?	?	+	NA	-	High
Vanichkachorn, 2021	+	+	-	-	-	?	+	+	+	NA	-	High

Braga, 2022	NA	NA	+	+	+	-	+	?	+	NA	-	Low/ Moderate
Davis, 2021	NA	NA	-	?	-	?	+	+	+	NA	-	High
Delgado- Alonso, 2022	NA	NA	+	?	-	+	+	+	+	NA	-	Low/ Moderate
Dressing, 2022	NA	NA	+	+	?	?	+	?	+	NA	-	Low/ Moderate
Farooqi, 2022	NA	NA	+	-	-	?	+	+	+	NA	-	High
LeGoff, 2023	NA	NA	+	?	-	+	+	+	+	NA	-	High
Lunt, 2022	NA	NA	-	+	+	?	+	-	+	NA	-	Low/ Moderate
Peter, 2022	NA	NA	-	?	+	+	+	+	?	-	-	Low/ Moderate
Mental Health Se	ervice Use Outcomes											
Decio, 2022	+	+	+	?	+	?	?	?	+	NA	-	High
Formoso, 2023	+	+	+	?	+	?	+	+	+	NA	-	High
Staples, 2023	-	+	+	+	-	?	+	?	+	NA	-	Low/ Moderate
Ahmed, 2022	NA	NA	+	?	-	?	+	+	?	-	-	High
Bek, 2023	NA	NA	+	+	+	?	+	+	+	NA	-	Low/ Moderate
Benzakour, 2021	NA	NA	+	?	-	?	+	+	+	NA	-	High
Bonazza, 2020	NA	NA	+	+	-	?	+	+	+	NA	-	Low/ Moderate
Brehon, 2022	NA	NA	+	?	-	?	+	+	+	NA	-	High
Chopra, 2021	NA	NA	+	?	-	?	+	+	+	NA	-	High

Chow, 2023	NA	NA	+	-	+	-	-	?	+	NA	-	High
Diem, 2022	NA	NA	+	-	-	?	?	+	+	NA	-	High
Farooqi, 2022	NA	NA	?	-	-	-	+	+	+	NA	-	High
Frontera, 2022	NA	NA	+	+	?	?	?	+	?	NA	-	Low/ Moderate
Gramaglia, 2021	NA	NA	+	+	-	+	?	+	+	NA	-	Low/ Moderate
Heeney, 2023	NA	NA	+	?	-	?	?	+	+	NA	-	High
Hodgson, 2021	NA	NA	+	?	?	?	?	+	+	NA	-	High
Holland, 2023	NA	NA	+	?	-	?	?	+	?	-	-	High
Huang, 2022	NA	NA	+	?	+	?	?	+	+	NA	-	Low/ Moderate
Kalyani, 2022	NA	NA	+	?	-	?	+	+	+	NA	-	High
Kisiel, 2023	NA	NA	+	?	-	+	+	+	?	-	-	Low/ Moderate
Lazzaroni, 2022	NA	NA	+	+	-	?	+	?	+	NA	-	Low/ Moderate
LeGoff, 2023	NA	NA	+	?	-	?	+	+	+	NA	-	High
Lynch, 2024	NA	NA	+	?	-	?	+	+	+	NA	-	High
Rival, 2023	NA	NA	+	-	-	-	+	+	+	NA	-	High
Umbrello, 2022	NA	NA	+	?	-	?	?	+	+	NA	-	High
Tager, 2023	NA	NA	+	?	-	?	?	-	+	NA	-	High

Van Wambeke, 2023	NA	NA	?	?	-	?	+	+	?	-	-	High
Wander, 2023	NA	NA	+	?	?	?	+	-	+	NA	-	High

+: Yes/low risk of bias; -: No/high risk of bias; ?: Unclear; NA: Not applicable

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity Enrollment dates	Comorbidities SES variables Employment status	COVID population description	Exposure and control group details
Anik, 2023 Bangladesh Cohort Industry funded: N <u>Sample</u> : hospitalized <u>Risk of bias</u> : High	45.3 (14.2) 39.7% <u>Race</u> : NR April, 2020 to December, 2020	Comorbidity: NRSES:Household SES (n = 382)Poor: 40.8%Middle: 29.3%Rich: 29.8%Completed years of educationMean (SD): 12.3 (4.8) $0-5$: 11.6% $6-10$: 23.3%11-12: 17.5%More than 12 years: 47.6%Monthly income (in BDT) (n = 391)Median (Minimum, Maximum):32,000 (2,000, 700,000) $\leq 20,000$: 24.8%20,001-30,000: 24.5%30,001-40,000: 11.8%40,001-60,000: 20.2%60,001+: 18.7%Monthly expenditure (in BDT) (n = 436)Median (Minimum, Maximum):30,000 (2,000, 600,000) $\leq 15,000: 20.6\%$ 15,001-25,000: 24.8%25,001-30,000: 14.7%30,001-50,000: 25.2%50,001+: 14.7%Employment:In paid employment: 54.3%Not in paid employment: 18.1%	481 patients admitted to the hospital with symptoms similar to COVID and discharged after recovery <u>Population</u> : COVID infected <u>Hospitalized</u> : 100% <u>Confirmation method</u> : NR	MH description: Screening positive for any one or more symptoms of depression, anxiety, and stress 6 months after being discharged from the hospital after recovery from symptoms similar to COVID <u>MH prevalence</u> : Any one or more symptoms of anxiety, depression or stress: 44.9% <u>Previous MH</u> : NR <u>Ascertainment</u> : Patient reported telephone survey using an electronic questionnaire <u>Control</u> : Participants without MH symptoms (no depression, anxiety, or stress) after being discharged from the hospital with symptoms similar to COVID 55% reported none of the above symptoms

Table S3a: Study Characteristics for Labour Force Outcomes with Control Groups

Country Female, % SES variables Study design Race/ethnicity Employment status Funding Enrollment dates Homemaker: 27.6% Findings Outcome:	
Study design Racevennicity Employment status Funding Enrollment dates Homemaker: 27.6% Findings Outcome:	
Findings Outcome:	
Findings Outcome:	
Outcome:	
Decrease in working hours after discharge from hospital with symptoms similar to COVID	
1. Among paid employees with MH symptoms vs. Paid employees without MH symptoms	
2. Among all participants (paid, unpaid and homemakers) vs. Total with and without MH	
Decrease in income due to MH symptoms (any one or more symptoms of depression, anxiety, and stress) after being discharged from	the
hospital with symptoms similar to COVID	
1. Among paid employees with MH symptoms vs. Paid employees without MH symptoms	
2. Among all participants (paid, unpaid and nomemakers) vs. Total with and without MH	
Timing: On average six months since discharge from the hospital (average 186 days)	
Results:	
1. 70/216 = 32.4% vs 52/265 = 19.6%	
2. 70/481 = 14.6% vs 52/481 = 10.8%	
3. 115/216 = 53.2% vs 116/265 = 43.8%	
4. $115/481 = 23.9\%$ vs $116/481 = 24.1\%$	
Adjustments, None Adjustments None Dapash 2021 Median: 52 IOP: Comorbidity: NP 200 adults with prolonged symptoms MH description:	
USA 41-61 200 addits with prolonged symptoms <u>Mindescription</u> .	
71% SES: NR onset) not resolved following usual subjective complaints of "brain foc	a."
Cohort primary or specialist care who were including confusion, poor	
Industry funded: Race: referred for COVID-specific follow-up concentration, memory loss, and/o	or
NR White: 79% through the COVID recovery clinic trouble word-finding. Symptoms or	ſ
Black: 12% COVID (>14 days after symptom	
<u>Sample</u> . Others. 9% <u>Population</u> . post-COVID with Offset) not resolved following usual outpatient clinic Hispanic/Latino:	
23% referred for COVID-specific follow	/-up
Risk of bias: Hospitalized: 30% through the COVID recovery clinic	ວ່
High November 2020 to	
February 2021 Confirmation method: NR MH prevalence: 26%	
Severity Previous MH: NR	
Home oxygen: 13%	
Ascertainment:	
Semi-structured interview guide u	sed
to incorporate common data elem	ents
Into evolving standard of care	

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity Enrollment dates	Comorbidities SES variables Employment status	COVID population description	Exposure and control group details				
				Consulting specialists from psychiatry—reviewed case narratives written by the internal medicine physicians conducting the post-COVID telemedicine assessments. <u>Control</u> : Without cognitive dysfunction				
	Outcome: Unable to1.With cogniti2.With cognitiTiming: Initial onset,Results:1.9 / 200 = 4.22.9 / 51 = 17.2Adjustments: None	 work due to the severity and persistence of COVID sequelae ive dysfunction / All with prolonged COVID symptoms vs. Without cognitive dysfunction ive dysfunction / All with prolonged COVID symptoms and cognitive dysfunction vs. Without cognitive dysfunction Median, days: 37; Persisting sequelae, Median days: 82 5% vs. 11 / 200 = 5.5% 7% vs. 11 / 149 = 7.4% 						
Diem, 2022 Switzerland Cohort Industry funded: N <u>Sample</u> : mixed (support groups, social media, and our post-COVID consultation) <u>Risk of bias</u> : Low/moderate	Overall: (n=309) 44.6 (NR); range 19-83 80.6% Nationality: Swiss: 95.1% German: 1.9% French: 1.9% Belgian: 0.6% Austrian: 0.3% Insomnia: (n=91) 42.5 (NR); range (42.8-47.6) Excessive daytime sleepiness: (n=126) 43.5 (NR); range (41.3-45.7) October 15, 2021 to December 12,	<u>Comorbidity</u> : Insomnia: 41.8% Excessive daytime sleepiness: 42.9% <u>SES</u> : Overall: Education ≥13 years: 59.5% <u>Employment</u> : Overall: Self-employment: 12.0%	309 with persistent symptoms >3 mos. (excluded if not fulfilling WHO post- COVID criteria) Population: PCC (WHO) 100% Hospitalized: 10.7% Insomnia 91/241 (37.8%) Labour force: 89/91 (97.8%) Hospitalized: 7.7% Positive PCR/Antigen Test: 83.5% Vaccinated, Yes: 88.9% Intubation: 8.9% ICU without intubation: 1.1% Oxygen requirement: 1.1% Excessive daytime sleepiness 126/224 (56.3%) Labour force: 125/126 (99%) Hospitalized: 11.1%	MH description: Insomnia: screening positive on the Insomnia Severity Index (ISI), with a cut-off score of ≥15 for clinical insomnia Excessive daytime sleepiness: screening positive on the Epworth Sleepiness Scale (ESS), with a cut-off score of ≥11 MH prevalence: Insomnia: 37.7% Excessive daytime sleepiness: 56.6% Previous MH: NR Ascertainment: Self report, online survey integrating validated scale Control: Without MH symptom (insomnia or				

Author, Year, Country Study design	Mean age (SD) yrs Female, % Race/ethnicity	Comorbidities SES variables Employment status	COVID population description	Exposure and control group details			
Funding	Enrollment dates						
			Vaccinated, Yes: 81%				
			Intubation: 0.8%				
			ICU without intubation: 2.4%				
			Oxygen requirement: 11.1%				
	Findings						
	<u>Outcome</u> :						
	Incapacity to work	aia / all with incompions (a. Mithaut inc	empie / ell without incompie				
	1. With incom	ia / an with insomina vs. without insomnia	Va Without incompio in total comple / Tota	al with and without incompio			
	2. With excess	With insomnia / Total with and without insomnia vs. without insomnia in total sample / Total with and without insomnia With excessive daytime sleepiness / all with EDS vs. Without excessive daytime sleepiness / all without EDS					
	4 With excess	 With excessive daytime sleepiness / Total with and without EDS vs. Without excessive daytime sleepiness in total sample / Tot 					
	with and with	hout EDS					
	Mean (95% CI) durat	an (95% CI) duration in weeks of incapacity to work					
	5. With insom	5. With insomnia vs. Without insomnia					
	6. With excessive daytime sleepiness vs. Without excessive daytime sleepiness						
	Timing: Time betwee	en onset of acute infection and questi	onnaire:				
	Insomnia: mean = 13	3.7 months, 95%Cl (12.7 - 14.7) mon	ths				
	Excessive daytime s	leepiness: mean = 12.8 months, 95%	6CI (12.0 - 13.6) months				
	Results:						
	1. 69/89 = 77	'.5% vs. 93 / 147 = 63.2%; p-value: 0	0.03				
	2. $69/236 = 2$	29.2% vs. 93 / 236 = 39.4%; p-value:					
	3.91/123 - 7	2.0% vs. 62 / 90 - 64.0%, p-value. 0	0.752				
	$4. \ 91/221 - 4$ $5 \ 20 \ 7 (2/3 - 3)$	(1.2% vs. 02/221 - 20.1%, p-value.)	3				
	6 26 3 (22 4.3	(21.3-30.0), $(1-33.2)$ $(21.3-30.0)$, $(1-33.2)$ $(21.3-30.0)$, $(1-33.2)$ $(21.3-30.0)$, $(1-33.2)$	2				
	Adjustments: None	50.1), n=51 v3. 27.5 (22.0-00.+), n=0.					
Garcia-Molina,	51 (12.4)	Comorbidity: NR	123 accessing outpatient	MH description:			
2022	58.5%		neurorehabilitation programme aimed	Cognitive alterations detected by			
Spain		<u>SES</u> :	at patients with PCC, fulfilling NICE	neurological exam also underwent			
	Race: NR	Level of education:	criteria of symptoms persisting beyond	treatment (mean 4.1 sessions/week for			
Cohort		Primary: 14.6%	12 weeks post-infection	8 weeks) for cognitive symptoms;			
Industry funded:	June 2020 to	Secondary education: 29.3%		programme included respiratory			
N	September 2021	Further education:56.1%	Population: PCC (NICE) 100%	therapy, physiotherapy, and			
Sampla		Employment: NP	Hospitalizad: 16.3%	neuropsychological renabilitation			
outpatient clinic				MH prevalence:			
			Confirmation method: PCR 100%	At follow-up for labour force outcomes:			
Risk of bias			Commutation method. 1 Or 10070	79 7%			
Low/Moderate			Severity:				

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity Enrollment dates	Comorbidities SES variables Employment status	COVID population description	Exposure and control group details						
			ICU: 50.9% <u>COVID diagnosis (variant)</u> : March 2020: 62.6% April 2020: 13% May-December 2020: 21.1% January 2021: 1.6% February 2021: 0.8% April 2021: 0.8%	Previous MH: None of the participants had neurological and/or psychiatric disease prior to COVID infection <u>Ascertainment</u> : Semi-structured interviews <u>Control</u> : Without MH (symptoms of cognitive alterations)						
	Findings <u>Outcome</u> : Temporarily unable t before COVID?") 1. Cognitive al 2. Cognitive al <u>Timing</u> : Outcome eva range 3 - 17.1 month <u>Results</u> : 1. 24 / 69 = 34 2. 24 / 55 = 43 Adjustments: None	Findings Outcome: Temporarily unable to work (if employed "Has the patient returned to work as normal?"; "Does the patient work in the same conditions as before COVID?") 1. Cognitive alterations among total sample vs. Without cognitive alterations among total sample 2. Cognitive alterations among all with cognitive alterations vs. Cognitive alterations among all without cognitive alterations Timing: Outcome evaluated at 6-7 months follow-up: n=69 (56.1%); time between infection and treatment onset, mean (SD) = 7.7 (3.5); range 3 - 17.1 months Results: 1. 24 / 69 = 34.8% vs. 7 / 69 = 10.1% 2. 24 / 55 = 43.6% vs. 7 / 14 = 50%								
Green, 2023	51 (NR)	Comorbidity:	214 Triaged patients referred to a long	MH description:						
UK	63%	<1 comorbially: 64%	multidisciplinary team and accepted	Prevalence of brain tog						
Cohort Industry funded:	Race: NR	<u>SES</u> : NR	referrals from both primary and secondary care	MH prevalence: Brain fog: 61%						
NR		Employment:		<u>Previous MH</u> : NR						
<u>Sample</u> : PCC clinic	January to September 2021	Employed / self-employed: 90% Unemployed: 3% Retired: 6% Student: 2%	 Population: PCC (persistent symptoms > 12 weeks) 100% Hospitalized: 12% 	Ascertainment: Self-reported in symptom assessment questionnaire at PCC clinic (based on						
<u>Risk of bias</u> : High			Confirmation method: NR	yes/no response)						
			<u>Severity</u> : ICU not intubated: 1% ICU intubated: 2%	<u>Control:</u> All patients referred to a PCC clinic who did not have brain fog, including students, unemployed, and retired individuals						

Author, Year,	Mean age (SD) yrs	Comorbidities	COVID population description	Exposure and control group details	
Study design	Race/ethnicity	Employment status			
Funding	Enrollment dates	p.o.J			
runaing	Findings <u>Outcome</u> : At work but struggling 1. Had brain fo 2. Had brain fo 3. Had brain fo 4. Had brain fo 5. Had brain fo 6. Had brain fo 6. Had brain fo 6. Had brain fo 7. Had brain fo 8. Had brain fo 8. Had brain fo 8. Had brain fo 9. Had brain fo 1. Had brain fo 9. Group 1 (at 9. Group 2 (at 9. Group 2 (at 9. Group 3 (offf Results: 1. 50 / 85 = 58 2. 50 / 130 = 3 3. 50 / 199 = 2 4. 50 / 214 = 2 5. 55 / 75 = 73 6. 55 / 130 = 4	g with symptoms (group 2) og / Struggling with symptoms og / Brain fog, including students, une ndividuals og / All referred to PCC clinic, excludi og / All patients referred to PCC clinic otoms (group 3) og / Struggling with symptoms og / Brain fog, including students, une ndividuals og / All referred to PCC clinic, excludi og / All referred to PCC clinic fter the initial infection; median time f work): 258 days work but struggling with symptoms): work due to symptoms): 285 days .8% 8.5% vs. 35 / 84 = 41.7% 1.5% 3.4% .3% 2.3% vs. 20 / 84 = 23.8%	employed, and retired vs. Did not have bra ng students, unemployed, and retired indi employed, and retired vs. Did not have bra ng students, unemployed, and retired indi from diagnosis of the original infection to th 274 days	in fog, including students, unemployed, viduals in fog, including students, unemployed, viduals he first appointment in clinic:	
	7. 55/199 = 2 8 55/214 = 2	7.6% 5.7%			
	Adjustments: None				
Kerksieck, 2023	42.1 (12.2)	Comorbidity:	672 individuals with COVID infection	MH description:	
Switzerland	54.2%	1: 16.8% >2: 4.0%	and of working age	neurocognitive symptom cluster (concentration	
Cohort	Nationality:	22. 4.0 %	Population: post-COVID with	memory or sleeping problems)	
Industry funded:	Swiss: 83.6%	<u>SES</u> :	symptoms	(scale 0-no ability to 10-best ability;	
Ν	Non-Swiss: 16.4%	 Income (Swiss Francs) 	 self-reporting at least one of 23 	poor: ≤6, moderate: 7-8, excellent:	
Somploy boolth		• <6,000: 29.2%	common PCC-related symptoms:	≥9),	
<u>oampie</u> : nealth database	Enrolled upon or	• 6,000-12,000: 43.7%	17.9%	 depression (defined as score ≥10 in depression related items) 	
นลเลมลอฮ	shortly after	• >12,000: 176 (27.2)		e anviety (score >8 in anviety related	
Risk of bias:	diagnosis between	Education	Hospitalized: 1.5%	items)	

Author, Year, Country	Mean age (SD) yrs Female, %	Comorbidities SES variables	COVID population description	Exposure and control group details
Study design	Race/ethnicity	Employment status		
Low/moderate	IdingEnrolment datesv/moderateAugust 2020 and January 2021• None/mandatory school:3.3% • Vocational training or specialized baccalaureate: 37.2% • Higher technical/college: 29% • University: 30.6%Employment (at infection): • Employed/self-employed: 87.4% • Student: 6.8% 		<u>Confirmation Method</u> : self-report <u>Severity</u> : 1-5 symptoms: 39.6% ≥6 symptoms: 48.7% ICU admission: 0.1% <u>Re-infection</u> : 0% <u>Vaccination</u> : All unvaccinated at time of infection	 stress (score ≥15 in stress-related items) <u>MH prevalence</u>: 11.9% <u>Previous MH</u>: Entire group: history of psychiatric diagnosis (any condition): 13.2% Neurocognitive: 5.5% Depression: 11.9% Anxiety: 10.7 Stress: 8.2% <u>Ascertainment</u>: Electronic questionnaire, self-report of symptoms and 21-item Depression, Anxiety and Stress Scale
				<u>Control</u> : Without MH (neurocognitive, depression, anxiety or stress)
	Findings <u>Outcome</u> : Current work ability (1. Those with 2. Those with 3. Those with 4. Those with 5. Those with 6. Those with 7. Those with 8. Those with 10. Those with 11. Those with 12. Those with 13. Those with 14. Those with	all self-reported; compared to highes neurocognitive vs. Those without ne neurocognitive among all those with depression vs. Those without depres depression among all those with CO anxiety vs. Those without anxiety anxiety among all those with COVID stress vs. Those without stress stress among all those with COVID o mental demand (all self-perceived; your work?" very bad/rather bad, moo neurocognitive vs. Those without ne neurocognitive among all those with depression vs. Those without depres depression among all those with CO anxiety vs. Those without anxiety anxiety among all those with COVID	st work ability ever, poor/moderate/exceller urocognitive COVID ssion VID based on question ""How do you rate you derate, rather good, very good) urocognitive COVID ssion VID	nt work ability)

Author, Year, Country Study design Funding	Mean ag Female, Race/eth Enrollm	ge (SD) yrs % hnicity ent dates	Comorbidities SES variables Employment status		COVID popula	tion o	description	Exposure and contro	l group details		
	15. 16	Those with st	ress vs. Those without sta ress among all those with	ress							
	Timina [.]	Survey conduc	cted one year after the inf	ection svi	nntoms assesse	d in tl	he nast 7 davs				
	Results:		fou one your and the in	oodon, oyi	no puot i uujo						
	Current	work ability	vork ability								
	1.	·									
			With neurocognitive	Without	neurocognitive	2.		Among all with COVID			
		Poor	10/37=27%	37/635=	6%		Poor	10/672=1.5%			
		Moderate	16/37=43.2%	163/635	=26.3%		Moderate	16/672=2.4%			
		Excellent	11/37=29.7%	419/635	=67.7%		Excellent	11/672=1.6%			
	3.										
			With depression	Without	depression	4.		Among all with COVID			
		Poor	24/78=30.8%	23/577=	4%		Poor	24/655=3.7%			
		Moderate	36/78=46.2%	140/577	=24.4%		Moderate	36/655=5.5%			
		Excellent	18/78=23.1%	411/577	=71.6%	1	Excellent	18/655=2.7%			
	5.										
			With anxiety	Without	anxiety	6.		Among all with COVID			
		Poor	22/70=31.4%	25/586=	4.3%		Poor	22/656=3.3%			
		Moderate	30/70=42.9%	148/586	=25.4%		Moderate	30/656=4.6%			
		Excellent	18/70=25.7%	410/586	=70.3%		Excellent	18/656=2.7%			
	7										
	7.		With stress	Without	stress	8		Among all with COVID			
		Poor	21/54=38.9%	26/602=	4.3%	0.	Poor	21/656=3.2%			
		Moderate	24/54=44.4%	153/602	=25.5%		Moderate	24/656=3.7%			
		Excellent	9/54=16.7%	420/602	=70.1%		Excellent	9/656=1.4%			
			I.								
	Work ab 9	ility related to	mental demand								
			With neurocognitive	Without	neurocoanitive	10.		Among all with COVID			
		Very bad	1/37=2.8%	3/635=0	.5%		Very bad	1/672=0.1%			
		Rather bad	3/37=8.3%	4/635=0	.6%	1	Rather bad	3/672=0.5%			
		Moderate	10/37=27.8%	62/635=	10%		Moderate	10/672=1.5%			
		Rather good	14/37=38.9%	202/635	=32.7%		Rather good	14/672=2.1%			
		Very good	8/37=22.2%	346/635	=56.1%		Very good	8/672=1.2%			
	11.	[I				1	I			
			With depression	Without	depression	12.		Among all with COVID			
		Very bad	4/78=5.1%	0/577=0	.0%		Very bad	4/655=0.6%			

Author, Year, Country Study design Funding	Mean age (SD) Female, % Race/ethnicity Enrollment dat	yrs	Comorbidities SES variables Employment status		COVID popula	tion d	escription	Exposure and control group details
	Rathe	er bad	5/78=6.4%	2/577=0	.3%		Rather bad	5/655=0.8%
	Mode	rate	34/78=43.6%	38/577=	6.6%		Moderate	34/655=5.2%
	Rathe	er good	28/78=35.9%	186/577	=32.5%		Rather good	28/655=4.6%
	Very g	good	6/78=7.7%	346/577	=60.5%		Very good	6/655=0.9%
	13.							
			With anxiety	Without	anxiety	14.		Among all with COVID
	Very b	bad	4/70=5.7%	0/586=0	.0%		Very bad	4/656=0.6%
	Rathe	er bad	4/70=5.7%	3/586=0	.5%		Rather bad	4/656=0.6%
	Mode	rate	29/70=41.4%	43/586=	7.4%		Moderate	29/656=4.4%
	Rathe	er good	26/70=37.1%	188/586	=32.4%		Rather good	26/656=4.0%
	Very g	good	7/70=10%	346/586	=59.7%		Very good	7/656=1.1%
	15.							
			With stress	Without	stress	16.		Among all with COVID
	Very b	bad	2/54=3.8%	2/602=0	.3%		Very bad	2/656=0.3%
	Rathe	er bad	6/54=11.3%	1/602=0	.2%		Rather bad	6/656=0.9%
	Mode	rate	26/54=49.1%	46/602=	7.7%		Moderate	26/656=4%
	Rathe	er good	16/54=30.2%	199/602	=33.3%		Rather good	16/656=2.4%
	Very g	good	3/54=5.7%	349/602	=58.5%		Very good	3/656=0.5%
	<u>Adjustments</u> : No	one						
Lemhofer, 2023	46.9 (10.9)		Comorbidity: NR		318 patients att	tendin	g post-COVID	MH description:
Germany	68.9%				outpatient clinic; with an average of 7.8			.8 Deficits in the mental component
.	NR		<u>SES</u> : NR		symptoms at 12	2 weel	KS	summary score of the SF-36
Cohort						~ ′		
Industry funded:	March 1, 2021 t	0	Employment: NR		Population: PC	C (syr	nptom evaluatio	n) <u>MH prevalence</u> : 50.9%
N	October 29, 202	21			100%			Desidence Mills ND
Sample: DCC					Heenitelized, 2	0 60/		Previous MH: NR
Sample. PCC					nospitalized. 5/	2.0%		Accortainment
outpatient clinic					Confirmation M	othod		Ascentamment.
Rick of hige:						eniou	. FCK 100%	Survey completed in person at clinic
Low/moderate								Control: Without MH
Lowinocoluco	Findings							
	Outcome:							
	Unable to work							
	1. With MH deficit / All attending post-COVID clinic vs. All attending post-COVID clinic							
	2. With MH deficit / All attending post-COVID clinic with MH deficit vs. Attending post-COVID clinic without MH deficit							
	Timing: majority of sample was 3 to 12+ months since COVID infection (6 participants were <3 months)							
	Results:							
	1. 74 / 316 = 23.4% vs. 52 / 316 = 16.5%							

Author, Year, Country	Mean age (SD) yrs Female, %	Comorbidities SES variables	COVID population description	Exposure and control group details
Study design	Race/ethnicity	Employment status		
Funding	Enrollment dates			
	2. 74 / 161 = 4 Adjustments: None	6% vs. 52 / 155 = 33.5%		
O'Sullivan, 2023 UK Cohort Industry funded: NR <u>Sample:</u> outpatient recovery service <u>Risk of bias</u> : Low/moderate	36.6 (10) 13.5% Race: NR August 2020 to December 2021 Findings Outcome: Nedically of restriction ('fully depleted in the construction of the consthe construction of the construction of the construction of the co	Comorbidity: NR <u>SES</u> : Military rank as proxy for SES: Junior NCO: 35.6% Senior NCO: 31.5% Officer rank: 30.2% <u>Employment</u> : military employees <u>downgraded to perform duties, base</u> oyable') or with limitations ('medically mptoms / All (medically downgraded mptoms among all (medically downgraded mptoms among all (medically downgraded try among all (medically downgraded ntration / All (medically downgraded ntration among all (medically downgraded All (medically downgraded and fully of mong all (medically downgraded and ser initial COVID infection 2.5% vs. 76 / 125 = 60.8%	222 military employees with ongoing symptomatic or initially severe COVID infection <u>Population</u> : post-COVID with symptoms (ongoing symptoms, physical limitations and neurocognitive impact at 6 months post-COVID) <u>Hospitalized</u> : 36.9% <u>Confirmation method</u> : NR <u>Severity</u> : Mean (SD) number of acute symptoms: 3 (1) d on medical deployment status to determ y downgraded') d and fully deployable) with cognitive symp graded and fully deployable) ully deployable) with poor memory vs. All v and fully deployable) with poor concentrat raded and fully deployable) ully deployable) with poor attention vs. All and fully deployable) iully deployable) with poor attention vs. All and fully deployable) iully deployable) with confusion vs. All without of d fully deployable) iully deployable) with confusion vs. All without of d fully deployable)	 <u>MH description</u>: All self-reported: cognitive impairment based on presence of 'any' cognitive symptoms individuals medically downgraded to perform duties due to MH conditions for poor memory, poor concentration, poor attention, and confusion <u>MH prevalence</u>: 5.8% <u>Previous MH</u>: Past MH condition: 7.7% <u>Ascertainment</u>: Comprehensive assessment, including symptom questionnaire, patient-reported outcome measures (validated tools for anxiety and PTSD) <u>Control</u>: Without MH ine ability to perform job role without poor memory ion vs. All without poor concentration without poor attention

Author, Year, Country Study design	Mean age (SD) yrs Female, % Race/ethnicity Eprollment dates	Comorbidities SES variables Employment status	COVID population description	Exposure and control group details		
	2. $80 / 222 = 3$ 3. $46 / 57 = 80$ 4. $46 / 222 = 2$ 5. $55 / 63 = 87$ 6. $55 / 222 = 2$ 7. $70 / 79 = 88$ 8. $70 / 222 = 3$ 9. $48 / 57 = 84$ 10. $48 / 222 = 2$ Adjustments: None	36% 0.7% vs. 110 / 165 = 66.7% 20.7% 7.3% vs. 101 / 159 = 63.5% 24.8% 3.6% vs. 86 / 143 = 60.1% 31.5% 4.2% vs. 108 / 165 = 65.5% 21.6%				
Romero- Rodrigue, 2023 Spain Cohort Industry funded: N <u>Sample</u> : community <u>Risk of bias</u> : High	Full cohort: (n=689) 46 (NR), IQR: 40-52 83.2% Active workers: (n=596) 48 (NR) IQR: 40-52 83% Race: March 2021 to January 2022 (Data collection)	<u>Comorbidity</u> : NR <u>SES</u> : Region (Autonomous Community) of residence Madrid: 26% Andalusia: 19% Aragon: 12% Catalonia: 11% Valencian: 6.1% Other: 27% <u>Employment</u> : 83% employed	689 with COVID and 596/689 (86.5%) active workers during the course of the disease (not unemployed or retired) <u>Population</u> : PCC (WHO) 100% Time since PCC: <361 days: 31% ≥361 days: 69% <u>Hospitalized</u> : 23% <u>Confirmation method</u> : PCR: 60% Clinically: 19% Rapid antigen test: 17% Serological test: 12% <u>Severity</u> : ICU: 3.6% Pneumonia COVID: 30% <u>Vaccination</u> : 87%	MH description: Mental confusion and PTSD as part of persistent COVID signs and symptoms MH prevalence: Mental confusion of those able to work before COVID: 58.9% Overall population: 68% Previous MH: Depression: 27%, Anxiety: 45%, Mental illness (psychosis, neurosis, Alzheimer's): 4.8% Ascertainment: Online questionnaire Control: Without MH symptoms		
	Findings Outcome: Some sick leave due to PCC 1. Mental confusion for active workers / Active workers vs. Active workers without mental confusion 2. Mental confusion for active workers / Active workers with mental confusion vs. Active workers without mental confusion 3. PTSD for active workers / Active workers vs. Active workers without PTSD 4. PTSD for active workers / All with PTSD vs. Active workers without PTSD Timing: NR (PCC defined as 12 weeks of persistent symptom) Results:					

Author, Year, Country	Mean age (SD) yrs Female, %	Comorbidities SES variables	COVID population description	Exposure and control group details
Study design Funding	Race/ethnicity Enrollment dates	Employment status		
Thompson, 2023 USA Cohort Industry funded: N <u>Sample</u> : mix (outpatient recovery program and community) <u>Risk of bias</u> : Low/moderate	1. 285 / 596 = 2. 285 / 351 = 3. 120 / 596 = 4. 120 / 141 = Adjustments: None 42 (NR) 69.5% Race: White: 71.2% Hispanic: 13.6% African American: 6.8% Asian/South Asian: 6.8% Other: 1.7% NR NR	47.8% vs. 182 / 596 = 30.5% 81.2% vs. 182 / 245 = 74.3% 20.1% vs. 347 / 596 = 58.2% 85.1% vs. 347 / 455 = 76.3% $\boxed{Comorbidity}$: Mean (SD) comorbidities, for those with: Time off: 1.6 (1.4) No time off: 1.2 (1.4) \underbrace{SES} : Mean (SD) years education Time off: 15.86 (2.24) No time off: 16.00 (2.13) $\underbrace{Employment}_{i}$: participants falling under broad skill level 3 and 4 which is predominantly professionals: 61%	59 with PCC symptoms; recruited from Post-COVID recovery program (59.3%) and community (40.7%); <u>Population</u> : PCC (symptom evaluation) 100% <u>Hospitalized</u> : 6.7% <u>Confirmation method</u> : 100% naso, antibody	MH description: Clinically significant depression, determined by scoring ≥10 on the Patient Health Questionnaire (PHQ-9) MH prevalence: Clinically significant depression: 55.9% Previous MH: Prior psychiatric history: Time off: 46.4% No time off: 45.2% Ascertainment: Self-reported questionnaire, supervised by a neuropsychologist Control: Without clinically significant depression, determined by not meeting criteria on PHQ-9
	Findings <u>Outcome</u> : Taking time off for PC 1. With clinical 2. With clinical without clinical 0ccupational perform 3. With clinical 4. With clinical without clinical <u>Timing</u> : Survey admin <u>Results</u> : 1. 22 / 59 = 37 2. 22 / 33 = 66	CC symptoms beyond the required q ly significant depression / Total sam ly significant depression / All with cli cally significant depression nance suffered upon RTW from PCC ly significant depression / Total sam ly significant depression / All with cli cally significant depression nistered after quarantine, at least 10 .3% vs. 6 / 59 = 10.2% .7% vs. 6 / 26 = 23.1%	uarantine period ple vs. Without clinically significant depres nically significant depression vs. Without of symptoms (all previously employed) ple vs. Without clinically significant depres nically significant depression vs. Without of -20 days after symptom onset	sion / Total sample linically significant depression / All sion / Total sample linically significant depression / All

Author, Year, Country Study design	Mean age (SD) yrs Female, % Race/ethnicity	Comorbidities SES variables Employment status	COVID population description	Exposure and control group details			
Funding	Enrollment dates						
	3. 19 / 59 = 32.2% vs. 9 / 59 = 15.3% 4. 19 / 33 = 57.6% vs. 9 / 26 = 34.6% Adjustments: None						
Isuchida, 2023 Japan Cohort Industry funded: N <u>Sample</u> : post- COVID outpatient clinic <u>Risk of bias</u> : High	41.6 (NR) 56.9% <u>Race</u> : NR January 18, 2021 to May 30, 2022	<u>Comorbidity</u> : 58.1% with comorbidity <u>SES</u> : NR <u>Employment</u> : NR	497 post-COVID patients visiting a PCC outpatient clinic treating patients suspected of having COVID sequelae and referred from elsewhere <u>Population</u> : post-COVID with symptoms (residual symptoms lasting at least 2 months post-infection) <u>Hospitalized</u> : NR <u>Confirmation method</u> : PCR 100%	MH description: Post-COVID psychological symptom cluster (cluster 3 comprised of many psychological symptoms, including anxiety, depressed mood, forgetfulness, insomnia in addition to fatigue, headache, and lack of motivation) MH prevalence: Anxiety: 42.3% Depressed mood: 40.2% Forgetfulness: 37.8% Insomnia: 29.6% Previous MH: NR Ascertainment: Cluster classification of post-COVID symptoms was performed based on symptoms described in the questionnaire at the time of the hospital visit Employment status self-reported Control: Patients in cluster 1 (fatigue only), cluster 2 (fatigue, dyspnea, chest pain, palpitations, forgetfulness), cluster 4 (hair loss only), and cluster 5 (taste and small disorders only)			
	Findings Outcome: Current employment 1. Outcome in 2. Outcome in Current employment	status: change in job description cluster 3 / All in cluster 3 vs. Outcon cluster 3 / All in cluster 1-5 status: leave of absence	ne in other clusters / All in other clusters	, ,			

Author, Year, Country	Mean age (SD) yrs Female, %	Comorbidities SES variables	COVID population description	Exposure and control group details		
Study design Funding	Race/ethnicity Enrollment dates	Employment status				
	 3. Outcome in cluster 3 / All in cluster 3 vs. Outcome in other clusters / All in other clusters 4. Outcome in cluster 3 / All in cluster 1-5 Timing: During the 1st year following presentation at the post-COVID outpatient clinic Results: 10 / 103 = 9.7% vs. 46 / 393 = 11.7% 10 / 496 = 2% 41 / 103 = 39.8% vs. 73 / 393 = 18.6% 41 / 496 = 8.3% Adjustments: Overall p< 0.001 for current employment status across 5 clusters 					
Vanichkachorn, 2021 USA Cohort Industry funded: NR <u>Sample</u> : outpatient clinic <u>Risk of bias</u> : High	45.4 (14.2) 68% <u>Race</u> : NR June 1, 2020 to December 31, 2020	<u>Comorbidity</u> : NR <u>SES</u> : 60,001+: 18.7% <u>Employment</u> : Fully employed: 91% Not employed: 9%	100 patients with PCC participating in COVID Activity Rehabilitation Program-CARP <u>Population</u> : PCC (symptom evaluation) 100% <u>Hospitalized</u> : 25% <u>Confirmation method</u> : PCR 93%; antibody test 8%	MH description: Cognitive symptoms were defined as any subjective reports of concentration difficulty, perceived memory loss, word finding difficulty, and inability to effectively multitask. Presenting symptom of sleep disturbance. MH prevalence: Cognitive impairment: 45% Previous MH: Pre-existing anxiety/depression: 34% Ascertainment: Presenting symptoms were recorded from clinical documentation Control: Without MH and employed prior to COVID		
	 Findings Outcome: Return to work in any capacity (including reduced hours or accommodated functional activities, at their usual work site or an alternative location such as home) 1. Those with cognitive impairment / All with PCC vs. Those without cognitive impairment 2. Those with cognitive impairment / All with PCC and cognitive impairment vs. With PCC and without cognitive impairment 3. Those with cognitive impairment / All with PCC and employed before COVID infection vs. PCC, employed and without cognitive impairment 4. Those with sleep disturbance / All with PCC vs. Those without sleep disturbance 5. Those with sleep disturbance / All with PCC and sleep disturbance vs. With PCC and without sleep disturbance 					

Author, Year, Country	Mean age (SD) yrs Female, %	Comorbidities SES variables	COVID population description	Exposure and control group details		
Study design Funding	Race/ethnicity Enrollment dates	Employment status				
	6. Those with sleep	o disturbance / All with PCC and emp	bloyed before COVID infection vs. PCC, er	mployed and without sleep disturbance		
	<u>Timing</u> : Mean time to	presentation: 93.4 ± 65.2 days				
	Results:					
	1. 29 / 100 = 2	9% vs. 34 / 100 = 34%				
	2. 29 / 45 = 64	.4% vs. 34 / 55 = 61.8%				
	3. 29 / 91 = 31	.9% vs. 34 / 91 = 37.4%				
	4. 18 / 100 = 1	8% vs. 45 / 100 = 45%				
	5. 18 / 30 = 60	% vs. 45 / 70 = 64.3%				
	6. 18 / 91 = 19	.8% vs. 45 / 91 = 49.5%				
	Adjustments: None					
Table S3b: Study Characteristics for Labour Force	Outcomes without Control Groups					
---	---------------------------------					
---	---------------------------------					

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity Enrollment dates	Comorbidities SES variables Employment status	COVID population description	MH details
Braga, 2022	47.6 (11.2)	Comorbidity: NR	614 patients with a diagnosis of	MH description:
Brazil	73%		COVID seeking treatment for cognitive	Treatment for cognitive issues
		<u>SES</u> :	issues	(attention, concentration, and memory
Cross-sectional	<u>Race</u> : NR	Education (years)		difficulties, slow reasoning, black-outs,
Industry funded:		5–8: 5%	Population: COVID infected	etc.) only diagnosed after the COVID
NR	April 2021 to January	9–11: 6%		and impacting daily lives following
	2022	12–15: 35%	Hospitalized: 33.3%	COVID
<u>Sample</u> :		16+: 54%		
outpatient			Confirmation method: PCR 100%	<u>MH prevalence</u> : 100%, all had memory
hospital unit		Employment:		problems after COVID
D: 1 (1)		Active: 74%	Severity:	
Risk of blas:		Retired: 12%	ICU: 17.3%	Previous MH: NR
Low/moderate		Unemployed: 10%	Intubated for oxygen support: 10.6%	
	Findings	Sick Leave/Disability. 4%		Ascentainment. medical chans
	Pindings			
	Sick leave in natients w	vith MH symptoms impacting daily	activities/ All natients with MH symptoms i	impacting daily activities
	Timing: 8 (4.3) months	from COVID diagnosis		input any addition
	Results: $26/614 = 4.2\%$			
	Adjustments: None	-		
Davis, 2021	NR	Comorbidity:	3762 with symptoms	MH description:
UK		At least one pre-existing		Cognitive dysfunction (sudden
	18-29 y: 7.4%	condition: 83.0%	Population: post-COVID with	confusion/disorientation, agnosia,
Cross-sectional	30-39 y: 24.1%		symptoms (lasting longer than 28	brain fog, difficulty thinking, difficulty
Industry funded:	40-49 y: 31.0%	<u>SES</u> :	days)	making decision, poor attention, etc.),
N	50-59 y: 25.0%	Participants in USA earning		memory loss (forgetting how to do
	60-69 y: 10.1%	more than \$85,000/year:	Hospitalized: 8.4%	routine tasks, long-term memory loss,
<u>Sample</u> : support	70-79 y: 2.3%	51.0%		inability to make new memories, etc.),
groups and	80+ y: 0.3%	Participants in USA earning	Confirmation method: some received	or both across all age groups
social media		more than \$150,000/year:	both tests	
	78.9%	22.5%	Diagnostic (RT-PCR/antigen): 61.9%	<u>MH prevalence</u> :
Risk of bias:		Participants from elsewhere	Antibody (IgG, IgM or both): 57.6%	Neuropsychiatric - Cognitive
High	Race:	earning less than		Dysfunction: 85.4%
	White: 85.3%	€20,000/year: 25%	Severity:	Neuropsychiatric - Memory: 72.8%
	Hispanic, Latino,	Participants from elsewhere	Visited ER or urgent care but not	
	Spanish: 3.7%	earning less than	admitted: 34.9%	Previous MH: NR
	Asian, South Asian,	€40,000/year: 51.1%		As a station such Oralin a summer
	SE Asian: 3.3%			Ascertainment: Online survey

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity Enrollment dates	Comorbidities SES variables Employment status		COVID po	pulation description	n	MH details	
	Black:2.0% Middle Eastern, North African: 1.7% Indigenous Peoples: 1.6% Pacific Islander: 0.1% Other: 2.5%	Employment: NR						
	September 6, 2020 to November 25, 2020							
	Findings Outcome: Work ability f <u>Timing</u> : Assessment at Results:	for participants with sus 1-4 weeks and 2-7 mo	pected/cor nths after tl	nfirmed COV he onset of il	ID among those who Iness	worked		
		20.20 1	40.40 v		50 50 1	60.6	20 v	70+ 1/
	10-29 y	30-39 y	40-49 y		20-29 y	20.0	99 y	20 7%
	Mederately upphic to	29.370	30.070		29.3%	30.2	. 70	39.7%
		20.2%	20.2%		25.7%	26.5	0/	15 3%
	Severely unable to wo	ork	23.270		20.170	20.0	//0	10.070
	26.7%	32.5%	30.3%		31.2%	26.8	8%	11.7%
	Adjustments: None							
Delgado-Alonso, 2022 Spain	46.3 (8.0) 87%	<u>Comorbidity</u> : NR <u>SES</u> :		77 with PC PCC in the	C attending program Department of Neu	n for rology	MH description Cognitive issue capacity and p	<u>n:</u> es influencing their work rofessional career,
Cross-sectional	<u>Race</u> : NR	Mean (SD) years of e 16.14 (3.03)	ducation:	Population	: PCC (WHO) 100%		based on mear	n scores of each scale
Industry funded: N <u>Sample</u> : PCC program	January to June, 2022	ISCO 08 classification occupation categories • Managers professio 3.9%	n of s: nals:	Hospitalize	<u>ed</u> : 19.5% <u>on method</u> : PCR 100)%	MH prevalence Excluded those disorder not ex Previous MH: N	<u>e:</u> e with active psychiatric plained by PCC NR
program		Professionals: 57 1	%	ICU admis	sion: 4%		<u>- 1011000 III 1</u>	
Risk of bias:		Technicians and as	sociate	Ventilatory	assistance: 5.2%		Ascertainment	
Low/moderate		professionals: 19.5%	%	,			Examined by a	trained
		• Service and sales w 13.0%	orkers:	Re-infectio	<u>n</u> : 29.9%		neuropsycholo	gist
		• Plant and machine of and assemblers: 1.3	Sperators					

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity Enrollment dates	Comorbidities SES variables Employment status	COVID population description	MH details	
		Elementary occupations: 5.2% <u>Employment</u> : active			
	Findings Outcome: Work capacity and prof 1. Cognitive issue 2. Sleep disorde 3. Anxiety/depres Timing: 20.7 ± 6.5 mon Results: 1. 71 / 77 = 92.2 2. 54 / 77 = 70.1 3. 42 / 77 = 54.5 Adjustments: None None	employment pror to mection ressional career influenced by: les and actively working before CC rs and actively working before CO ssion and actively working before ths after clinical onset % %	VID / All actively working before COVID VID / All actively working before COVID COVID / All actively working before COVII	D	
Dressing, 2022 Germany Cross-sectional Industry funded: N <u>Sample</u> : outpatient clinic <u>Risk of bias</u> : Low/moderate	53.6 (12) 64.5% <u>Race</u> : NR June 16, 2020 to January 29, 2021	<u>Comorbidity</u> : NR <u>SES</u> : Mean (SD) years of education: 13.6 (2.6), range 8-18 <u>Employment</u> : NR	31 admitted to outpatient clinic with PCC and neurocognitive symptoms in the chronic phase (>3 mo) after COVID Population: PCC (NR) 100% <u>Hospitalized</u> : NR <u>Confirmation method</u> : PCR 100% <u>Severity</u> : Endotracheal ventilation at ICU: 13%	MH description: All admitted to outpatient clinic due to lasting neurocognitive symptoms MH prevalence: 100% Previous MH: None with pre-existing neurodegenerative disorders Ascertainment: Neurologic deficits were examined in a complete neurologic assessment by a board-certified neurologist	
	Findings Outcome: 1. Reduced work quota with neurocognitive symptoms persisting after COVID / All with neurocognitive symptoms persisting after COVID 2. Inability to work and impairment in daily activities with neurocognitive symptoms persisting after COVID / All symptoms persistence symptom				

Author, Year,	Mean age (SD) yrs	Comorbidities	COVID population description	MH details
Study design	Race/ethnicity	Employment status		
Funding	Enrollment dates			
	2. 9/31 = 29%			
Earoogi 2022	Adjustments: None	Comorbidity:	30 patients referred and assessed for	MH description:
LISA	87%	Mean (SD) number of medical	nsychiatric complications of COVID to	Adult patients complaining of
00/1	0170	comorbidities: 1.13 (0.96)	the outpatient department of an	neuropsychiatric symptoms (anxiety.
Cross-sectional	Race:		academic Behavioral Health Center	depression, fatigue, and cognitive
Industry funded:	Caucasian: 53%	<u>SES</u> : NR		problems)
N	Black: 13%		Population: PCC (symptom evaluation)	
O amonto a	Hispanic: 13%	Employment:	100%	MH prevalence:
Sample:	Asian: 3% Other: 20%	Not employed/retired before	Hospitalized: 36.7%	Appiety disorder: 17%
	Other: 2070	pandemic: 17%	<u>1103phalized</u> . 30.7 //	Depressive disorder: 47%
Risk of bias:	December 1, 2020 to	Significant interruption: 60%	Confirmation method: NR	Anxiety/depressive disorder: 7%
High	July 26, 2021			Adjustment disorder: 17%
			Severity:	
			Moderate illness constituting	Previous MH:
			pulmonary symptoms, short-term	Past psychiatric history: 56.7%
			symptoms while at home: 33.3%	Ascertainment: Self-report
			Significant illness requiring intubation	
			for hypoxia and prolonged	
			hospitalization: 3.3%	
			COVID Diagnosis (variant):	
			February-March 2020: 30%	
			January-February 2021: 30%	
	Findings		January 2020-March 2021: 40%	
	Outcome:			
	1. Those experie	ncing a significant interruption in t	their professional lives / All COVID patients	s with MH symptoms
	2. Unable to retu	rn to work for all COVID patients v	with MH symptoms and significant interrup	tions in professional lives / All COVID
	patients with	/IH symptoms		
	Timing: Mean (SD) mo	nths from COVID diagnosis to timi	ng of consult: 7.23 (4.89)	
	$\frac{\text{KeSUITS}}{1}$	0/		
	1. 19/30 = 03.3 2. 6/30 = 20%	/0		
	Adjustments: None			
LeGoff, 2023	48.3 (NR)	<u>Comorbidity</u> : NR	67 California employees referred by	MH description:
USA	54.7%		occupational physician's outpatient MH	"Brain fog" including mental fatigue,
		<u>SES</u> : NR	provider panel for assessment and	forgetfulness/impaired short-term

Author, Year, Country	Mean age (SD) yrs Female, %	Comorbidities SES variables	COVID population description	MH details
Study design Funding	Race/ethnicity Enrollment dates	Employment status		
Cross-sectional Industry funded: NR <u>Sample</u> : outpatient MH clinic <u>Risk of bias</u> : High	Race: NR January 2021 to December 2022 (referral cases) April 2020 to February 2022 (contracted COVID)	<u>Employment</u> : Occupational Category: Healthcare services: 50% Corrections: 21.9% First responders: 14.1% Facilities maintenance: 14.1%	treatment due to diagnosis of PCC with neurocognitive complaints of "brain fog," including mental fatigue, forgetfulness/impaired short-term memory, difficulties concentrating, inattentiveness, diminished task focus, confusion, etc. <u>Population</u> : PCC (neurocognitive screening) 100% <u>Hospitalized</u> : NR <u>Confirmation method</u> : NR	memory, difficulties concentrating, inattentiveness, diminished task focus, confusion were affecting returned to work at time of initial referral for NCSE (study enrollment), with or without restrictions <u>MH prevalence:</u> 100%, All with neurocognitive complaints <u>Previous MH</u> : NR <u>Ascertainment</u> : Self-reported neurocognitive complaints after PCC diagnostic
	Findings <u>Outcome</u> : 1. Returned to w 2. Mean duration <u>Timing</u> : The sample me being at MMI, was 16 m <u>Results</u> : 1. 0/64 = 0% 2. 459.4 days (14) Adjustments: None	ork at time of initial referral for neu of work leave from doctor's first re can total duration of illness, from do nonths (462.8 days; SD, 187.2 day 5 months: from 19 weeks to 2.5 yrs	rrocognitive screening/ Assessed by neuro eport illness to date of return to full or mod ate of initial diagnosis to date of discharge /s), with a range of 4 1/2 months (134 days s [range 134-903 days [SD 126.6 days]]; n	cognitive screening with MH symptoms ified duty from all healthcare services due to s) to 2 1/2 years (903 days) nedian 425.5 days)
Lunt, 2022 UK Cross-sectional Industry funded: NR	NR, range 25-65 88% <u>Race</u> : NR March 16, 2020 to	<u>Comorbidity</u> : NR <u>Employment:</u> Nurses: 17% Medics: 15% Allied health: 10%	145 workers who had either tested positive for COVID or suspected infection <u>Population</u> : COVID infected	<u>MH description</u> : Poor concentration and symptom interaction with cognitive job demands (applied to having to 'concentrate,' 'word find' and to meta-cognitive task')
<u>Sample</u> : mix (community and COVID support group) <u>Risk of bias</u> :	July 1, 2020	Teachers: 12% Social or support workers: 6%	<u>Hospitalized</u> : 12% <u>Confirmation method</u> : NR <u>Severity</u> Mild/moderate at home: 35% Severe at home: 45%	Psychological workability/return-to- work status determined by asking: "How do you rate your current workability with respect to the psychological and demands of your work?

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity Enrollment dates	Comorbidities SES variables Employment status	COVID population description	MH details
Low/moderate				<u>MH prevalence</u> : over half (52%) of participants reported pre-existing mental or physical health conditions <u>Previous MH</u> : 6%
				Ascertainment: open-ended interviews
	Outcome: Return to work1.Poor concentr2.Symptom interPsychological workabili 3.Reporting outceTiming: More than 6 mode Results:1.2.12 / 145 = 13.32.12 / 145 = 8.33.Very good 2 / 88 = 2.3%	ation leading to obstacles / Total s raction with cognitive job demands ty come on scale / All reporting outco onths previously with their symptor 8% % <u>Rather good Moderate</u> 14 / 88 = 16% 25 / 88 = 2	ample s / Total sample me ns continuing for longer than 6 months, 68 Rather poor Poor 8.4% 27 / 88 = 30.7% 20 / 88 = 22	5% 2.7%
Peter, 2022	44.1 (13.7)	Comorbidity: NR	11,710 with COVID 6 to 12 months	MH description:
Germany	58.8%		prior to enrollment	Symptom clusters 6-12 months after
Cross-sectional Industry funded:	<u>Nationality</u> : German: 94.1%	<u>SES</u> : University entrance qualification: 51.9%	Population: post-COVID with symptoms	acute infection (not present before acute COVID infection)
N	Other: 5.9%			MH prevalence:
Sample: health	Late August -	Place of birth: Germany: 88 7%	Hospitalized: 3.6%	Anxiety/Depression (sleep disorder, depressive mood, anxiety): 21.1%
database	September 2021 (COVID infected	Other: 11.3%	Confirmation method: PCR 100%	Neurocognitive impairment (confusion.
<u>Risk of bias</u> : Low/moderate	Òctober 1 2020 - April 1 2021)	<u>Pre-pandemic employment:</u> Full-time: 56.8% Part-time: 27.7%	<u>Severity</u> ICU admission: 0.8%	memory disturbance, concentration difficulties): 31.3%
		Studying/vocational education: 9.8%	Vaccination: first dose before positive PCR test: 1.9%	Previous MH: 12.8% had pre-existing mental disorders
		Current employment: Full-time: 54.4%		Ascertainment: Self-report, questionnaires mailed to individuals

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity Enrollment dates	Comorbidities SES variables Employment status	COVID population description	MH details
		Part-time: 27.6% Studying/vocational education: 8.8%		
	Findings			
	Outcome:			
	Mean percentage loss	of current working capacity:		
	1. All patients aft	er COVID infection with anxiety/de	epression (population attributable loss of v	vorking capacity) / All patients after
		on or cov/ID infontion with onviots/da		w) / All potients often COV/ID infection
	 All patients all with apprint //d/ 	er COVID Infection with anxiety/de	epression (associated loss of work capacit	y) / All patients after COVID Infection
	3 All nations aff	epiession er COVID infection with neurocoa	nitive impairment (population attributable l	oss of working canacity) / All natients
	after COVID in	er covid intection with heurocogi		uss of working capacity) / An patients
	4. All patients aft	er COVID infection with neurocoa	nitive impairment (associated loss of work	capacity) / All patients after COVID
	infection with I	neurocognitive impairment	·····	·
	Timing: Mean (SD) time	e since positive PCR test, months:	8.5 (1.6) (range: 6-12 months)	
	Results:			
	1. 0.8% (n=10,32	24)		
	2. 3.8% (n=2,422	2)		
	3. 1.86% (n=10,3	324)		
	4. 5.9% (n=3,56	1)		
	Adjustments: None			

Author, Year,	Mean age (SD) yrs	Comorbidities	COVID population description	MH service description and		
Study design	Race/ethnicity. %	SES Vallables		control group details		
Funding	Enrollment dates					
Decio, 2022	Overall: n=2894088	Comorbidity: NR	2,894,088 adult patients with COVID	MH service:		
France	18–39: 23.1%		(3.3%) or another medical reason	Subsequent re-hospitalization (at		
	40–59: 21.2%	SES: Social deprivation index	(96.7%)	least once) following discharge for		
Cohort	60–74: 25.9%	(quintiles)		the reference hospital stay for		
Industry funded:	75+: 29.8%		Population: COVID infected	COVID or hospitalization for another		
N		Overall		reason in the adult general		
	Female: 56.1%	1 (least deprived): 16.7%	Hospitalized: 100%	population:		
Sample:		2: 19%	Confirmation mathedu ICD 10 and an	• psychiatric disorder of any type		
nospitalized	$\frac{\text{Hospitalized for COVID}}{\text{p}=06313}$	3. 20.8%	Confirmation method: ICD-10 codes	psychotic disorders		
Risk of hias	18_39.8.2%	4. 21.3% 5: (most deprived): 21.9%	Severity:	mood disorders		
High	40-59:21.5%	Unknown: 1.6%	Overall	anxiety disorders		
. iigii	60-74: 27.5%		ICU: 10.4%	 personality disorders 		
	75+: 42.8%	Hospitalized for COVID	ICU with invasive procedures: 2.2%	Overall		
		1 (least deprived): 23.8%		Psychiatric history: 11%		
	Female: 47.4%	2: 17.4%	Hospitalized for COVID			
		3: 17.2%	ICU: 14.1%	Hospitalized for COVID		
	Hospitalized for other	4: 18%	ICU with invasive procedures: 10.3%	Psychiatric history: 13.6%		
	reason: n=2797775	5: (most deprived): 23.7%				
	(96.7%)	Unknown: 1.3%	Hospitalized for other reason	Hospitalized for other reason		
	18-39:23.04%	Hospitalized for other reason	ICU: 10.3%	Psychiatric history: 11%		
	40-39.21.1%	1 (least deprived): 16 5%	100 with invasive procedures. 2 /			
	75+ 29.4%	2. 19 1%	Variant: study conducted during the	Ascertainment:		
		3: 21%	first wave of the SARS-CoV-2	healtheare database		
	Female: 56.4%	4: 21.7%	pandemic			
		5: (most deprived): 21.8%		Control		
	Race: NR	Unknown: 1.5%		Adults previously hospitalized for		
				another medical reason other than		
	<u>Enrollment</u> : NR			COVID infection		
	Findings					
	Outcome:					
	Subsequent re-hospitaliza	ition (at least once) for:				
	1. Psychiatric disorder / Previously hospitalized for COVID vs. Psychiatric disorder / Previously hospitalized for reason other than					
	2 Psychotic disord	are / Previously bospitalized for C	N/ID ve Revenatic disorders / Provinuely	hospitalized for reason other than		
			ovid va. i ayonotic disolucia/ Fieviously	nospitalized for reason other than		
	3. Mood disorders /	Previously hospitalized for COVI) vs. Mood disorders / Previously hospita	lized for reason other than COVID		
	3					

Table S4a: Study Characteristics for Mental Health Service Use with Control Groups

Author, Year, Country	Mean age (SD) yrs Female, %	Comorbidities SES variables	COVID population description	MH service description and control group details
Funding	Enrollment dates			
Funding Formoso, 2023 Italy Cohort Industry funded: NR Sample: health database Risk of bias: High	Enrollment dates 4. Anxiety disorders 5. Personality disord COVID Timing: During the 12 mor Results: 1. 10,685 / 96,313 = 2. 1,019 / 96,313 = 3. 4,115 / 96,313 = 4. 5,834 / 96,313 = 5. 766 / 96,313 = 19 Adjustments: adjusted for duration of hospitalization 1. Un-adjusted OR: 2. Un-adjusted OR: 3. Un-adjusted OR: 4. Un-adjusted OR: 4. Un-adjusted OR: 4. Un-adjusted OR: 51.3% Race: NR September 2020 to May 2021	/ Previously hospitalized for COV ders / Previously hospitalized for Cov aths following hospital discharge fr = 11.1% vs. 258,566 / 2,797,775 = 1.1% vs. 26,595 / 2,797,775 = 1% 4.27% vs. 106,861 / 2,797,775 = 5 6.1% vs. 140,819 / 2,797,775 = 5 % vs. 27,182 / 2,797,775 = 1% socio-demographic characteristics (days) and level of clinical care 1.20 (95% Cl: 1.18, 1.23), p<0.00 1.11 (95% Cl: 1.05, 1.19), p<0.00 1.12 (95% Cl: 1.09, 1.16], p<0.00 1.22 (95% Cl: 1.18, 1.25], p<0.00 6 Cl: 0.76, 0.88], p<0.0001; Adjus Comorbidity: Moderate comorbidity according to Charlson Index (>=2): 5.8% <u>SES</u> : NR	/ID vs. Anxiety disorders / Previously hosp /ID vs. Personality disorders / Previou rom a medical, surgical, or obstetrics ward 9.2% 3.8% % s, psychiatric history and characteristics o 001; Adjusted OR: 0.93 (95% CI: 0.91, 0.9 01; Adjusted OR: 1.06 (95% CI: 0.99, 1.1 01; Adjusted OR: 0.87 (95% CI: 0.99, 1.1 01; Adjusted OR: 0.88 (95% CI: 0.95, 1.0 ted OR: 0.82 (95% CI: 0.76, 0.88), p<0.00 36,036 diagnosed with COVID using outpatient service use Population: COVID infected Hospitalized: 2% Confirmation method: PCR 100% Severity: At least one emergency room access: 9.4% Vaccination: Received before testing positive: 3%	Distalized for reason other than COVID sly hospitalized for reason other than d f the reference hospitalization: (5), p<0.0001 4], p=0.09), p<0.0001 1), p=0.1536 001 MH service: outpatient MH specialist visits (e.g., anxiety, depression, sleep problems) Total visits: n=190 (n=117 first visit, n=57 >1 visit) Ascertainment: Administrative database Control: Matched sample from local health authority database with equal distribution of sex, age, and comorbidities Hospitalized for any reason (at least
				Access to emergency room (at least
	Findings		1	01003. 0.3 /0
	Outcome: 1. Those with at lea infected with CO	st one visit to MH specialist / All p /ID	atients in database with convalescent CC	VID vs. general population never

Author, Year, Country Study design	Mean age (SD) yrs Female, % Race/ethnicity, % Enrollment dates	Comorbidities SES variables	COVID population description	MH service description and control group details
	 Total first visits to infected with CO' <u>Timing</u>: median follow-up <u>Results</u>: 174 / 36036 = 0.3 117 / 36036 = 0.3 Adjustments: Hazard ratio (95% emergency room 	o outpatient MH specialist visit / all VID of 152 days (range 1–180) 5% vs. 175 / 36036 = 0.5% 3% vs. 104 / 36036 = 0.3% % CI): 0.87 (0.72–1.07), adjusted f over the 365 days before the inde	patients in database with convalescent (for age, sex and occurrence of hospital ar	COVID vs. general population never
Staples, 2023 Australia Cohort Industry funded: N <u>Sample</u> : MH outpatient clinic <u>Risk of bias</u> : Low/moderate	Recovered COVID(n=7468):33.2 (12.1)76.2%Australian, non-Indigenous Australian:4.3%Born outside Australia:23.7%PCC (n=1873):35.8 (13)77.8%Australian, non-Indigenous Australian:5.8%Born outside Australia:27.6%No COVID (n=6151):38 (15.5)71.2%Australian, non-Indigenous Australian:4.7%	Comorbidity: NR SES Recovered COVID: Education Secondary school or below: 32.6% Trade certificate or diploma: 25.7% University degree: 41.6% Income Employed full or part time: 73.3% Unemployed, no income: 11.9% Pension or benefit: 10.9% Other source of income: 4% <u>PCC</u> : Education Secondary school or below: 31.9% Trade certificate or diploma: 30.8% University degree: 37.3% Income Employed full or part time: 63.4%	15492 with assessment at MindSpot clinic, a national digital MH service: <u>Population</u> : • Recovered at 3 months: 48.2% • PCC (WHO): 12.1% • No COVID: 39.7% <u>Hospitalized</u> : NR <u>Confirmation method</u> : self-report	MH service: Current MH professional use for those with COVID completing an assessment at national digital MH service <u>Ascertainment</u> : Self-report during assessment at MindSpot (digital MH service for symptoms of anxiety or depression) <u>Control</u> : General population (without COVID) completing an assessment at national digital MH service

Author, Year, Country Study design	Mean age (SD) yrs Female, % Race/ethnicity, %	Comorbidities SES variables	COVID population description	MH service description and control group details
Funding	Enrollment dates			
	Born outside Australia: 26%	Other source of income: 3.2%		
		No COVID:		
	September 5, 2022 to	Education		
	May 8, 2023	Secondary school or below: 35.9%		
		Trade certificate or diploma:		
		University degree: 36.9%		
		, , , , , , , , , , , , , , , , , , , ,		
		Income		
		Employed full or part time:		
		57%		
		Unemployed, no income:		
		14.7% Denoion or honofit: 21.8%		
		Other source of income: 6.5%		
	Findings			
	Outcome:			
	Current MH professional u	lse		
	1. With COVID (rec	overed and PCC) / With COVID (n	non-symptomatic and symptomatic after 3	3 months) vs. Without COVID / General
	population witho	ut COVID		
	2. With PCC / With	PCC (symptomatic after 3 months	s) vs. Without COVID / General populatio	n without COVID
	Timing: At least 3 months	after COVID infection		
	Results:			
	1. $1862 / 9341 = 19$	7% vs. 1318 / 6151 = 21.4%		
	2. 443/10/3 - 23. Adjustments: None	//0 v5. 1310/0131 - 21.4%		

Table S4b: Study Characteristics for Mental Health Service Use without Control Groups

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity, % Enrollment dates	Comorbidities SES variables	COVID population description	MH service description
Ahmed, 2022 USA Cross-sectional Industry funded: N <u>Sample</u> : post COVID clinic <u>Risk of bias</u> : High	53 (IQR: 21-89) 66.7% <u>Race</u> : Caucasian: 40.4% Hispanic: 31.6% Black: 21.1% June 1, 2020 to December 1, 2020	<u>Comorbidity</u> : NR <u>SES</u> : NR	1511 COVID positive patients 114/1511 (7.5%) attended post- COVID clinic for initial evaluation of long-term sequelae, early rehabilitation, and targeted specialist referrals <u>Population</u> : COVID infected <u>Hospitalized</u> : 87.7% <u>Confirmation method</u> : NR <u>Severity</u> : ICIL admission: 7.0%	<u>MH service</u> : Psychiatry service use at the post- COVID clinic when presenting with depressed mood, hopelessness, anxiety, and/or fatigue <u>Ascertainment</u> : Medical record
	Findings <u>Outcome</u> : Psychiatry service use 1. For those attending p 2. For those attending p <u>Timing</u> : Over the initial 6 mont <u>Results</u> : 1. 22/1511 = 1.5% 2. 22/114 = 19.3% Adjustments: None	bost-COVID clinic / All COVID p bost-COVID clinic / All COVID p ths follow-up, with any re-evalua	ositive patients ositive patients referred to post COVI ations occurring around 1 month after	D clinic for baseline evaluation initial evaluation
Bek, 2023	59.7 (11.4)	Comorbidity:	617 patients attending the COVID	MH service:
Cross-sectional	Race:	Pre-COVID educational	after hospital discharge	Allended psychologist session for anxiety or depression
Industry funded: N	North African: 4%	Low [primary or secondary]:	Hospitalized: 100%	disorder at baseline
Sample: outpatient	Asian: 6%	Middle [high school]: 35%	riospitalized. 10070	Ascertainment:
post-COVID clinic	Turkish: 4%	High [post-secondary or university]: 30%	Confirmation method: PCR or multidisciplinary team decision	Electronic data capture system
<u>Risk of bias</u> : Low/Moderate	July 1, 2020 to June 13, 2022	Pre-COVID employment: Unemployed: 15%	based on symptoms: 100% <u>Severity</u>	

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity, % Enrollment dates	Comorbidities SES variables	COVID population description	MH service description
		Employed: 60% Retirement: 25%	ICU admission: 41% Oxygen supplementation: 97% High flow nasal cannula: 33% Invasive mechanical ventilation: 35%	
	<u>Outcome</u> : Consulted a psych <u>Timing</u> : 3 months from hospit <u>Results</u> : 71/617 = 11.5% <u>Adjustments</u> : None	ologist / All patient after COVID al discharge for acute COVID ir	infection nfection	
Benzakour, 2021 Switzerland Cross-sectional Industry funded: NR <u>Sample</u> : outpatient clinic after hospitalization <u>Risk of bias</u> : High	56.8 (range: 18-86) 38.5% <u>Race</u> : NR March 30, 2020 to July 1, 2020	<u>Comorbidity</u> : NR <u>SES</u> : NR	109 hospitalized for COVID and attending CoviCare program (a multidisciplinary strategy, including specialists in internal medicine, pulmonary disease, primary care, infectious diseases and psychiatry) <u>Population</u> : COVID infected <u>Hospitalized</u> : 100% <u>Confirmation method</u> : NR <u>Severity</u> : ICU: 16.5%	MH service: Psychiatric follow-up: the psychiatrist provided an intervention depending on patients' mental status at assessment. Patients whose questionnaire scores exceeded the established cut-off (PDEQ>15 or/and HADS-A>11 or/and HADS-D>11 or/and PCL5>31), were referred to a psychiatric consultation by the liaison psychiatry team, consisting of an adapted psychiatric and/or psychotherapeutic intervention <u>Ascertainment</u> : Questionnaire sent out by e-mail or postal mail, and phone call to follow- up by CoviCare team
	Findings Outcome: 1. Patients taking psyc 2. Patients taking psyc Timing: One month following Results: 1. 26/109 = 23.9% 2. 26/64 = 40.6% Adjustments: None	hiatric follow-up/ All COVID pat hiatric follow-up/ All COVID pat hospitalization for COVID pneu	ients after hospitalization ients attending CoviCare service after monia	hospitalization
Bonazza, 2020 Italy	59 (13.3) 31.8%	<u>Comorbidity</u> : NR <u>SES</u> : NR	261 recovered COVID patients previously hospitalized and offered a multidisciplinary follow-	MH service: Psychological service use (interview) provided by the hospital psychologist

Author, Year, Country	Mean age (SD) yrs Female, %	Comorbidities SES variables	COVID population description	MH service description
Study design Funding	Race/ethnicity, % Enrollment dates			
Cross-sectional Industry funded: NR <u>Sample</u> : outpatient	Race: NR April 2020 to July 2020 (data collection)		up screening program within 2 months <u>Population</u> : COVID infected	when Hospital Anxiety and Depression scale (HADs) score was >11 for abnormal severe anxiety, and the Impact of Events Scale-Revised (IES-R) was >33 for possible ongoing
program			Hospitalized: 100%	acute stress disorder or PISD
<u>Risk of bias</u> : Low/moderate			<u>Confirmation method</u> : NR <u>Severity</u> : Sub-ICU treatments: 27.7% ICU treatment: 7.5%	Psychologist service use, 8 free sessions after psychological interview by psychotherapists if the cut-off score for HADs and IES-R is above normal
				Ascertainment: Face to face data collection interview and needed referral for psychologist
	Findings Outcome: 1. Participants using ps hospitalized 2. Participants using ps hospitalized Timing: Within 2 months of dis Results: 1. 36/261 = 13.8% 2. 16/261 = 6.1% Adjustments: None	ychological service (interview) ychologist service (after psycho scharge of hospital	provided by the hospital psychologist/ plogical interview) by psychotherapists	All COVID patients previously
Brehon, 2022 Canada Cross-sectional	48.9 (10.5) 64% <u>Race</u> : NR	<u>Comorbidity</u> : NR <u>SES</u> : Employed at admission:	81 workers discharged from post- COVID occupational rehabilitation program	<u>MH service</u> : Psychology services received prior to beginning the post-COVID rehabilitation program
Industry funded: N <u>Sample</u> : post- COVID rehabilitation clinic	March 2020 to mid-May 2021	95% Health-related occupations: 53 % Employed at discharge: 94%	Population: post-COVID with symptoms <u>Hospitalized</u> : 17% Confirmation method: NR	Ascertainment: Provincial databases managed by WCB-Alberta Health Care Strategy
<u>Risk of bias</u> : High	Findings Outcome: Those receiving psychology s	ervices / All workers participatir	ng in the occupational post-COVID reh	nabilitation program

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity, % Enrollment dates	Comorbidities SES variables	COVID population description	MH service description
	<u>Timing</u> : Mean (SD) days betw <u>Results</u> : 26 / 81 = 32% <u>Adjustments</u> : None	een symptom onset and progra	am admission: 165.2 (73.0)	
Chopra, 2021 USA	Median (IQR): 62 (50-72) 48.2%	<u>Comorbidity</u> : NR	1250 hospitalized with COVID	<u>MH service</u> : Health care use related to MH
Cross-sectional	Race:	<u>SES</u> : Residence before	Population: COVID infected	Ascertainment: Medical record and
Industry funded: N	Black: 51.6% White: 37.3%	hospitalization: Home: 82.8%	Hospitalized: 100%	phone call to participants
<u>Sample</u> : hospitalized	Other/unknown: 11.1%	Congregated living facility: 15.2%	Confirmation method: NR	
<u>Risk of bias</u> : High	<u>Ethnicity</u> : Hispanic: 4.4% Non-Hispanic: 86.7%	Subacute rehabilitation facility: 0.6% Other/unknown: 0.4%	<u>Severity</u> : Treated in an ICU: 13.2% Treated with invasive mechanical	
	March 16, 2020 to July 1,		Treated with supplemental	
	2020		oxygen: 69.2% Discharged to a health care facility: 12.6%	
	Findings <u>Outcome</u> : Health care use relations 1. Among those surviving 2. Among those surviving <u>Timing</u> : 60-day post discharge <u>Results</u> : 1. 28 / 1250 = 2.2% 2. 28 / 488 = 5.7% <u>Adjustments</u> : None	ated to MH ng COVID hospitalization ng COVID hospitalization and c e for outcome	completing telephone survey	
Chow, 2023 USA	48.1 (12.9) 72%	<u>Comorbidity</u> : NR	156 patients with PCC attending specialty outpatient clinic for	MH service: Referral to psychiatrists
Cross sectional	Passi		recovery	Previous MH:
Industry funded:	Hispanic: 47% White: 36%	<u>5E5</u> : NK	Population: PCC (self-reported symptoms) 100%	Anxiety: 29%
<u>Sample</u> : outpatient	Black: 8% Asian: 4%		Hospitalized: 20%	Ascertainment: Electronic medical record
Clinic Risk of bias:	Uther: 4%		Confirmation method: NR	
High	March 2020 - April 10, 2022		<u>Severity</u> :	

Author, Year, Country Study design	Mean age (SD) yrs Female, % Race/ethnicity, %	Comorbidities SES variables	COVID population description	MH service description
Funding	Enrollment dates			
			Symptoms with no hospitalization: 80% Symptoms hospitalized: 20%	
	Outcome: Referral to psychiat	trists with new psychiatric symp	toms after COVID / All patients see w	ith PCC
	Timing: NR (all with PCC) <u>Results</u> : 44 / 156 = 28.2% <u>Adjustments</u> : None			
Diem, 2022 Switzerland	44.6 (NR); range 19-83 80.6%	<u>Comorbidity</u> : Yes: 36.2%	309 with PCC and persistent symptom over 3 months	<u>MH service</u> : Consulted a psychiatrist/psychologist
Cross-sectional	<u>Nationality</u> : Swiss: 95.1%	<u>SES</u> : Education ≥13 years: 59 5%	Population: PCC (WHO) 100%	Ascertainment: Self-report survey
Samplo:	German: 1.9%		Hospitalized: 10.7%	
community and	Belgian: 0.6%		Confirmation method: PCR,	
Social media	Austrian. 0.57			
<u>Risk of bias</u> : High	October 15, 2021 to December 12, 2021		<u>Severity</u> : Intubation: 2%	
			ICU without intubation: 2.6%	
			Oxygen requirement: 9.4%	
			Vaccination:	
			Spikevax (Moderna): 50%	
			Comirnaty (Pfizer/Biotech): 49.1%	
			Janssen (Johnson & Johnson):	
	Findings	1		1
	Outcome:	vehologist / all patients includes	t in suprov with BCC	
	Timing: survey completed after	er acute infection: mean = 13 m	onths. range 0.2 - 24.5 months	
	Results:	, -	, 3	
	Adjustments: None			
Farooqi, 2022	51.3 (12.6)	Comorbidity:	30 patients complaining of	MH service:
USA	87%	Medical comorbidities;	neuropsychiatric symptoms	Recommendation for group or
Orean eastions!	Deser	mean (SD) = 1.13 (0.96)	referred and assessed for	individual psychotherapeutic
Uross-sectional	<u>Kace</u> : Caucasian: 53%	SESINR	COVID to outpatient department	treatment
maasay fundea. N		<u>020</u> . NIX		

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity, % Enrollment dates	Comorbidities SES variables	COVID population description	MH service description
<u>Sample</u> : outpatient department <u>Risk of bias</u> : High	Black: 13% Hispanic: 13% Asian: 3% Other: 20% December 1, 2020 to July 26, 2021 Findings <u>Outcome</u> : recommended psyc recovery program and referred Timing: Mean (SD) months for	Employment: Currently employed: 23% Not employed/retired before pandemic: 17% Significant interruption: 60%	of an academic Behavioral Health Center <u>Population</u> : PCC (symptom evaluation) 100% <u>Hospitalized</u> : 36.7% <u>Confirmation method</u> : NR <u>Severity</u> : Moderate illness constituting pulmonary symptoms, short-term hospitalization, or significant symptoms while at home: 33.3% Significant illness requiring intubation for hypoxia and prolonged hospitalization: 3.3% <u>COVID diagnosis (variant)</u> : February-March 2020: 30% January-February 2021: 30% January 2020-March 2021: 40% COVID patients with MH symptoms processed department f consult: 7, 23 (4, 89)	Ascertainment: Treatments recommended by Post COVID Recovery Program
	Adjustments: None	1	r	
Frontera, 2022 USA	<u>Overall</u> : (n=242) 65 (NR); IQR: 53-73 36%	<u>Comorbidity</u> : 122 (50%) reported >=1 PCC symptom (median 3,	242 hospitalized with COVID <u>Population</u> : PCC (CDC) 50%	<u>MH service</u> : Psychological talk therapy to deal with prolonged COVID symptoms
Cross-sectional Industry funded: NR	<u>Race</u> : NR <u>PCC</u> : (n=122/242)	IQK 1–5) lasting a median of 12-months (range 1–15) post-COVID diagnosis;	Hospitalized: 100%	Ascertainment: Self-report survey
<u>Sample</u> : hospitalized <u>Risk of bias</u> :	o4 (NK); IQK: 55-71 38% <u>Race</u> : White: 50%	according to CDC criteria as new or persistent symptoms occurring >=4 weeks after COVID infection	<u>Severity</u> : Invasive mechanical ventilation: 34%	

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity, % Enrollment dates	Comorbidities SES variables	COVID population description	MH service description
Low/moderate	March 10, 2020 to May 20, 2020 (hospitalized between)	SES: With PCC, Education level >12 years: 73.8%	Neurological complication during hospitalization: 47% With PCC and mechanically ventilated: 47%	
	Findings <u>Outcome</u> : Use of psychological talk thera 1. All with COVID / Tota 2. All with COVID / Tota <u>Timing</u> : Follow-up interviews p <u>Results</u> : 1. 11 / 242 = 4.5% 2. 11 / 122 = 9% Adjustments: None	apy al sample with COVID al sample with PCC performed at 12-months (+/- 2 n	Those with PASC: 67.2%	January 10 - July 20, 2021)
Gramaglia, 2021 Italy Cross-sectional Industry funded: N <u>Sample</u> : hospitalized <u>Risk of bias</u> : Low/moderate	61 (IQR: 50-71) 40.3% March 1 to June 29, 2020 (discharged from hospital)	<u>Comorbidity</u> : Total median (IQR): 2 (1-3) <u>SES</u> : NR	238 participants (or their caregivers) aged 18 years or older with COVID <u>Population</u> : COVID infected <u>Hospitalized</u> : 100% <u>Confirmation method</u> : PCR 97.3% <u>Severity</u> : Oxygen via nasal cannula or Venturi masks: 42.9% Non-invasive ventilation: 20.6% Mechanical ventilation: 8.8% ICU: 11.8%	MH service:Referred to further psychiatricconsultation provided by psychiatristwhich was determined during face-to-face interview by an experiencedpsychiatristAscertainment:Face-to-face interview by anexperienced psychiatrist and self-reported outcome during hospital stayand follow-up visits
	Findings <u>Outcome</u> : Participants referred <u>Timing</u> : 4 months, median tim <u>Results</u> : 26/237 = 10.97% Adjustments: None	d to further psychiatric consulta e after discharge 131 (119–145	tion / All COVID patients previously he	ospitalized
Heeney, 2023 Ireland Cross-sectional Industry funded: N	Median (IQR): 43 (31-53) 66% <u>Race</u> : NR	<u>Comorbidity</u> : At initial post- COVID clinic visit 221 of 311 patients (71%) had ongoing symptoms	311 patients at first visit to outpatient post-COVID clinic after their acute illness and to screen for potential sequelae of COVID infection	<u>MH service</u> : Patients referred to clinic psychology service and onward referrals to psychology. Onward referrals

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity, % Enrollment dates	Comorbidities SES variables	COVID population description	MH service description
<u>Sample</u> : post- COVID clinic <u>Risk of bias</u> : High	March 10 to June 14, 2020	SES: Healthcare staff: 62%	Population: post-COVID with symptoms 71% <u>Hospitalized</u> : 44% <u>Confirmation method</u> : PCR 100% <u>Severity</u> : Required admission to ICU or high dependency unit: 12% Required supplemental oxygen therapy: 50% Required invasive ventilation: 6.5% <u>Variant</u> : Based on timing of recruitment we infected exclusively with the original Wythan variant of COVID	required further follow-up beyond first clinic visit. <u>Ascertainment:</u> In-person clinic visits with a member of the infectious diseases medical team
Hodgson, 2021 Australia Cross-sectional Industry funded: N	Findings Outcome: 1. Patient referral to clir 2. Patients with onward attending outpatient 3. Patients with onward physio, psychology, r 4. Patients with onward Timing: Median (IQR) days from the comparison of the com	hic psychology service / All patie referrals to psychology / All pa post COVID clinic referrals to psychology / All pa heurology, or other after attendi referrals to psychology / All pa im positive PCR test to first clin <u>Comorbidity</u> : NR <u>SES</u> : Hospital cohort:	ents attending outpatient PCC clinic tients with further follow-up arranged tients requiring onward referral to one ng outpatient post COVID clinic tients attending outpatient post COVII ic appointment: 95 (77–105.5) 212 COVID patients admitted to ICU, 160/212 (75.5%) followed-up at 6 mos, and 115 alive at 6 mos and reporting persistent	(not necessarily being referred) after of following: respiratory, cardiology, D clinic <u>MH service</u> : Treatment for anxiety/depression at 6-month follow-up Ascertainment:

Author, Year, Country Study design	Mean age (SD) yrs Female, % Bace/ethnicity, %	Comorbidities SES variables	COVID population description	MH service description
Funding	Enrollment dates			
<u>Sample</u> : ICU admitted <u>Risk of bias</u> : High	62 (NR) range 55-71 39.4% <u>Alive and interviews at 6- mos</u> : n=115 58 (NR) range 51-69 42.6% <u>Race</u> : NR March 06, 2020 to October 04, 2020	Mean (range) years of education: 14 (11-16) Healthcare worker: 11.7% Hospital readmission: Mean (range) years of education: 14 (11-16) Healthcare worker: 9.8% Alive and interviews at 6- mos: Mean (range) years of education: 14 (11-16) Healthcare worker: 13%	symptoms. 50/115 (43.5%) reporting three or more symptoms <u>Population</u> : COVID infected: 100% Post-COVID with symptoms: 43.5% <u>Hospitalized</u> : 100% <u>Confirmation method</u> : PCR 100% <u>Severity</u> : Hospital cohort: ICU mortality: 18.4% 6-mos follow-up: n=160 Hospital readmission: 16.7% ICU mortality: 24.4% Death or new disability at 6 months: 56.3% Alive and interviews at 6-mos:	Surviving patients contacted prospectively by mail and invited to in telephone interviews at 6 mo after ICU admission Anxiety in follow-up cohort at 6- months: 4.3%
Holland, 2023 Australia	Findings Outcome: Treatment for anxiety/depress1.Among all assessed 2.2.Among all assessed 2.1.Final 6-month follow-u Median days (IQR) between s Median days (IQR) between s Median days (IQR) between s 2.1.16 / 109 = 14.7% 2.2.16 / 212 = 7.5% Adjustments: None 53 (NR), range (18-78) 65%	ion at 6-month follow-up at 6 mo follow-up paseline up was conducted on April 21, 2 ymptoms - hospital admission: ymptoms - ICU admission: 8.1	2021 6.1 (3.6-9.2) (5.3-11) 726 people with COVID completing 8 weeks follow-up	<u>MH service</u> : Referral to neuropsychology
Cross-sectional		<u>SES</u> : NR	questionnaire	Ascertainment:

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity, % Enrollment dates	Comorbidities SES variables	COVID population description	MH service description
Industry funded: NR <u>Sample</u> : inpatients and those managed as home-based acute medical service <u>Risk of bias</u> : High	March 2020 to December 2022 Findings Outcome: Participants who got a referral Timing: 8 weeks after the onso Results: 92/726 = 12.7% Adjustments: None	to neuropsychology/ COVID pa et of COVID	Population: COVID infected <u>Hospitalized</u> : 90.1% <u>Confirmation method</u> : NR <u>Severity</u> : ICU: 2.9% <u>Reinfection</u> : In 2022: 1% atients followed up at the Alfred Healt	Online questionnaire with free text answers h Post-COVID service
Huang, 2022 China Cross-sectional Industry funded: N <u>Sample</u> : hospitalized <u>Risk of bias</u> : Low/moderate	57 (IQR: 48-65) 46% January 2020 to May 2020	<u>Comorbidity</u> : NR <u>SES</u> : Education: College or higher: 28% High school or lower: 72% Work status before COVID: Retired: 55% Full-time or part-time job: 42% Jobless: 4% Homemaker: 0%	 1192 COVID survivors who were previously hospitalized and completed 3 follow-up visits <u>Population</u>: COVID infected At 2 year follow up 650/1190 (54.6%) had PCC symptoms defined as at least one sequelae symptom <u>Hospitalized</u>: 100% <u>Confirmation method</u>: laboratory confirmed 100% <u>Severity</u>: ICU admission: 4% Hospitalization, requiring supplemental oxygen: 68% Hospitalization, requiring HFNC or non-IMV, or both: 7% Hospitalization, requiring ECMO or IMV, or both: 1% 	<u>MH service</u> : Use of psychological help as health- care use after discharge <u>Ascertainment</u> : Self-reported questionnaire

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity, % Enrollment dates	Comorbidities SES variables	COVID population description	MH service description
	<u>Outcome</u> : Use of psychologica <u>Timing</u> : From symptom onset <u>Results:</u> 3/1187 = 0.25% <u>Adjustments:</u> None	al help as health-care after disc to 2-year follow-up, median da	harge/ COVID survivors completed as ys (IQR): 685 (675-698)	ssessments for healthcare use
Kalyani, 2022 India Cross-sectional Industry funded: NR <u>Sample</u> : hospitalized <u>Risk of bias</u> : High	55.2 (6.1) 29.1% <u>Race</u> : NR June 2020 to November 2020	<u>Comorbidity</u> : NR <u>Going to work</u> : Returned to work: 64% Not returned to work: 36%	86 of 2654 (3.2%) COVID infected reporting back with persistent symptoms (various complaints related to medical problems and ENT) at 3 months <u>Population</u> : COVID infected (n=2654), post-COVID with symptoms (n=86/2654) <u>Hospitalized</u> : 100% <u>Confirmation method</u> : PCR 100% <u>Severity</u> : Admitted to ICU: 22.1%	<u>MH service</u> : Previously hospitalized patients being readmitted to hospital with complaint of confusion <u>Ascertainment</u> : Hospital records
	Findings <u>Outcome</u> : 1. Patients readmitted f 2. Patients readmitted f <u>Timing</u> : PCC symptoms devel <u>Results</u> : 1. 34 / 86 = 39.5% 2. 34 / 2654 = 1.3% <u>Adjustments</u> : None	for confusion / all patients who for confusion / all patients admi oped 3 months after hospital di	reporting back with any persistent sym tted to hospital during same period for scharge	ptoms treatment of COVID
Kisiel, 2023 Sweden Cross-sectional	43.5 (NR) 73.4% <u>Race</u> : NR	<u>Comorbidity</u> : 0: 50.6% 1: 30.3% ≥2: 19.1%	359 symptomatic non-hospitalized healthcare workers and other occupational groups, receiving outpatient follow-up care	<u>MH service</u> : Newly introduced treatment for depression/anxiety after COVID (including psychological treatment or medication)
<u>Sample</u> : outpatient care	March 10, 2020 - December 30, 2020	Education level: University: 55.9% No university: 44.1% <u>Place of birth</u> :	Population: post-COVID with symptoms <u>Hospitalized</u> : 0%	Ascertainment: Survey administered within 45 to 51 weeks following diagnosis
Low/mouerate			Commination method. FCR 100%	

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity, % Enrollment dates	Comorbidities SES variables	COVID population description	MH service description
		Sweden and both parents: 70.2% Sweden and one parent: 7.8% Sweden, not parents: 2.6% Not in Sweden: 19.4%	<u>Self-reported severity</u> : Mild: 42% Moderate: 39.1% Severe: 18.9%	
	Findings Outcome: Newly introduced tr Timing: 12-month follow-up at Results: 17/359 = 4.7% Adjustments: None	reatment for depression or anxie fter COVID	ety after COVID / all patients with CO	/ID
Lazzaroni, 2022 Italy Cross-sectional Industry funded: NR <u>Sample</u> : outpatient clinic <u>Risk of bias</u> : Low/moderate	All patients: n=523 60 (IQR 55-74) 34.2% Those with MH symptoms: n=93 65 (IQR 55-75) 36.5% Patient with 4-6 visits with psychologist: n=58 61 (IQR 55-69) 47.5% Race: NR March 2020 - November 2021	Comorbidity: NR <u>SES</u> : NR	523 patients previously hospitalized with COVID, attending a COVID outpatient clinic after hospital discharge <u>Population</u> : COVID infected <u>Hospitalized</u> : 100% <u>Confirmation method</u> : PCR 100% <u>All patients</u> : CPAP or ICU: 23.5% Other oxygen treatment or none: 76.5% <u>Those with MH symptoms</u> : CPAP or ICU: 32% Other oxygen treatment or none: 68% <u>Patient with 4-6 visits with</u> <u>psychologist</u> : CPAP or ICU: 51.8% Other oxygen treatment or none: 48.2%	MH service: Psychologist consultation; 4-6 visits among patients after COVID (previously hospitalized) that screened positive for PTSD or depression Trauma-focused psychological support intervention was proposed to patients with positive scores aimed to facilitating the resumption of the daily life by reducing the impact of this recent traumatic experience Ascertainment: Electronic data capture system
	Findings Outcome: 1. Patients agreeing to	undergo psychologist consultat	ion / All patients after COVID infection	1

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity, % Enrollment dates	Comorbidities SES variables	COVID population description	MH service description
	 2. Patients being referred 3. Patients agreeing to <u>Timing</u>: NR (post-hospitalization <u>Results</u>: 58 / 523 = 11.1% 93 / 523 = 17.8% 58 / 93 = 62.3% <u>Adjustments</u>: None 	ed for psychologist consultation undergo psychologist consultat on, during outpatient COVID cli	/ All patients after COVID infection ion / Patients being referred for psych nic visit)	nologist consultation
LeGoff, 2023 USA Cross-sectional Industry funded: NR <u>Sample</u> : outpatient MH clinic <u>Risk of bias</u> : High	48.3 (NR) 54.7% <u>Race</u> : NR January 2021 to December 2022 (referral cases) April 2020 to February 2022 (contracted COVID)	<u>Comorbidity</u> : NR <u>SES</u> : NR <u>Employment</u> : Occupational Category: Healthcare services: 50% Corrections: 21.9% First responders: 14.1% Facilities maintenance: 14.1%	67 California employees referred by occupational physician's outpatient MH provider panel for assessment and treatment due to diagnosis of PCC with neurocognitive complaints of "brain fog," including mental fatigue, forgetfulness/impaired short-term memory, difficulties concentrating, inattentiveness, diminished task focus, confusion, etc. <u>Population</u> : PCC (neurocognitive screening) 100% <u>Hospitalized</u> : NR	MH service:Recommended (referred) for MHtreatment after assessment byneurocognitive screening evaluationAttended MH treatment afterassessment by neurocognitivescreening evaluation with an averagenumber of therapy session of 2.4(range 0-42)MH Prevalence: 100%, All withneurocognitive complaintsAscertainment:Self-reported neurocognitivecomplaints after PCC diagnosis
	Findings <u>Outcome:</u> 1. Referred to MH treat 2. Attended MH treat MH symptoms <u>Timing</u> : The mean duration of weeks (67.7 days) to 25 mont <u>Results:</u> 1. 29/64 = 45.3% 2. 9/64 = 14.1% Adjustments: None	ment after neurocognitive scree ent after assessment by neuroc illness before the referral for M hs (751.0 days), and a median	<u>confirmation method</u> : NR ening evaluation / Assessed by neuroo ognitive screening evaluation / Asses H services was 11 months (341.5 day of 315.5 days	cognitive evaluation with MH symptoms sed by neurocognitive evaluation with /s; SD, 178.3 days), with a range of 9
Lynch, 2024 USA	43.5 (15) 70.7	Comorbidity:	75 undergoing neuropsychological, psychiatric	MH Service:

Author, Year, Country Study design	Mean age (SD) yrs Female, % Race/ethnicity, %	Comorbidities SES variables	COVID population description	MH service description
Funding	Enrollment dates			
Cross-sectional Industry funded: N Sample: mix (outpatient & health practitioner) <u>Risk of bias</u> : High	Race: Black: 8.0% Asian/South Asian: 8.0% White: 64% Hispanic/Latino: 17.3% Other/Unknown: 2.7% Enrollment: NR	Mean (SD) number: 1.5 (1.5) <u>SES</u> : Mean (SD) years of education: 16.0 (2.2)	and medical assessments. More than half referred from outpatient post-COVID recovery program offering treatment for various medical symptoms of PCC <u>Population</u> : mixed; not specified <u>Hospitalized</u> : 12% <u>Confirmation Method</u> : 100% naso, antibody <u>Severity</u> : acute COVID symptom severity was mostly moderate (score 11-20 on 0-33 scale) with an average length of acute illness 3 weeks Peak COVID symptom score, mean (SD): 16.6 (6.2) Required ICU or ventilator support: 0% <u>Vaccination</u> : At least 1 dose at study assessment: 42.3% At least 1 dose py second concentent and the second	Participants hospitalized psychiatrically, received neurocognitive rehabilitation, started seeing a psychiatrist or started psychotherapy Based on interval history between initial visit and follow-up assessments after 6 months. At enrollment, participants excluded if currently unstable psychiatric symptoms, such as active symptoms of psychosis or active suicidal ideation. Patients currently engaged in psychiatric care were not excluded. <u>Ascertainment:</u> Self-reported; psychiatric and medical information collected by study assessors during in-person assessments
	Findings <u>Outcome</u> : Hospitalized psychiatrically 1. Among those with lov 2. Among all undergoin Neurocognitive rehabilitation 3. Among those with lov 4. Among all undergoin Started seeing a psychiatrist 5. Among those with lov 6. Among all undergoin Started psychotherapy 7. Among those with lov	w (≥1) or extremely low score (a g neuropsychological assessm w (≥1) or extremely low score (a g neuropsychological assessm w (≥1) or extremely low score (a g neuropsychological assessm w (≥1) or extremely low score (a	 22) on neuropsychological assessmer 	nt at initial visit; nt at initial visit; nt at initial visit; nt at initial visit;

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity, % Enrollment dates	Comorbidities SES variables	COVID population description	MH service description
	 8. Among all undergoin <u>Timing</u>: On average 208 days <u>Results</u>: 0 / 37 = 0% 0 / 75 = 0% 2 / 37 = 5.4% 2 / 75 = 2.7% 4 / 37 = 10.8% 4 / 75 = 5.3% 12 / 37 = 34.4% 12 / 75 = 16% Adjustments: None 	g neuropsychological assessm after their initial assessment, o	ent at initial visit r 430 days since their initial COVID in	fection
Rival, 2023 France Cross-sectional Industry funded: N <u>Sample</u> : hospitalized in ICU or non-ICU units <u>Risk of bias</u> : High	64 (13) 45% <u>Race</u> : NR March 12 to April 15, 2020 (admitted between)	<u>Comorbidity</u> : NR <u>SES</u> : NR	 40 hospitalized for COVID, with and without ICU admission <u>Population</u>: COVID infected <u>Hospitalized</u>: 100% <u>Confirmation method</u>: NR <u>Severity</u>: Admitted to ICU: 45.0% Post-ICU neuromyopathy: 61.1% Mean invasive mechanical ventilation: 15 days <u>Variant</u>: Hospitalization during the first wave of the pandemic (i.e. Wild type) 	MH service: Accepting psychological follow-up (N=1: agoraphobia, 2: PTSD,3: doubt PTSD, 10: anxiety, 22: doubt PTSD, 38: PTSD). A psychological or psychiatric consultation was offered to patients with a positive Post- Traumatic Stress Checklist-5 (PCL-5) screening result (score of ≥33/80 or 4/4 positive clusters) <u>Ascertainment</u> : NR
	Findings <u>Outcome</u> : Accepting psycholo <u>Timing</u> : Approximately 6 mont <u>Results</u> : 6 / 40 = 15% <u>Adjustments</u> : None	ogical follow-up / All undergoing ths post-discharge; mean time b	PTSD assessments between COVID hospitalization and th	e follow-up consultation: 196±34 days
Umbrello, 2022 Italy Cross-sectional	Median (IQR) 63 (57-71) 16% <u>Race</u> : NR	<u>Comorbidity</u> : Pre-existing: 52% More than one: 23% <u>SES</u> :	79 Italian-speaking patients admitted to ICU (>24 h) <u>Population</u> : COVID infected	<u>MH service</u> : Met and unmet needs for psychologist based on information on health service utilization and need for care after ICU discharge

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity, % Enrollment dates	Comorbidities SES variables	COVID population description	MH service description
Industry funded: NR <u>Sample</u> : ICU admissions <u>Risk of bias</u> : High	March 5 to April 30, 2020	Employment status Active worker: 42.0% Retired: 54.0% Monthly income (€)- ≤ 1500: 54.0% > 1500: 46.0% Education (International Standard Classification of Education - ISCED): 0–2: 34% > 2: 65%	Hospitalized:100%Confirmation method:NRSeverity:•Required invasive mechanical ventilation:87.3%•Non-invasive ventilation with PEEP ≥ 5 cmH20:90 CFA score on ICU admission, median (IQR):6 (4-7)	<u>Ascertainment</u> : Self-reported in interviews performed on the telephone, by an experienced ICU physician previously involved in patient clinical management
	Findings Outcome: Need for psycholog Timing: 6 months after ICU dis Results: 11 / 79 = 13.9% Adjustments: None	jist / All COVD ICU survivors scharge (time from symptoms to	o hospital admission, median [IQR]: 7	[5–10] days)
Tager, 2023 Argentina Cross-sectional Industry funded:	47.8 (11.8) 64.2% <u>Race</u> : All recruited from Spanish-	<u>Comorbidity</u> : NR <u>SES</u> : All healthcare professionals Physicians: 67.5%	4673 Latin-American health professionals with COVID; some reported that the symptoms had not lasted more than one month since COVID episode	<u>MH service</u> : Required new consultation for psychotherapy <u>Ascertainment</u> :
NR <u>Sample</u> : occupational	speaking social network (all Latin American countries)	Nurses: 11.5%	Population: COVID infected <u>Hospitalized</u> : 11.7%	Self-report; based on questionnaire response
<u>Risk of blas</u> : High	Findings Outcome: Requirement for ps Timing: At least 1 month after Results: 672 / 4673 = 14.4% Adjustments: None	ychotherapy / All patients with (initial COVID infection	COVID	<u> </u>
Van Wambeke, 2023 France Cross-sectional	49.6 (11.2) 62.2% <u>Race</u> : NR	<u>Comorbidity</u> : Only six subjects (14%) were fully healthy, i.e., without comorbidity before	45 COVID patients receiving consultations with study team, including follow-up through the first and second phone call.	<u>MH service</u> : Psychological support therapy attendance Patients contacted the post-COVID
Industry funded: N		<u>SES</u> : NR		coordination team and received

Author, Year, Country Study design Funding	Mean age (SD) yrs Female, % Race/ethnicity, % Enrollment dates	Comorbidities SES variables	COVID population description	MH service description
<u>Sample</u> : community <u>Risk of bias</u> : High	September 2021 to March 2022		Population: post-COVID with symptoms <u>Hospitalized</u> : 0% <u>Confirmation method</u> : NR	phone consultations with an advanced practice nurse (45-65 minutes), who proposed therapeutic follow-up focused on patients' main symptoms. Outcome reported as those who had the opportunity to benefit from the psychological support therapy Ascertainment: Telephone interview
	Findings <u>Outcome</u> : Those attending ps (attended two telephone cons <u>Timing</u> : COVID occurrence at months (last follow-up) <u>Results</u> : 11 / 45 = 24.4% Adjustments: None	sychological support therapy am sultations) nd the first phone call delay: 15.	ong those with COVID who contacted 1 ± 7.8 months; COVID occurrence a	d coordination team for assessment nd the second phone call 22.6 ± 7.7
Wander, 2023 USA	Total with COVID (n=388980) 614 (16 1)	Comorbidity: All COVID CCI 0: 39.6%	388980 with COVID in the national US Veterans Affairs (VA) health care system	MH service: MH clinic encounters
Cross-sectional Industry funded: N <u>Sample</u> : health database	Race: American Indian or Alaska Native: 0.8% Asian: 1.4%	CCI 1: 20.3% CCI 2: 14.8% CCI 3: 8.6% CCI 4: 5.9% CCI 5-6: 6.4% CCI 5-8: 3.0%	18587 (4.8%) documentation of ICD-10 code U09.9 in the VA health care system	Ascertainment: Identified this code in records for all outpatient and inpatient encounters in the VA health care system using the Corporate Data Warehouse. To get the most complete ascertainment of
<u>Risk of bias</u> : High	Asian: 1.4% Black or African American: 20.7% Native Hawaiian or Pacific Islander: 1% White: 67.8% <u>Ethnicity</u> : Hispanic or Latino: 9.3% Not Hispanic or Latino: 84.7% <u>U09.9 Encounters</u> (n=18587)	CCI 7-6. 3.0% CCI >=9: 1.5% PCC CCI 0: 33.7% CCI 1: 20.9% CCI 2: 15.4% CCI 3: 9.8% CCI 4: 6.9% CCI 5-6: 7.7% CCI 7-8: 3.8% CCI >=9: 1.9%	<u>Population</u> 18887 PCC (ICD) 100% <u>Hospitalized</u> : All with COVID 10.3% PCC 24.3% <u>Confirmation method</u> : PCR 100% <u>Severity</u> : Mechanical ventilation All with COVID 1% PCC 2.4% <u>Vaccination</u> :	Ine most complete ascertainment of U09.9 documentation possible, we also identified whether this code was documented in 2 non-VA health care sources Previous MH: Depression at baseline: All with COVID: 35.9% PCC: 37.8% PTSD at baseline: All with COVID: 27% PCC: 27.1%

Author, Year, Country Study design	Mean age (SD) yrs Female, % Race/ethnicity, %	Comorbidities SES variables	COVID population description	MH service description
Funding	Enrollment dates 13% Race: American Indian or Alaska Native: 1% Asian: 1% Black or African American: 14.8% Native Hawaiian or Pacific Islander: 1.1% White: 72.9% Ethnicity: Hispanic or Latino: 14.5% Not Hispanic or Latino: 79.8% October 1, 2021 to January 31, 2023	<u>SES</u> : NR	All with COVID 34.6% PCC 38.6% Booster All with COVID 35.5% PCC 30.9% <u>Number of acute symptoms at presentation with acute infection</u> : All with COVID 0: (44.9% 1-2: 23% 3-4: 15.4% ≥5: 16.6% PCC 0: 39.4% 1-2: 24% 3-4: 17.4%	
	Findings Outcome: MH U09.9 clinic encounters 1. Among those with U 2. Among all VA patien Timing: clinical notes were reverse more after acute COVID infect COVID conditions Results: 1. 804 / 35875 = 2.2% 2. 804 / 388980 = 0.2% Adjustments: None	09.9 documentation ts COVID positive viewed up to 6 months after acu tion were captured in accordan	ute COVID infection, and only new-on ce with the Centers for Disease Contr	set symptoms present for 30 days or ol and Prevention definition of post–

Supplementary Figure 1: Labour Force by Risk of Bias



Supplementary Figure 2: Labour Force Long-Term Timing by Risk of Bias





Supplementary Figure 3: Labour Force MH Symptoms Alone vs. MH and Other Symptoms

Suppementary Figure 4: Labour Force by Narrow vs. Broad Spectrum of Symptoms



Supplementary Figure 5: Mental health service, use by type of professional

		%
Study	Proportion	Weight
Psychiatrist		
Benzakour 2021	0.24 (0.17, 0.33)	4.22
Ahmed 2022	0.01 (0.01, 0.02)	4.60
Lynch 2024	0.05 (0.02, 0.13)	4.05
Diem 2022	0.20 (0.16, 0.25)	4.48
Subtotal I^2 = 98.18%	0.11 (0.01, 0.28)	17.35
Psychologist		
Bonazza 2020	0.06 (0.04, 0.10)	4.45
Tager 2023 📥	0.14 (0.13, 0.15)	4.62
VanWambeke 2023	0.24 (0.14, 0.39)	3.75
Lazzaroni 2022 - 🖌 💌	0.11 (0.09, 0.14)	4.54
Bek 2023	0.12 (0.09, 0.14)	4.55
Brehon 2022	0.32 (0.23, 0.43)	4.09
Frontera 2022	0.05 (0.03, 0.08)	4.44
Rival 2023	0.15 (0.07, 0.29)	3.66
Umbrello 2022	0.14 (0.08, 0.23)	4.08
Huang 2022 🔹	0.00 (0.00, 0.01)	4.59
Lynch 2024	0.16 (0.09, 0.26)	4.05
Kisiel 2023 -	0.05 (0.03, 0.07)	4.50
Diem 2022	0.17 (0.13, 0.21)	4.48
Subtotal I^2 = 97.64%	0.11 (0.06, 0.17)	55.79
Unspecified		
Wander 2023	0.00 (0.00, 0.00)	4.63
Formoso 2023	0.00 (0.00, 0.01)	4.63
Chopra 2021 💽	0.02 (0.02, 0.03)	4.59
Hodgson 2021	0.08 (0.05, 0.12)	4.41
LeGoff 2023	0.14 (0.08, 0.25)	3.97
Staples 2023	0.20 (0.19, 0.21)	4.63
Subtotal I^2 = 99.92%	0.05 (0.01, 0.11)	26.86
Heterogeneity between groups: p = 0.248		
Overall 1/2 = 99.77%	0.09 (0.06, 0.13)	100.00
0 .25	5	

		%
Study	Proportion	Weight
Inpatient		
Benzakour 2021	0.24 (0.17, 0.33)	4.61
Ahmed 2022	0.01 (0.01, 0.02)	5.02
Bonazza 2020 🔹	0.06 (0.04, 0.10)	4.86
Lazzaroni 2022 🔶	0.11 (0.09, 0.14)	4.96
Bek 2023 🔸	0.12 (0.09, 0.14)	4.97
Frontera 2022	0.05 (0.03, 0.08)	4.85
Rival 2023	0.15 (0.07, 0.29)	4.01
Umbrello 2022	0.14 (0.08, 0.23)	4.46
Huang 2022	0.00 (0.00, 0.01)	5.02
Chopra 2021 🔹	0.02 (0.02, 0.03)	5.02
Hodgson 2021	0.08 (0.05, 0.12)	4.82
Subtotal I^2 = 96.76%	0.07 (0.04, 0.11)	52.61
After 1		
Wander 2002	0.00 (0.00, 0.00)	5.00
	0.00 (0.00, 0.00)	5.00
	0.00 (0.00, 0.01)	0.00
	0.03 (0.03, 0.07)	4.51
	0.14 (0.08, 0.25)	4.00
Stanles 2023	0.14 (0.13, 0.13)	5.05
	0.20 (0.13, 0.21)	1.14
	0.21 (0.14, 0.32)	4.44
Brahon 2022	0.24 (0.14, 0.33)	4.10
	0.32 (0.23, 0.43)	4.40
Subtotal 1/2 = 99 90%	0.13 (0.07, 0.42)	4.03
	0.10 (0.07, 0.21)	47.00
Heterogeneity between groups: p = 0.100		
Overall I^2 = 99.80%	0.10 (0.06, 0.14)	100.00
	1	
0 .20 .0 .75		

Supplementary Figure 7: Mental Health Service Use by Severity and Variant

Study	Proportion	% Weight
InpatientAlpha/Delta		
Benzakour 2021	0.24 (0.17, 0.33)	4.61
Ahmed 2022	0.01 (0.01, 0.02)	5.02
Bonazza 2020 🔹	0.06 (0.04, 0.10)	4.86
Lazzaroni 2022 - Contractional Contraction	0.11 (0.09, 0.14)	4.96
Bek 2023	0.12 (0.09, 0.14)	4.97
Frontera 2022	0.05 (0.03, 0.08)	4.85
Rival 2023	0.15 (0.07, 0.29)	4.01
Umbrello 2022	0.14 (0.08, 0.23)	4.46
Huang 2022	0.00 (0.00, 0.01)	5.02
Chopra 2021 🛛 🖌	0.02 (0.02, 0.03)	5.02
Hodgson 2021	0.08 (0.05, 0.12)	4.82
Subtotal I^2 = 96.76%	0.07 (0.04, 0.11)	52.61
MixAlaba/Dalta		
	0.01 (0.14, 0.00)	
Lynch 2024	0.21 (0.14, 0.32)	4.44
	0.37 (0.31, 0.42)	4.09
	0.14 (0.13, 0.15)	5.05
	0.32(0.23, 0.43)	4.48
	0.05(0.03, 0.07)	4.91
	0.14 (0.06, 0.25)	4.30
F0111050 2023	0.00(0.00, 0.01)	0.00
Subiolal 1-2 = 99.73%	0.15 (0.05, 0.30)	33.17
MixOmicron		
Wander 2023	0.00 (0.00, 0.00)	5.06
Staples 2023	0.20 (0.19, 0.21)	5.05
VanWambeke 2023	0.24 (0.14, 0.39)	4.10
Subtotal I [^] 2 = .%	0.11 (0.00, 0.39)	14.22
Heterogeneity between groups: p = 0.418		
Overall I^2 = 99.80%	0.10 (0.06, 0.14)	100.00
	l F	
0	5	

Supplementary Figure 8: Mental Health Service Use by Risk of Bias

		%
Study	Proportion	Weight
LowModerate		
Bonazza 2020	0.06 (0.04, 0.10)	4.86
Lazzaroni 2022	0.11 (0.09, 0.14)	4.96
Bek 2023	0.12 (0.09, 0.14)	4.97
Frontera 2022 -	0.05 (0.03, 0.08)	4.85
Huang 2022	0.00 (0.00, 0.01)	5.02
Kisiel 2023	0.05 (0.03, 0.07)	4.91
Staples 2023	0.20 (0.19, 0.21)	5.05
Subtotal I/2 = 99.28%	0.07 (0.01, 0.16)	34.63
High		
Wander 2023	0.00 (0.00, 0.00)	5.06
Formoso 2023	0.00 (0.00, 0.01)	5.06
Ahmed 2022	0.01 (0.01, 0.02)	5.02
Chopra 2021	0.02 (0.02, 0.03)	5.02
Hodgson 2021	0.08 (0.05, 0.12)	4.82
Umbrello 2022	0.14 (0.08, 0.23)	4.46
LeGoff 2023	0.14 (0.08, 0.25)	4.35
Tager 2023 🔶	0.14 (0.13, 0.15)	5.05
Rival 2023	0.15 (0.07, 0.29)	4.01
Lynch 2024	0.21 (0.14, 0.32)	4.44
Benzakour 2021	0.24 (0.17, 0.33)	4.61
VanWambeke 2023	0.24 (0.14, 0.39)	4.10
Brehon 2022	0.32 (0.23, 0.43)	4.48
Diem 2022	0.37 (0.31, 0.42)	4.89
Subtotal I/2 = 99.59%	0.11 (0.07, 0.15)	65.37
Heterogeneity between groups: p = 0.390		
Overall I ² = 99.80%	0.10 (0.06, 0.14)	100.00
	1	
0 .25	5	